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Abstract Lymphoid	organs	such	as	spleen	and	lymph	nodes	have	significantly	lower	oxygen	levels	(lymphoid	organs	~0.5-4.5%	O2)	compared	to	atmospheric	air	(~20%	O2)	due	to	the	vascular	anatomy.	Previous	studies	have	shown	that	low	oxygen	concentrations	can	alter	the	transcriptome	of	primary	monocytes	although	how	such	chances	impact	DENV	infection	is	unknown.	This	thesis	explore	the	possibility	that	that	O2	levels	would	significantly	alter	mononuclear	phagocytes’	susceptibility	to	DENV	infections.	Results	show	that	under	3%	O2	conditions,	FcγRIIA	expression	in	monocytes	is	significantly	upregulated	due	to	the	activity	of	hypoxia	inducible	factor	1α	(HIF1α).	Increased	FcγRIIA	expression	enhanced	antibody-opsonized	DENV	infection	in	both	primary	monocytes	and	THP-1	cells.	However,	stabilizing	HIF1α	in	cells	incubated	under	normoxia	with	the	iron	chelator,	desferrioxamine	increased	binding	of	antibody-opsonized	DENV	on	the	receptor	but	did	not	increase	virus	entry.	Instead,	for	enhanced	antibody-dependent	virus	entry,	a	HIF1α	independent	but	hypoxia	driven	increase	in	membrane	ether	lipid	concentrations	is	required	to	complement	the	increased	expression	of	FcγRIIA.	Indeed,	silencing	enzymatic	synthesis	of	ether	lipids	in	cells	cultured	under	hypoxic	conditions	reversed	enhanced	DENV	infection	without	altering	FcγRIIA	expression.	Our	findings	thus	indicate	that	the	increased	viral	burden	associated	with	secondary	DENV	infection	is	antibody-dependent	but	hypoxia-mediated.	In	addition,	we	show	that	hypoxia	driven	changes	in	cellular	membrane	lipid	compositions	results	in	alterations	in	DENV	progeny	membranes,	leading	to	the	increased	infectivity	of	DENV.		Collectively,	this	thesis	shows	that	physiological	oxygen	tensions	serves	as	an	important	
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factor	in	DENV	infections	and	suggest	a	role	for	targeting	hypoxia-induced	factors	for	anti-dengue	therapy.	
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Chapter 1: Introduction 
1.1 Dengue 
1.1.1 Dengue epidemiology 
Dengue is the most prevalent arthropod-borne viral disease globally and is rapidly transmitted 
between humans by the Aedes mosquito. In 2008 according to the World Health Organization 
(WHO), 50 million dengue cases occur annually with an estimate 2.5 billion people living in 
dengue endemic countries. However, this figure likely underestimates the global burden of 
dengue. In 2013, cartographic approaches estimated 390 million dengue infections occur 
annually (Bhatt et al, 2013) (Figure 1-1).  
 Urban cycle of dengue virus (DENV) is transmitted between humans and the Aedes 
mosquito (Gubler, 1998). Now, dengue is most prevalent in tropical regions and is encroaching 
into sub-tropical areas of the world with more than 125 countries in the world endemic with 
the virus (Murray et al, 2013). All four serotypes of DENV (DENV1-4) circulating in Asia, 
America and Africa has the potential to cause epidemics and severe disease (Guzman et al, 
2010) (Figure 1-2). Several factors contribute to the emergence of epidemic dengue – 
unprecedented growth in global population, uncontrolled urbanization and the lack of effective 
and sustainable vector control programmes. Aedes aegypti, the primary vector for the 
transmission of DENV, is widely distributed across tropical countries. The increase in trade 
and travel has resulted in the geographic expansion of Aedes aegypti and DENV’s secondary 
vector, Aedes albopictus. The expansion of the geographic distribution of the mosquito vectors 
amplify regions in which epidemics can occur. Furthermore, increased travel between 
countries has facilitated the movement of mostly asymptomatic but viremic people and hence 
contribute to hyperendemicity, where all four DENV serotypes circulate at any given time. 
Prevention of DENV transmission can be achieved by elimination of human-vector contact. 
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While vector control has been proven successful in the Americas (Schliessmann & Calheiros, 
1974), Cuba (Kouri et al, 1989) and Singapore (Ooi et al, 2006), it is however unsustainable 
on the long term due to reintroduction and subsequent re-establishment of the vector 
population. 
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Figure 1-1: Global burden of Dengue in 2010.  
Cartogram depicting the annual number of DENV infections. This is shown as a proportion of 
the national geographical area. Numbers include infection for all ages. Figure adapted from 
Bhatt et al, 2013 (Bhatt et al, 2013).  
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Figure 1-2: Global distribution of DENV serotypes.  
Global distribution of DENV1-4 in 2004. Figure adapted from Guzman et al, 2010 (Guzman et 
al, 2010) 
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1.1.2 Clinical Manifestations of Dengue  
DENV infections can result in a wide spectrum of clinical outcomes that ranges from dengue 
fever (DF) to the more severe forms of disease, namely dengue hemorrhagic fever (DHF) and 
dengue shock syndrome (DSS). Following infection and an incubation period of 3-7 days, DF 
patients exhibit symptoms such as high fever (>38.5oC), headache, vomiting, myalgia, joint 
pain and a transient macular rash. Symptoms generally persist for 2 to 7 days and most patients 
recover without complications.  
 In a small proportion of patients, symptoms worsen around the time of defervescence 
with the occurrence of systemic vascular leakage, thrombocytopenia (platelet count <100,000 
cells/mm3) and haemorrhage. During this phase of infection, hemoconcentration, 
hypoproteinemia, pleural effusions and bleeding from the mucosa or gastrointestinal tract may 
occur (Simmons et al, 2012). The increase in vascular permeability is generally resolved 
within 48-72 hours but in certain cases can be fatal for patients unless timely and adequate 
fluid support is administered. With no antiviral therapy available, treatment for DENV remains 
largely supportive, with careful management of patient’s fluid levels. The expanded 2009 
World Health Organization case definition scheme for dengue classifies according to severity, 
ranging from dengue without warning signs, with warning signs (vomiting, mucosal bleeding, 
lethargy, increasing heamatocrit with decreasing platelets and abdominal pain) to severe 
dengue (severe bleeding, plasma leakage or organ failure)	(World Health Organization, 2009). 
This revised scheme is expected to aid in clinical management of dengue infection.  
 
1.1.3 DENV genome and structure 
 DENV is an enveloped, single stranded, positive-sense RNA virus belonging to the 
Flaviviridae family, which includes several other clinically important pathogens such as yellow 
fever (YFV), West Nile (WNV), tick-borne encephalitis (TBV) and Japanese encephalitis 
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viruses (JEV). DENV has an approximately 11kb genome which encodes three structural 
proteins (capsid (C), envelope (E), membrane (M)) and seven non-structural (NS) proteins 
(NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) (Rice et al, 1985; Green & Rothman, 2006; 
Chambers et al, 1990) (Figure 1-3). Structural proteins of DENV assemble to form the viral 
particle and the non-structural proteins play a vital role in DENV RNA assembly, virus 
replication and modulating the host immune response (Table 1-1). DENV structural and non-
structural genes are flanked by the 5’ and 3’untranslated regions (UTR), which has been shown 
to play a role in viral RNA replication and evasion of the host immune response (Manokaran et 
al, 2015; Alvarez et al, 2005).  
 DENV has a spherical shape and is approximately 50nm in diameter, with its genome 
and capsid proteins encased in a host derived lipid bilayer surrounded by 180 copies of viral E 
protein (Kuhn et al, 2002). The E protein is made up of 3 domains connected by flexible hinge 
regions: DI (central structural domain), DII (dimerization domain and fusion peptide) and DIII 
(putative receptor binding site). The conformation of the E protein is dependent on the acidity 
of the environment and is essential for mediating fusion between the viral and endosomal 
membranes (Figure 1-4). At normal pH, E proteins exist as dimers that lie flat on the surface of 
the virion. However in acidic conditions, the dimers dissociate into monomers and 
subsequently form trimers, enabling fusion of the virion and release of its genomic material.   
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Figure 1-3: Genome organization of DENV.  
(Top) DENV consist of a single stranded positive strand RNA that is translated as a one 
polyprotein consisting of structural and non-structural genes. (Bottom) Predicted membrane 
topology of the polyprotein and its cleavage sites by host or viral proteases. Figure adapted 
from Assenberg et al 2009 (Assenberg et al, 2009).
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Table 1-1: Brief summary of functions of structural and non-structural genes of DENV. 
Protein Function 
Envelope (E)  - Viral attachment 
- Entry 
Capsid (C)  - RNA binding 
- Interaction with lipids 
- Interact with host nuclear proteins (DAXX and core 
histones) 
- Interact with nucleolin (Balinsky et al, 2013)  
Membrane (M),  
pre-membrane (prM) 
- chaperone during maturation of the virus 
- blocks premature viral fusion 
NS1 - Induce interferon-lambda1 
- Disrupt endothelial glycocalyx layer (EGL) 
- Activate TLR4 leading to vascular leakage (Modhiran et al, 
2015 
- Antibody target 
NS2A - RNA replication 
- Vision assembly 
- Inhibition of interferon signaling (Munoz Jordan et al, 
2003) 
NS2B - Required in cleavage of NS2A/NS2B, NS2B/NS3, 
NS3/NS4A (Falgout et al, 1991)  
- Alters membrane permeability (Leon Juarez et al, 2016) 
NS3 - Serine protease (N-terminus) 
- Helices (C-terminus) 
- Required for RNA replication (Matusa et al, 2001) 
- Regulate poly-protein processing (Teo et al, 2007) 
NS4A - Aid in maintenance of viral replication complex (Miller et 
al, 2007) 
NS4B - Inhibition of interferon signalling 
NS5 - RNA dependent RNA polymerase activity (RdRp) activity 
essential for virus replication  
- Inducer of IL8 
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Figure 1-4: Organization of E proteins on DENV surface.  
Image depicts packing of DENV E protein highlighting DI (red) DII (yellow), DIII (blue) and 
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1.1.4 DENV Life Cycle  
The first step in DENV infection involves binding of the E protein to cellular receptors on 
target host cells and subsequent internalization of the virion via receptor mediated endocytosis. 
Several candidate receptors, such as heparan sulfate (Chen et al, 1997), DC-SIGN (Lozach et 
al, 2005; Tassaneetrithep et al, 2003), HSP70/HSP90 (Reyes-Del Valle et al, 2005), mannose 
receptor (Miller et al, 2008), CD14 (Chen et al, 1999), TIM (Meertens et al, 2012), claudin-1 
(Che et al, 2013) and CLEC5A (Chen et al, 2008) have been identified in recent years, in vitro 
(Table 1-2). Although the role of these candidate receptors in clinical infection remain to be 
definitively demonstrated, it is possible that DENV utilizes multiple receptors to enter host 
cells via clathrin-dependent (van der Schaar et al, 2008) or -independent endocytosis (Acosta 
et al, 2009). Following internalization, endocytic vesicles containing the virion undergoes 
endosomal maturation into late endosomes. Low pH in the late endosomal compartments then 
triggers fusion of viral and endosomal membranes mediated by the trimerization of the E 
protein (Modis et al, 2004; Nayak et al, 2009). In addition to pH, Zaitseva and collegues 
showed that DENV membrane fusion may requires the presence of anionic lipids (Zaitseva et 
al, 2010), which are mostly present in late endosomal membranes of mammalian cells. This 
finding potentially explains why DENV fusion predominantly initiates in late endosomal 
compartments.  
 Mechanisms by which DENV genome is released into the cytosol post fusion has not 
been well characterized. However, a recent study by Byk et al suggests that ubiquitination of 
the capsid protein may serve as a signal for uncoating and is thus a vital step for release of the 
nucleocapsid into the cytoplasm (Byk et al, 2016). Once released, replication of viral RNA is 
postulated to occur at vesicle packets or convoluted membranes derived from the rough 
endoplasmic reticulum (RER) (Welsch et al, 2009). Subsequently, newly synthesized RNA is 
packaged by the capsid protein and buds into the ER. Immature progeny virions displaying the 
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prM protein are assembled within the ER and transported through the trans golgi network. 
Throughout this process, prM proteins remain associated with the E protein to prevent 
premature fusion of the virion in the acidic environment of the golgi compartments (Li et al, 
2008; Yu et al, 2008). These trimers of E-prM heterodimers on the virion surface give the 
immature virion its characteristic spiky appearance (Kostyuchenko et al, 2013). The transition 
between the “spiky” and “smooth” appearance of DENV occurs while progressing through the 
trans-golgi network (TGN) due to E protein conformational changes at approximately pH6 
(Modis et al, 2003; 2004; Zhang et al, 2004). During maturation, prM is cleaved to M by the 
host furin protease and dissociates with the E protein to form a mature virion. Mature virions 
thus have DENV RNA complexed with capsid proteins surrounded by a lipid bilayer 
membrane. 180 copies of E proteins are anchored on the surface. As furin cleavage is 
relatively inefficient, structural studies show that progeny virions can either be immature, 
mature or partially mature (Junjhon et al, 2010) (Figure 1-5).  
 DENV infection generally occurs at the site of inoculation and is subsequently 
trafficked to lymphoid organs for further infection and dissemination of the virus (Prestwood 
et al, 2012). Therefore the replication cycle of DENV (Figure 1-6) occurs in major targets of 
DENV infection such as monocytes, macrophages, dendritic cells that reside in these organs.  
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Table 1-2: List of putative receptors for DENV in mammalian cells  
Molecule Cell Type DENV Serotype 
Heparin Sulfate (Chen et al, 1997) - Vero  
- CHO K1 
DENV-2 
DC-SIGN (Lozach et al, 2005; 
Tassaneetrithep et al, 2003) 
- THP-1   
- Monocyte derived 
DC 
DENV-1,2,3,4 
HSP90 / HSP70 (Reyes-Del Valle et al, 
2005) 
- U937  
- SK-SY-5Y  
- Monocyte derived 
macrophages 
DENV-2 





(Jindadamrongwech et al, 2004) 
- HepG2 DENV-1,2,3 
TIM-1 - A549  
- Huh7,5  
- Vero 
DENV-2,3 
AXL - A549  
- Vero  
- Primary kidney 
epithelial cells  
- Primary astrocytes 
DENV-2,3 
 
Claudin-1 - Huh7  
- Huh7.5 
DENV-2 
CD14 (Chen et al, 1999) - Monocytes 
- Macrophages 
DENV-2 
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Figure 1-5: Conformation of E proteins at different stages of DENV maturation.   
a. Structure of an immature virus at pH 7.0 shows the E protein existing as a heterodimer with 
prM, forming 60 spikes on the surface of the virion. b. In the trans-golgi network (TGN), the 
prM-E proteins of the immature virion at low pH of 6.0 rearranges to form 90 dimers that lie 
flat on the surface. The virion is still immature at this stage. c. In the TGN, host protease furin 
cleaves the ‘pr’ peptide from the prM-E but still remains on the surface of E as a cap. The 
virion is still non-infectious at this stage. d. Secretion of the virion into the extracellular space 
causes the cleaved ‘pr’ to be released, thus resulting in a mature virus that can participate in 
subsequent rounds of infection. Figure adapted from Perera et al, 2008 (Perera & Kuhn, 2008).  
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Figure 1-6: DENV life cycle.  
DENV enters the cell via receptor-mediated endocytosis, fuses with endosomal membranes 
upon acidification and subsequently releases its genome into the cytosol for translation. Virus 
assembly occurs at the ER and virions mature through the trans golgi network. Cleavage of 
PrM takes place in the trans golgi network (TGN) and virions are released via exocytosis. 
Figure adapted from Screaton et al, 2015 (Screaton et al, 2015).
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1.1.5 Dengue vaccine  
 
 One of the major challenges facing the development of dengue vaccine is the need to 
elicit a long-lasting protective humoral response to protect against all four DENV serotypes. 
This is essential as sub-neutralizing or non-neutralizing concentrations of antibodies are able to 
opsonize heterologous DENV serotypes and engage fragment crystallizable receptors (FcγRs) 
of myeloid cells, thus enhancing internalization and subsequently infection (Halstead & 
O'Rourke, 1977; Halstead et al, 1984). This hypothesis, known as antibody dependent 
enhancement (ADE), is the leading hypothesis for the association between severe disease and 
secondary dengue infections, which will be further elaborated in the later sections of this 
introduction. Ideally, any dengue vaccine has to induce a balanced long-lasting protective 
immune response to prevent ADE of DENV infection.  
 The live attenuated chimeric vaccine from Sanofi Pastuer (Dengvaxia) is the leading 
candidate and has recently been licensed for use in 9 countries, including Singapore, Thailand, 
Indonesia, Phillipines, Brazil and Mexico. This tetravalent formulation consist of each of the 
four-DENV serotypes with its structural genes (prM and E) inserted into the backbone of the 
live attenuated yellow fever 17D (YF17D) vaccine strain, which has excellent efficacy and 
safety records. However, protective efficacy of the vaccine against dengue was 56.6% and 
60.8% in phase III Asian and Latin American trials, respectively. Stratified analyses also 
showed that its protective efficacy varied by viral serotype, age of individuals and prior 
exposure to DENV or other flaviviruses (Guy & Jackson, 2016). Efficacy increased with both 
age (> 9 years old) and seropositive individuals (Hadinegoro et al, 2015). Similar to Phase IIb 
studies conducted in Thailand (Sabchareon et al, 2012), both Phase III trials showed higher 
efficacy rates against DENV3 (74%) and DENV4 (74%) as compared to DENV1 (50.3%) and 
DENV2 (43%) (Villar et al, 2015; Guy & Jackson, 2016).  
 Various serological tests are available to detect antibodies raised against DENV, in 
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vitro. These include hemagglutinin inhibition assays (Clark & Casals, 1958), complement 
fixation test (Casey, 1965), enzyme-linked immunosorbent assays (ELISA) (Chungue et al, 
1989; Innis et al, 1989) and neutralization assays. However, the gold standard to assess dengue 
vaccine immunogencity in vitro is the measurement of neutralizing antibody titers using plaque 
reduction neutralization titer (PRNT) assay (Roehrig et al, 2008). In contrast to clinical 
observations where DENV1 and DENV2 had lower efficacy rates, PRNT results from serum 
collected from vaccinated patients showed induced production of neutralizing antibodies from 
all four DENV serotypes (Capeding et al, 2014; Villar et al, 2015; Sabchareon et al, 2012). 
While regression analysis between PRNT titers and protection does suggest that higher 
antibody titers are associated with decreased probability of disease, it is now clear that 
different thresholds may be required for varying serotypes (Buddhari et al, 2014). 
 The result of this clinical trial highlights a problem for vaccine development - the lack 
of accurate in vitro correlates of protection for dengue. Evidently, good neutralizing antibody 
titers as assessed by PRNT may not necessarily translate to clinical efficacy. Collectively this 
suggest that in vitro detection of antibodies may not correlate with protection in vivo (Morrison 
et al, 2010). This raises the possibility that other physiological factors such as tissue 
microenvironments in which dengue infections occur should be considered in in vitro analysis 
of dengue vaccine immunogenicity.  
 
1.2 Immune responses to DENV infections 
1.2.1 T cell responses to DENV infection 
As part of cellular immunity, T cell responses play an intergral role in combating intracellular 
pathogens. However its role during DENV pathogenesis has been shown to be both protective 
and pathogenic	(Weiskopf & Sette, 2015; Mongkolsapaya et al, 2003; An et al, 2004; Yauch et 
al, 2009; 2010). During the course of a natural infection, viral peptides presented by major 
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histocompatibility complexes (MHC) on the surface of infected cells are recognized by CD8 T 
cells, leading to the release of pro-inflammatory cytokines such as TNFα and IFNγ (Kurane et 
al, 1989; Yauch et al, 2009). Similarly, CD4 T cells are essential to the enhancement of B cells 
and CD8 T cells responses, directly mediate cytotoxicity and promote memory responses (Sant 
& McMichael, 2012; Gagnon et al, 1999). This protective response then results in the 
restriction of viral replication.  
 T cell epitopes are highly conserved throughout the DENV polyprotein (Rothman, 
2011). NS3, NS4B and NS5 proteins are most frequently recognised by CD8 T cells	(Kurane et 
al, 1993; Weiskopf et al, 2013). CD4 T cells, however, preferentially targets the C, E and NS1 
proteins, which are also targets of the antibody response against DENV. In a cohort of DENV 
infected children, Duangchinda and colleagues studied both CD4 and CD8 T cell responses 
across the DENV proteome and observed that responses were against most of the viral proteins 
and particularly dominant against NS3	(Duangchinda et al, 2010). This was similarly observed 
in a cohort of secondary dengue infected Vietnamese adults, which emphasized the importance 
of NS3 as a CD8 T cell target	(Simmons et al, 2005). Antigen immunodominance in the T cell 
response differs between the serotype of DENV infection. Weiskopf et al showed that 
structural proteins (E and prM) were dominant in DENV3 but not in DENV2 infection	
(Weiskopf et al, 2014).  
 Several studies that identified associations between human leukocyte antigen (HLA) 
and disease susceptibility suggest that T cells play a role in controlling DENV infection	
(Stephens, 2010; Malavige et al, 2011; Stephens et al, 2002; Loke et al, 2001). In a 
prospective study involving Thai children with either primary or secondary DF/DHF, Stephens 
and colleagues identified a number of HLA associations associated with severe disease in 
patients with secondary infections. This suggests that HLA may play a role in determining 
disease outcome in immunologically primed individuals, which is an important consideration 
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for vaccine development	(Stephens et al, 2002).  
 T cell protection against DENV has also been demonstrated in in vivo murine 
experiments.  Depletion of CD8 T cells in IFN receptor knockout mice resulted in higher viral 
loads (Yauch et al, 2009) but depletion of CD4 T cells did not show the same trend. Depletion 
of CD8 T cells also resulted in the lack of protection against a secondary heterotypic infection 
in IFN receptor knockout mice; re-introduction of DENV specific CD8 T cells resulted in 
reduced viral load	upon	reinfection	(Zellweger et al, 2015). Additionally, depletion of CD8 
negated the protective effects of immunization in BALB/c mice infected with a lethal strain of 
DENV	(Gil et al, 2009). Conversely, mice inoculated with DENV specific CD8 T cells showed 
reduced mortality when infected with a lethal dose of DENV	(An et al, 2004). In humans, 
protective roles of T cells has also been observed in a cohort study conducted in Thailand 
which reported increased frequencies of DENV specific CD4 and CD8 T cells among children 
who experienced subclinical as compared to symptomatic DENV infection	(Hatch et al, 2011). 
Collectively, these studies suggest that T cells play an important role in controlling DENV 
infections.  
 However, the original antigenic sin involving T cells has been used to explain the 
correlation between severe disease and secondary DENV infections. In the event of a 
secondary infection, it is hypothesized that T cell immunity is skewed to the memory of the 
previous infection. This then leads to lower avidity cross-reactive memory T cells from the 
previous infection dominating the immune response during the subsequent infection, resulting 
a cytokine storm and an inability to control the disease (Mongkolsapaya et al, 2003). However 
this hypothesis does not explain for the observations of severe disease in infants, who do not 
have heterologous T cells from a previous infection	(Nguyen et al, 2004). In addition, 
Weiskopf and colleagues demonstrated that heterologous infections (DENV2/3 and DENV3/2) 
resulted in either constant or expanded recognition of cross-reactive epitopes as compared to a 
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homologous infection	(Weiskopf et al, 2014). Therefore further investigations are required to 
elucidate the contribution of T cell to DENV pathogenesis in secondary infection.  
 
1.2.2 Humoral responses 
Antibody responses post DENV infection  	
Antibody responses to primary DENV infection occurs 6-10 days post illness onset when 
immunoglobulin M (IgM) antibodies are produced, peaking at approximately 2 weeks and 
waning to non-detectable levels 3 months post illness onset. Immunoglobulin G (IgG) 
antibodies can be detected at low levels one week post fever onset and titers slowly increase 
cross reactive IgG antibodies can be found in secondary DENV infections during the acute 
phase, due to the reactivation of memory B cells from the previous infection (Guzman et al, 
2010).  
 
Neutralizing antibodies to DENV 	
Antibody responses to DENV infections have been well characterized to identify epitopes of 
neutralizing antibodies, in the hope of developing vaccine targets or antibody therapeutics for 
treatment(Wahala et al, 2009). From mouse monoclonal antibody studies, a major target of 
neutralizing antibodies were found to be against viral E protein domain III (EDIII) 
(Gromowski & Barrett, 2007; Sukupolvi-Petty et al, 2007). Anti-EDIII antibodies such as 1H9 
(Serafin & Aaskov, 2001), 14A4 (Matsui et al, 2010), 8A1 (Zhou et al, 2013) and 1A1D-2	
(Lok et al, 2008) have been shown to be able to neutralize DENV infections. Furthermore, a 
potently neutralizing antibody, Ab513 that is engineered to bind to the para-epitope interphase 
of EDIII of all 4 DENV serotypes, has been recently developed and tested both in vitro and in 
over time (Guzman et al, 2010). These antibodies target the surface E and prM proteins as well 
as the secreted NS1 proteins (de Alwis et al, 2011; Lai et al, 2008). In contrast, high levels of 
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mouse models (Robinson et al, 2015).  
 Though humans can produce neutralizing antibodies with epitopes similar to those 
found in mice, only a small fraction of human antibodies produced are specific and potently 
neutralizing (de Alwis et al, 2012; Smith et al, 2014). Instead, antibodies produced during 
DENV infection in humans are dominated by cross-reactive antibodies and are weakly 
neutralizing (Beltramello et al, 2010; Crill & Chang, 2004). Furthermore, studies have shown 
that anti-EDIII antibodies are only present at low levels in human sera. Even though Crill and 
colleagues show a correlation with the levels of anti-EDIII antibodies and neutralization 
potency (Crill & Roehrig, 2001), depletion of anti-EDIII antibodies did not lead to significant 
reduction in neutralizing potency.  
 This body of work also showed that instead of EDIII, neutralizing monoclonal 
antibodies from humans (hMAb) target EDI/II and the quaternary epitopes of the intact DENV 
virion. Examples include hMAb 5J7 (Fibriansah et al, 2015b), which binds across 3 E proteins 
and neutralizes DENV3 at nanogram range concentrations, HM14c10 (Teoh et al, 2012)which 
recognizes a discontinuous epitope spanning adjacent E-protein dimers on DENV1 and hMAb 
4.8A, D11C and 1.6D which binds to highly conserved fusion loop in EDII (Costin et al, 
2013). Using blood samples from DENV patients, antibodies such as 752-2B2, 747C4 and 
752-2C8 that target the envelope dimer epitope (EDE) spanning within or across adjacent E 
dimers were produced. The authors show EDE antibodies to be highly cross-reactive and 
potent in neutralization assay against all four DENV serotypes	(Dejnirattisai et al, 2015). In 
addition to being strongly neutralizing, another hMAb 1C19, which binds to a novel conserved 
site known as the bc loop in EDII has also been shown to compete for binding to the FL with 
less-potent antibodies (Smith et al, 2013). Collectively these findings suggest that the main 
epitopes for DENV neutralization targeted by potent neutralizing antibodies in human immune 
sera are not limited to EDIII, as suggested by mouse studies   
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Requirements for DENV neutralization 	
Two models exist to understand the requirements for the mechanisms of DENV neutralization; 
the (1) “single hit” and (2) “multiple hit” hypothesis. The “single hit” hypothesis posits that on 
a virion exists a critical and functional site that when blocked will result in viral neutralization. 
However, with the complexity of virion structures, it is unlikely that binding of a single site 
will result in neutralization. The more widely accepted “multiple hit” hypothesis instead 
suggests that neutralization will only occur when the concentration of antibodies bound to the 
virion exceeds a threshold required (Diamond et al, 2008). In this case, both epitope 
accessibility and antibody affinity play a role in determining the threshold required for 
neutralization (Figure 1-7).  
 Epitope accessibility refers to the number of epitopes available for binding by an 
antibody on a virions surface. This availability can be influenced by factors such as virion 
structure, size, structural dynamics and different oligomeric states of the virion (Dowd & 
Pierson, 2011). For example, broadly neutralizing MAb 2H12 binds to a conserved epitope on 
EDIII that is only accessible following a conformational change of DENV E proteins at 370C 
(Midgley et al, 2012). mAb 1A1D2 is another antibody which binds to hidden epitopes in 
EDIII that is only exposed at 370C (Lok et al, 2008). Antibody affinity on the other hand refers 
to the number of epitopes bound by antibodies under non-saturating conditions. In vitro, 
varying neutralizing activity of an antibody against different strains of DENV in the same 
serotype has been attributed to difference in antibody affinity (Sukupolvi-Petty et al, 2010). 
 Collectively, this suggest that an antibody which binds with high affinity will not be 
able to neutralize unless the number of epitopes accessible exceeds the threshold required for 
neutralization. Similarly, an antibody with low affinity will be able to neutralize a virion as 
long as enough epitopes are accessible for binding (Wahala & Silva, 2011). 
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Figure 1-7: Epitope accessibility and occupancy requirements are determinants of 
neutralization.  
According to the multiple hit hypotheses, poorly accessible epitopes must be engaged 
at high occupancy to achieve neutralization. Conversely, highly accessible epitopes 
supports neutralization following engagement at low occupancy. Image adapted from 
Diamond and Pierson, 2008 (Diamond et al, 2008). 
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Mechanisms of DENV neutralization 	
Antibody mediated neutralization of DENV neutralization occurs either by  (1) inhibiting viral 
internalization (Crill & Roehrig, 2001) or (2) inhibiting viral fusion (Gollins & Porterfield, 
1986) (Figure1-8). Many potent neutralizing antibodies mediate neutralization by blocking the 
interaction between the virion and host cellular receptors that is needed for virus entry into the 
target cell. For example, CD4BS antibodies bind to gp120 protein on the surface of human 
immunodeficiency virus (HIV), preventing it from binding to host cell chemokine receptors 
required for internalization	(Raja et al, 2003). Other examples of neutralizing antibodies that 
prevent conformational changes in host cell receptors required for virus entry has been shown 
for influenza virus (Kida et al, 1985), poliovirus (Emini et al, 1983), rabies virus (Raux et al, 
1995) and adenovirus (Wohlfart, 1988). However, using antibodies to block attachment of 
DENV is insufficient as DENV can alternatively enter FcγR bearing cells via FcγR mediated 
phagocytosis, which is independent of EDIII activity. This suggests that inhibiting viral fusion 
could be a more effective mechanism of neutralization.  
 Antibodies that mediate neutralization by inhibiting viral fusion prevent DENV from 
fusing with the endosomal membrane (Fibriansah et al, 2015a). This renders the virion unable 
to release its genome into the cytoplasm for replication. With the inability to escape from the 
phagosomal pathway, the virion is destined for degradation in the phagolysosome upon 
exposure to lysosomal hydrolases	(Acosta et al, 2012). While most neutralization assays utilize 
epithelial cells, the main targets of DENV infection are FcγR bearing cells such as monocytes. 
In neutralization assays using monocytic cells, serotype specific antibodies neutralize DENV 
in this manner; at levels that permit DENV immune complex phagocytosis but inhibit 
intracellular viral fusion with host endosomal membranes (Wu et al, 2012; Chan et al, 2011). 
Cross reactive antibodies, however, appear unable to inhibit DENV infection in the presence of 
FcγR-mediated uptake and only neutralizes DENV at high antibody concentrations that form 
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viral aggregates that co-ligate the inhibitory FcγRIIB to inhibit phagocytosis (Chan et al, 2011; 
Wu et al, 2012). Knockdown of FcγRIIB increases the cross-reactive antibody concentration 
needed for DENV neutralization (Chan et al, 2011) whereas silencing FcγRIIA reduces the 
amount of cross reactive antibodies needed to inhibit DENV infection (Chawla et al, 2013). 
Therefore, just as types of antibodies affect neutralization, changes in the surface expression of 
FcγRs will likewise affect the mechanism of neutralization.  
 
Non-neutralizing antibodies to DENV 	
The majority of antibodies produced following DENV infection are weakly neutralizing, cross-
reactive and target E, prM and NS1 proteins (Beltramello et al, 2010; de Alwis et al, 2011; 
Dejnirattisai et al, 2010; Smith et al, 2012). In both in vitro and in vivo mouse models, these 
cross-reactive antibodies have been shown to increase internalization and infection of DENV 
in activating FcγR bearing cells via ADE (de Alwis et al, 2014; Dejnirattisai et al, 2010; 
Beltramello et al, 2010), which will be further discussed in later sections.  
 Cross reactive DENV antibodies have been shown to enhance viremia and lethality in 
AG129 mouse models (Zellweger et al, 2010; Balsitis et al, 2010). For example, MAb DD11-4 
and DD18-5, which are antibodies targeting EDII generated against DENV4, exhibited 
enhanced mortality in AG129 mice (Tang et al, 2015).  Structural studies on WNV suggest 
that cross reactive antibodies targeting EDII bind with higher affinity to immature or partially 
immature virions as compared to mature ones (Cherrier et al, 2009), leading to increased 
chances of ADE. In influenza infections, the dominant production of these cross-reactive 
antibodies in response to infection results in competition with neutralizing antibodies that 
recognize similar epitopes, thus leading to steric interference and consequently leading to 
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 Antibodies against DENV prM are poorly neutralizing antibodies but commonly 
found in the sera of DENV patients. In vitro, approximately 30% of progeny viruses are prM-
containing immature particles (van der Schaar et al, 2007; Zybert et al, 2008). These non-
infectious immature DENV, when bound to anti-prM antibodies, are internalized into myeloid 
cells via FcγR. This alternative entry pathway allows fully immature and non-infectious 
DENV to become infectious in the presence of anti-prM antibodies (Rodenhuis-Zybert et al, 
2010). From a panel of prM monoclonal antibodies collected from individuals infected with 
DENV, Smith and colleagues proposed that an immunodominant region exist on the prM 
protein, suggesting that recognition of any epitope within this major antigenic site is sufficient 
to result in ADE	(Smith et al, 2015).  However, in a recent study involving sera collected from 
30 acute DENV2 patients, no observed correlation between the amount of antibodies against 
immature virions and disease severity was found (Rodenhuis-Zybert et al, 2015). From these 
results, further investigation into the role of anti-prM antibodies in the course of DENV 
infection in human is required.   
 In addition to structural proteins, non-neutralizing antibodies can also be raised 
against NS1, a secreted glycoprotein that accumulates in sera and on plasma membranes of 
cells during infection (Avirutnan et al, 2007). Patients with DHF has been shown to have 
higher levels of NS1 as compared to patients with DF (Libraty et al, 2002). In addition, anti-
NS1 antibodies can bind to NS1 anchored on cellular membrane, triggering signal 
transductions that potentially affects DENV replication (Jacobs et al, 2000).  
 Collectively, it is clear that the antibody response to DENV infections have both 
protective and pathogenic roles. Therefore a clearer understanding of the roles of antibodies 
and the host response is imperative to the development of vaccines and antibody therapeutics 
for dengue.    
ADE (Ndifon et al, 2009).  




Neutralization of DENV in FcγR bearing cells occurs either by inhibition of virus 
internalization or uncoating. Cross-reactive antibodies mediate neutralization at levels that 
form viral aggregates and engaging the inhibitory receptor FcγRIIB to prevent phagocytosis of 
the immune complex. Serotype specific antibodies are able to mediate intracellular 
neutralization by preventing viral fusion with the host endosomal membrane for viral 
uncoating. This ultimately results in phagosomal degradation of the virion. Figure adapted 
from Chan et al, 2013 (Chan et al, 2013).   
Figure 1-8: Mechanisms of DENV neutralization.  
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1.2.3 Antibody dependent enhancement (ADE) of DENV infections 
Antibodies raised following DENV infections are potentially double-edged swords. While 
serotype specific antibodies can confer lifelong protection, cross-reactive antibodies offers 
only short-term protection against heterologous serotypes for approximately 3-6 months. 
Albert Sabin, during world war II, conducted human challenge studies in hopes of developing 
a DENV vaccine and relevant diagnostic tools. He noticed complete protection in the human 
volunteers re-infected with the same DENV strain. However, immunity to heterologous strains 
of DENV was observed only up till 2 months post infection with significant individual 
variation (Sabin, 1952). Upon recent review of Sabin’s original notebooks, it was interesting to 
note that patients with secondary infections had a shorter incubation period (3-5 days) as 
compared to patients with primary infections (Snow et al, 2014). Although no enhancement of 
disease was observed, it does suggest that cross-reactive antibodies potentially mediate a more 
efficient DENV infection. ADE, supported by evidence from epidemiological, in vitro, in vivo 
animal models and recently been demonstrated clinically (Chan et al, 2016), has been used to 
explain this observation. 
 Epidemiological evidence has widely correlated secondary infections to higher risk 
(15-80 times) of severe clinical disease (Guzman et al, 2013). Studies in Thailand observed 
that DHF/DSS occurrences peaked in (1) infants with dengue immune mothers and (2) 
children with a secondary DENV infection of a different serotype (Halstead, 1970; Halstead et 
al, 1970). Both suggest that heterologous secondary infections result in more severe disease. 
These observations were independently observed in Cuba, which had a DENV1 epidemic in 
1977 followed by a DENV2 epidemic in 1981. Of the 300,000 cases, 10000 severe cases and 
158 fatalities, 98% of DHF cases were shown to have secondary infections in the sequence of 
DENV1/DENV2 (Kouri et al, 1989). Furthermore, DHF/DSS were not observed in children 
born after the 1977 DENV1 epidemic since that they were only at risk for a primary DENV 
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infection (Guzman et al, 1987). The 1997 (DENV2) and 2001-2002 (DENV3) epidemics in 
Cuba also pointed towards secondary infections being a major risk factor for severe dengue 
(Guzman et al, 2000; Valdéez et al, 1997; Kouri et al, 1998; González et al, 2005; Peláez et al, 
2004). This epidemiological correlation was also observed in prospective studies in Sri Lanka 
(Malavige et al, 2006) and travellers in the European Network on Surveillance of Imported 
Infectious Diseases (Wichmann et al, 2007). 
 The association between ADE and severe clinical disease of dengue was uniquely 
demonstrated when infants, born to dengue immune mothers, exhibited DHF following a 
primary DENV infection. While infection with a heterologous DENV serotype can trigger 
cross reactive responses from both T and B cells in young children and adults, only maternal 
antibodies but not T cells, can cross the placenta. In these infants, the decay of maternally 
transferred IgG antibodies presents a window of opportunity in which the infant possesses sub-
neutralizing levels of antibodies capable of ADE (Simmons et al, 2007; Perret et al, 2005). The 
first experimental model to test the role of maternally acquired antibodies in dengue disease 
was performed by Ng and colleagues. Adult female AG129 mice infected with DENV1 were 
allowed to recover prior to mating with naïve AG129 adult males. 5-week-old mice from 
DENV1 immune mothers infected with DENV2 died earlier then control mice, displayed 
higher viremia and increased vascular leakage. However, at 2 weeks old, the mice were 
protected from DENV2 infection. This data supports the epidemiological evidence that 
maternal antibodies against DENV initially provide pan-serotypic protection. As the level of 
antibodies wane over time, maternal antibodies are no longer able to neutralize DENV and 
instead enhances heterologous DENV(Ng et al, 2014a). In addition, a recent study 
demonstrated that due to the high levels of sequence and structural homology of DENV and 
Zika, sera from nine Thai patients previously infected with DENV was able to enhance Zika 
infection in vitro (Priyamvada et al, 2016).    
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 Conversely, studies have also shown that only a small subset of dengue patients 
with secondary heterologous infections exhibit severe symptoms (Olkowski et al, 2013; 
Thanachartwet et al, 2015; Watts et al, 1999). This is exemplified by reintroduction of DENV1 
to Iquitos, Peru, in 1990 following the reintroduction of the Aedes aegypti.  Longitudinal 
prospective studies began in 1993 in anticipation of the introduction of DENV2 from South 
America, and indeed secondary infections during the DENV2 epidemic in 1995 did not result 
in DHF/DSS (Watts et al, 1999; Kochel et al, 2002). The authors postulate that DENV1 
antibodies from the previous infection instead of causing ADE, aided in neutralization of the 
specific strain of DENV2 introduced into Iquitos, Peru. Indeed, the authors demonstrated that 
convalescent serum from DENV1 infection were able to neutralize the American DENV2 
more efficiently then Asian DENV2. This could account for the lack of severe disease 
following secondary American DENV2 genotype infection in Iquitos in 1995 (Kochel et al, 
2002). Another prospective study conducted at the Mahidol University in Bangkok, Thailand 
recruited a small cohort of 153 patients and found no association between secondary 
heterotypic infections and clinically severe dengue disease (Thanachartwet et al, 2015).  
 All the above studies, however, were epidemiological and clinical observations 
supporting ADE and were hence not gold-standard evidence. To address the clinical 
authenticty of ADE experimentally, a recent clinical trial utilizing two licensed vaccines 
against JEV (lxiaro) and YF (Stamaril) showed cross-reactive JEV antibodies augment 
immunogenicity by enhancing the live attenuated YF vaccine infection in antigen presenting 
cells (Chan et al, 2016). The authors showed that enhanced YF infection led to prolonged 
viremia, increased production of pro-inflammatory lipids and metabolites and increased 
semaphorin expression induced by FcγR signaling. Interestingly the enhancement was only 
observed within a limited range, which is likely due to the stoichiometric requirements for 
optimal co-ligation of FcγR. Low titers of cross-reactive antibodies result in sub-optimal 
  30 
ligation of FcγR. High titers of antibodies will result in aggregation of immune complexes, 
leading to the co-ligation of inhibitory FcγRIIB (Chan et al, 2016; 2011). The results from this 
clinical trial suggests that ADE is not the result of increased infection of FcγR cells, but rather 
a sustained infection that leads to prolonged viremia. As enhancement was only observed in 
the presence of a limited range of cross reactive antibodies, it possibly explains why only a 
small subset of patients infected with secondary heterologous DENV develop severe disease.   
 Given the importance antibodies play in both protection from and enhancement of 
DENV infection, understanding the function and regulation of FcγRs is important to defining 
dengue pathogenesis. Therefore any physiological factor that influences the expression of 
FcγRs is essential for our understanding of DENV infections.  
  





Figure 1-9: Model of antibody dependent enhancement.  
ADE is hypothesized to occur when sub-neutralizing antibodies from a previous infection or 
from maternal transfer binds to DENV but is unable to neutralize the virion. These antibody-
opsonized DENV immune complexes then infect FcγR bearing cells, resulting in increased 
viral load and postulated severe disease. Figure adapted from Whitehead et al, 2007 
(Whitehead et al, 2007). 
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1.3 FcγR role in DENV neutralization and enhancement 
1.3.1 Family of FcγR 
FcγR is the family of cell surface Fc receptors that binds the Fc regions of IgG antibodies. 
They are widely expressed throughout the heamatopoietic system and are primarily responsible 
for maintaining a well-balanced immune response by setting thresholds for cell activation 
through simultaneous activating and inhibitory signaling pathways (Guilliams et al, 2014a). 
This then allows for fine-tuning of the host response to pathogens. Primates have a complex 
Fc𝛄R system, which consists of Fc𝛄RI (FcγRIA, FcγRIB, FcγRIC), FcγRII (FcγRIIA, 
FcγRIIBI, FcγRIIBII, FcγRIIBIII, FcγRIIIC) and FcγRIII (FcγRIIIA, FcγRIIIB). Human FcγR 
can be classified into 2 broad categories; activating (FcγRI, FcγRIIA, FcγRIIC, FcγRIIIA and 
FcγRIIIB) and inhibitory (FcγRIIB) (Figure 1-10). Each FcγR differs in function, expression, 
affinity to antibody Fc regions and the signaling pathway they induce (Nimmerjahn & 
Ravetch, 2008; Smith & Clatworthy, 2010).  
 FcγRI is the only activating receptor with high affinity for monomeric IgG. It is 
expressed broadly in human cells such as monocytes, dendritic cells, macrophages, neutrophils 
and eosinophils (Bruhns, 2012). FcγRIIA, FcγRIIC, FcγRIIIA, FcγRIIIB and FcγRIIB are low 
affinity receptors, which bind to immune-complexed IgG (Maenaka et al, 2001). Immune cells 
such as natural killer (NK) cells only express activating FcγRIII (Trinchieri & Valiante, 1992) 
and B cells only express inhibitory FcγRIIB (Tackenberg et al, 2009). As majority of 
monocytes, DC and macrophages only express FcγRI, FcγRIIA and FcγRIIB (Guilliams et al, 
2014b), they are the main FcγRs with the most impact on DENV neutralization and ADE 
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(Rodrigo et al, 2006; Chawla et al, 2013). It has recently been suggested that DENV infection 
stimulates the expansion of FcγRIII bearing monocytes for plasmablast differentiation (Kwissa 
et al, 2014). FcγRIII has also been postulated to play a pro-inflammatory role during DENV 
infection by stimulating release of cytokines such as TNFα, CCL2, CCL3 and CLL4 (Wong et 
al, 2012). However, as only 10% of healthy monocytes express FcγRIII, it is unlikely to play a 
major role in DENV pathogenesis (van de Winkel & Anderson, 1991).   
 The physiological role of FcγRs in phagocytes is to clear immune complexes from 
the blood circulation either by FcγR mediated endocytosis or phagocytosis. The engagement of 
FcγRs trigger membrane ruffling and the formation of actin protrusions that aids in 
phagocytosis of immune complexes (Ayala-Nunez et al, 2016). More importantly, binding of 
IgG to FcγRI results in the phosphorylation of tyrosine in its accessory immunoreceptor 
tyrosine-based activating motifs (ITAMs) bearing gamma chain to induce signal transduction 
(Isakov, 1997). FcγRIIA circumvents the need for the gamma chain with an internal ITAM 
motif in its cytoplasmic domain. Upon ITAM phosphorylation, protein and lipid kinases such 
as proto-oncogene tyrosine-protein kinase (src) and spleen tyrosine kinase (Syk) are recruited 
and activated (Lowell, 2011). Fyn, Hck, Lyn, Yes, Src are members of the Src tyrosine-kinase 
family that are postulated to be essential for early phosphorylation events post FcγR 
engagement, in addition to increasing the synthesis of signalling molecules such as 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3), phosphatidylinositol 4,5-bisphosphate 
(PI(4,5)P2) and diacylglycerol (DAG) (Ibarrola et al, 1997; Ezumi et al, 1998; Ghazizadeh et 
al, 1994). Phosphorylated ITAM enables the docking, phosphorylation and subsequent 
activation of Syk, which activates signalling cascades involving phosphoinositide 3-kinase 
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(PI3K), phosphoinositide phospholipase C (PLC), phospholipase D (PLD) and protein kinase 
C (PKC) (Melendez et al, 1999; Rankin et al, 1993). These signaling events allows for 
phagocytosis of DENV immune complexes which, depending on the characteristics of the 
antibody, may either lead to neutralization or enhancement of DENV.  
 Engagement of inhibitory FcγRIIB leads to the phosphorylation of immunoreceptor 
tyrosine-based inhibitory motif (ITIM) in its cytoplasmic domain, which instead recruits 
phosphatases Src homology region 2 domain containing phosphatase-1 (SHP-1) and 
phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 (SHIP-1) to shut down signaling 
mediated by activating FcγR (Daëron et al, 1995). This essentially inhibits FcγR mediated 
phagocytosis, which leads to neutralization of DENV immune complexes (Huang et al, 2003; 
Chan et al, 2014). Boonnak and colleagues attributed the inhibitory activity of Fc𝛄RIIB to its 
ITIM tail as compared to activating FcγR, which have an ITAM tail. When ITAM and ITIM 
tails of FcγRIIA and FcγRIIB were swapped (FcγRIIA-ITIM and FcγRIIB-ITAM), the authors 
showed no change in the binding of immune complexes to each FcγR. However, ADE was 
observed in FcγRIIB-ITAM and not FcγRIIA-ITIM, clearly demonstrating that the activity of 
activating FcγR is dependent on ITAM and its resulting signaling cascades (Boonnak et al, 
2013).    
 Collectively, it is clear that the balance between activating and inhibitory signals 
from FcγR can play a major determining role in either neutralization of enhancement of DENV 
immune complexes.   
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Figure 1-10: Family of FcγRs.  
FcγRs differ in cellular expression, structure, signaling pathways and binding affinity to IgG. 
They are classified into two categories – activating (FcγRI, FcγRIIA, FcγRIIC, FcγRIIIA, 
FcγRIIIB) and inhibitory receptors (FcγRIIB). All activating FcγRs signal through an ITAM 
tail in the common γ chain. FcγRIIA and FcγRIIC do not require the γ chain as they have an 
ITAM in its cytoplasmic domain. Inhibitory FcγRIIB signals through the ITIM motif in its 
cytoplasmic tail to counteract activating FcγR signaling. Figure adapted from Smith and 
Clathworthy, 2010 (Smith & Clatworthy, 2010).   
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1.3.2 Role of FcγRs in DENV neutralization 
Several studies have focused on how antibodies mediated neutralization of virions by 
preventing viral attachment to target host cell receptors (Fibriansah et al, 2015b; 2015a; Lok et 
al, 2008; Rouvinski et al, 2015). However, recent works have highlighted the role of activating 
and inhibitory FcγRs in DENV neutralization.  
 Indeed, studies have shown that the type of FcγR affects the stoichiometry of 
antibodies required for neutralizing DENV. Rodrigo et al showed, using CV-1 cells transfected 
to express either FcγRI or FcγRIIA, that the lower affinity FcγRIIA required more antibodies 
for neutralization (Rodrigo et al, 2009). As CV-1 cells do not naturally express FcγRs and may 
not be an accurate representation of FcγR function, a follow up study performed by Chawla et 
al used THP-1 and K562 cells that naturally expressed FcγRs. K562, which are deficient in 
FcγRI required 4 fold more antibodies for DENV neutralization as compared to THP-1 cells, 
which expresses both FcγRI and FcγRIIA (Chawla et al, 2013). The molecular mechanism for 
the difference in antibody stoichiometry required for neutralization has not been fully 
elucidated. Engagement of FcγRI was shown to trigger PLD-SPHK signaling which induces 
trafficking to late endosomes and lysosomes for degradation and subsequent antigen 
presentation (Dai et al, 2009). FcγRIIA mediated phagocytosis however activates 
phospholipase C-gamma-1, which result in immune complex trafficking to compartments that 
conversely impaired pro-inflammatory cytokine responses and antigen presentation (Dai et al, 
2009).  
 Mechanistically, neutralization mediated by serotype specific and cross reactive 
antibodies in FcγR bearing cells are generally different (Wu et al, 2012). Using convalescent 
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sera from dengue infected patients, Chan and colleagues observed that neutralization by 
serotype specific antibodies occurred despite FcγR mediated internalization of DENV immune 
complexes. Unlike serotype specific antibodies, neutralization by cross reactive antibodies 
occurred in the absence of internalization. The authors showed that cross reactive antibodies 
form large aggregates with DENV and co-ligates inhibitory FcγRIIB to prevent phagocytosis, 
resulting in neutralization (Chan et al, 2011). Thus the presence of FcγRs could be an 
important feature to distinguish between serotype specific and cross-reactive antibodies. Using 
this strategy in a blinded experiment using 30 convalescent sera from DENV infection patients, 
Wu et al correctly identified the serotype of infection in 93.3% of cases as compared to 76.7% 
using traditional PRNT methods (Low et al, 2006; Wu et al, 2012). As serotype specific 
antibodies mediate long-term protection and cross-reactive antibodies generally only provide 
short-term protection, the ability to better distinguish between the 2 is essential for assessing 
protective immunity. With the current knowledge of the role of FcγRs in DENV neutralization, 
it has become increasingly clear that traditional methods of measuring DENV neutralization 
with protective antibodies in non-FcγR bearing cells are inadequate.   
 
1.3.3 Role of FcγR in ADE 
At sub-neutralizing antibody levels, DENV immune complexes interact with FcγRs, resulting 
in enhancement of infection. This was demonstrated when FcγRs blocked with monoclonal 
antibodies in peripheral blood mononuclear cells (PBMC) resulted in reduced ADE (Boonnak 
et al, 2011). Additionally, antibody-opsonized DENV infection of COS cells expressing either 
FcγRI or FcγRIIA suggests that FcγRIIA mediates ADE more efficiently compared to FcγRI 
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(Boonnak et al, 2013). This observation may be attributed to differences in FcγRI and 
FcγRIIA phagocytosis pathways. In THP-1 cells, DENV immune complexes are trafficked to 
compartments that promote viral degradation, however those that are internalized by FcγRIIA 
end up in compartments that promote viral replication (Chawla et al, 2013).  
 However, whether FcγR directly mediates internalization of DENV immune 
complexes or only serves to concentrate the virus on cellular surface still remains to be solved 
(Ayala-Nunez et al, 2016; Mady et al, 1991; Chotiwan et al, 2014). Using CV-1 cells 
transfected with FcγRIIA, Chotiwan et al did not observe any enhancement under ADE 
conditions. In addition, 4G2 opsonized DENV with triple mutations in the E protein did not 
result in ADE. This inability to bypass the viral attachment defect suggests that the E protein 
of DENV is still required to interact with the host receptors to permit endocytosis (Chotiwan et 
al, 2014). However, as CV-1 does not naturally express FcγRs, it is possible that downstream 
mediators required for ADE may not be intact, thus resulting in the lack of enhancement. 
Additionally, as the authors did not visualize DENV immune complexes interaction with 
FcγRIIA on the host cell surface, this explanation still remains to be confirmed.  
 It is clear that FcγRs play an important in both neutralization and enhancement of 
DENV. Therefore any factor that alters its expression may potentially affect DENV infections. 
One factor that has been consistently overlooked is the physiological conditions of lymphoid 
organs in which DENV infection and replication occurs. 
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1.4 Microenvironment of DENV infection in organs 
1.4.1 DENV organ tropism 
Upon subcutaneous inoculation of DENV into the skin by mosquitoes, DENV encounters and 
infects several cell types such as langerhan cells (Wu et al, 2000; Limon-Flores et al, 2005), 
keratinocytes (Limon-Flores et al, 2005), monocytes (Durbin et al, 2008), dendritic cells (DC) 
(Tassaneetrithep et al, 2003; Schmid & Harris, 2014), macrophages (Miller et al, 2008) and 
mast cells (St John et al, 2011). DENV infections in the skin and the site of inoculation has not 
been well characterized, instead, research has focused on identifying cells that permit DENV 
replication at sites of viral dissemination after inoculation.  
 In both animal models and human post mortem analysis, DENV antigens have been 
detected in lymphoid organs such as the lymph nodes (Balsitis et al, 2009; Jessie et al, 2004; 
Basílio-de-Oliveira et al, 2005), spleen (Balsitis et al, 2009; Blackley et al, 2007; Basílio-de-
Oliveira et al, 2005; Jessie et al, 2004) and liver (Balsitis et al, 2009; Basílio-de-Oliveira et al, 
2005; Jessie et al, 2004) where immune cells such as monocytes and macrophages are targets 
of infection and dissemination of the virus (Marchette et al, 1973; Prestwood et al, 2012; 
Nisalak et al, 1970). In addition, DENV has also been found in the bone marrow (Balsitis et al, 
2009; Jessie et al, 2004), kidneys (Basílio-de-Oliveira et al, 2005; Jessie et al, 2004), lungs 
(Balsitis et al, 2009; Jessie et al, 2004), thymus (Killen & O'Sullivan, 1993) and brains 
(Miagostovich et al, 1997). Although multiple organs are susceptible to DENV infection, the 
primary site of replication and dissemination of the virus has been shown in mice to be the 
draining lymph nodes (Prestwood et al, 2012). This is essential as while immune cells can host 
DENV replication, they are also responsible for mounting an immune response for viral 
clearance. Primary infections require more time to mount an adaptive immune response 
consisting of both B and T cell activity. However, having already been exposed to the virus, 
secondary infections rely on neutralizing antibodies for early protection (St John et al, 2013).  
  40 
1.4.2 Physiological oxygen tensions in organs 
Oxygen is vital for all living cells and is the basic component of the cellular microenvironment 
that is required for activity and survival. While in vitro experiments are conducted in 
atmospheric air, which has an approximate 20% O2  tension, it is interesting to note that site of 
active DENV replication such as the lymph nodes, spleen and liver (Nisalak et al, 1970; 
Balsitis et al, 2009; Basílio-de-Oliveira et al, 2005) have oxygen microenvironment that are 
substantially lower than that of atmospheric oxygen (Caldwell & Wittenberg, 1974; Caldwell 
et al, 2001).  
 Due to its poor solubility in liquids, oxygen is transported around the body by 
hemoglobin in red blood cells. Each hemoglobin molecule carries up to a maximum of 4 
oxygen molecules with its affinity for each oxygen molecule increases as each of its binding 
sites is occupied. Oxygen delivery in the human respiratory system depends on several factors 
such as the partial pressure of oxygen, efficiency of gas exchange, concentration and affinity of 
hemoglobin to oxygen and cardiac output (Law & Bukwirwa, 1999). The highest O2 
concentration typically starts in the respiratory tract, diffuses to alveolar gas, arterial blood, 
host cells and finally, where it reaches its lowest level of O2 tension, mitochondria, where is it 
used to make energy. Coined as the “oxygen cascade”, the decrease in oxygen tension from 
atmospheric air to its cellular destination is largely due to vascular anatomy (Habler & 
Messmer, 1997) (Figure 1-13).  
 As respired air enters the trachea and subsequently the alveoli, oxygen concentration 
lowers due to humidity and dilution with carbon dioxide (Law & Bukwirwa, 1999). Further 
dilution occurs as oxygen diffuses in and out of arteries. For example, Caldwell and colleagues 
showed in spleens that oxygen concentrations are higher nearest the splenic artery compared to 
more distant locations (Caldwell et al, 2001). The physiological oxygen microenvironment of 
lymphoid organs have been estimated to be between 0.5% - 4.5% O2 (Caldwell et al, 2001; 
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Carreau et al, 2011).  
 It is apparent that atmospheric oxygen concentration, in which most DENV 
experiments are conducted, is significantly higher than physiological oxygen tension in organs. 
It is therefore imperative to understand how cells adapt to physiological oxygen tensions in 
order to better mimic an in vivo environment.   
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Partial pressure of oxygen decreases from the levels in atmospheric air down to the levels in 
mitochondira.  Conversion of partial pressure to percentage concentration is calculated by 
1mmHg = 7.6% O2 (1mmHg = 133.322Pa, 1% O2  = 1.013kPa). PiO2: partial pressure of 
oxygen in air. PAO2: alveolar PiO2. PaO2: arterial PiO2. Figure adapted from Habler et al, 
1997(Habler & Messmer, 1997). 
Figure 1-11: Summary of the oxygen cascade.  
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1.4.3 Molecular mechanisms of oxygen sensing 
 
Essential cellular survival pathways such as metabolism, cholesterol synthesis and signaling 
are heavily dependent on the consumption of oxygen. A hypoxic cellular environment occurs 
when O2 supplied to cells falls short of the required O2 consumption. Depending on the degree 
of decrease in O2 supply, hypoxia can lead to the collapse of aerobic metabolism, adenosine 
triphosphate (ATP) production and subsequently result in cellular death (Miriam J 
Schönenberger, 2015).  
 During O2 deficiency, cells regulate their gene expression to adapt and survive. For 
example, the adaptation to low oxygen environments induces genes that control angiogenesis, 
iron metabolism and drive the cell to rely on glycolysis instead of oxidative phosphorylation to 
produce ATP (Ke & Costa, 2006). The earliest observation of this phenomenon is the 
upregulation of erythropoietin (EPO) in response to hypoxia to stimulate the proliferation of 
red blood cells. Subsequent analysis of the cis-acting sequences that were required for the 
increase in transcription of EPO under hypoxic conditions, led to a cascade of studies that 
identified (Semenza & Wang, 1992), purified (Wang & Semenza, 1995), molecularly cloned 
(Wang et al, 1995) and characterized the master transcription factor of hypoxia – hypoxia 
inducible factor (HIF).  
 
The HIF family 	
HIF transcription factors are basic helix-loop-helix DNA binding proteins of the PER-ARNT-
SIM family (bHLH-PAS). Generally HIFs function as heterodimers –alpha subunits HIF1α, 
HIF2α, HIF3α (Semenza	&	Wang,	1992;	Gu	et	al,	1998;	Ema	et	al,	1997) and a 
constitutively expressed beta subunit HIF1β, also known as the aryl hydrocarbon receptor 
nuclear translocator 1 (ARNT1) (Wang & Semenza, 1993a). HIF1α and HIF2α are oxygen 
sensitive subunits that share 48% genetic sequence homology and similar function(Hellwig-
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Bürgel et al, 1999). Both dimerize with HIF1β during hypoxic conditions to induce gene 
transcription (Ema et al, 1997). HIF3α shares less sequence homology and function with 
HIF1α or HIF2α and itself has 6 splice variants (Gu et al, 1998). Interestingly HIF3α4, a 
variant of HIF3α, shows neither oxygen sensitivity nor transcriptional activity. Instead it acts 
as a negative regulator by sequestering HIF1α and preventing its heterodimerization with 
HIF1β to induce the hypoxic response (Makino et al, 2002; Maynard et al, 2003).  
 Both HIF1α and HIF2α proteins have multiple conserved domains involved in DNA 
binding (bHLH), protein interaction and dimerization (PAS), oxygen dependent degradation 
(ODD) and transcriptional activity (N-TAD and C-TAD). HIF3α isoforms are shorter and 
carry only an N-TAD domain together with a leucine zipper motif with unknown function 
(Maynard et al, 2003; Pasanen et al, 2010). HIF1β however carries no transcriptional 
activation domains (Figure 1-14). With 70%, 85% and 100% homology between their PAS, 
bHLH and remaining basic domains respectively, it is not surprising that HIF1α and HIF2α 
binds DNA indistinguishably (Tian et al, 1997). While extremely similar in both homology 
and function, there are subtle difference between HIF1α and HIF2α. The C-TAD domains of 
HIF1α and HIF2α controls target gene transcription through the recruitment of co-factors but 
target gene selectivity between the 2 proteins have been postulated to arise from the N-TAD 
domains which recognizes distinct transcriptional co-factors (Aprelikova et al, 2006; Hu et al, 
2007; Dayan et al, 2006; Ema et al, 1999).   
 Besides differences in protein domains, the expression of this protein is also different 
in different cells. HIF1α is expressed in almost all immune cell types including neutrophils 
(Walmsley et al, 2005), monocytes (Shalova et al, 2015; Bosco et al, 2006), macrophages 
(Cramer et al, 2003b), dendritic cells (Jantsch et al, 2008; Bosco et al, 2010) and lymphocytes 
(McNamee et al, 2013; Bollinger et al, 2016). HIF2α however is only expressed in certain cell 
types such as endothelial cells (Hu et al, 2003) and tumor associated macrophages (Imtiyaz et 
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al, 2010). As DENV has been shown to replicate in immune cells, this thesis will focus on the 
functions of HIF1α.         
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HIF proteins are composed of several domains that modulate protein-protein interaction and 
dimerization (PER-ARNT-SIM, PAS-A, PAS-B), DNA binding (basic helix-loop-helix, 
bHLH), oxygen-dependent degradation domains (ODD) and transcriptional activation (C-
TAD, N-TAD). The leucine zipper is only observed in HIF3. Stability and transcriptional 
activity of HIF is controlled by post-translational modifications, several of which are depicted 
along with the enzyme responsible for it. Positive regulations are denoted (+) and negative 
regulations with a (-). Figure adapted from Dengler et al, 2013(Dengler et al, 2013).  
 
  
Figure 1-12: The family of HIF protein domains and post-translational modifications.  
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Oxygen sensing mechanisms of HIF1a 	
HIF1α sensitivity to cellular oxygen tension is largely dependent on post-translational 
modifications that determine its fate. While HIF1α is constitutively expressed under normoxic 
conditions (~20% O2), it is highly regulated by oxygen and has a half-life of approximately 
5mins (Salceda & Caro, 1997). Sufficient O2 in the cellular environment will result in rapid 
proteasomal degradation of HIF1α in the cytoplasm (Ema et al, 1999).  
 In oxygen rich environments, a family of prolyl hydroxylase domains (PHD1-3) 
hydroxylate highly conserved proline residues (Pro402 and Pro564) in the ODD domain of 
HIF1α in an iron (Fe), α-ketogluterate, ascorbate and oxygen dependent manner (Masson et al, 
2001; Semenza, 2014) (Figure 1-14). This hydroxylation enables the binding of the von-hippel 
Lindeau (VHL) E3 ubiquitin ligase complex to HIF1α. Ubiquitination of HIF1α then initiates 
the process of proteasomal degradation. In addition to PHDs, an independent regulatory 
hydroxylation step by Factor Inhibiting HIF (FIH) hydroxylates an aspargine (Asn803) to 
interfere with HIF1α ability to recruit and bind to co-factors to its C-TAD domain (Dames et 
al, 2002; Freedman et al, 2003). Additional negative regulation of HIF1α occurs by acetylation 
of Lys532 by acetyl transferase arrest-defective 1 (ARD1) (Jeong et al, 2002), GSK3β 
phosphorylation of Ser551, Ser 558 and Ser559 (Mottet et al, 2003) and PLK3 
phosphorylation of Ser576 and Ser 659 (Xu et al, 2010) (Figure 1-14). All these contribute to 
HIF1α destabilization leading to proteasomal degradation of HIF1α, which prevents 
transcription of hypoxia inducible genes. Clinically, patients with von Hippel-Lindau 
syndrome, where VHL is defective, have an overproduction of hypoxia-inducible genes 
encoding for angiogenesis leading to the development of multiple tumors	(Rathmell	et	al,	2004) (Figure 1-15).  
 As PHD and FIH hydroxylation of HIF1α is oxygen dependent, a decrease in oxygen 
levels then leads to stabilization and nuclear translocation of HIF1α. This transport occurs 
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when importin-α binds to the nuclear localization signal in the C-terminal NLS of HIF1α, 
recruits importin-β and initiates nuclear translocation (Depping et al, 2008). In the nucleus, 
HIF1α forms a heterodimer with HIF1β. It has been postulated that HIF1β preferentially binds 
to HIF1α phosphorylated by MAPK (Suzuki et al, 2001), therefore increasing transcriptional 
activity of HIF1α (Richard & Gothie, 1999). However transcriptional activity requires N-TAD 
and C-TAD domains to recruit co-factors CBP/p300, SRC-1 and TIF2 to induce efficient 
transcription of target genes (Lando et al, 2002; Carrero et al, 2000). Through its interaction 
with CBP/p300, S-nitrosation on cysteine800 has also been shown to increase HIF1α 
transcription activity (Yasinska & Sumbayev, 2003). Other co-factors for HIF1α include 
pyruvate kinase M2 isoform (PMK2) (Luo et al, 2011) and mediator associated kinase CD8K 
(Galbraith et al, 2013), ATPase/helicase chromatin remodeling factor Pontin (RUVBL1) (Lee 
et al, 2011) and SWI/SNF nucleosome remodeling complex (Kenneth et al, 2009).  
 Transcription of hypoxia inducible genes occurs when HIF1α/HIF1β heterodimer bind 
to a core consensus sequence 5’– (A/G)CGTG –3’ within the hypoxia response element (HRE) 
at the proximal promoters of target genes (Schödel et al, 2011). Though the HRE sequence is 
abundant throughout the human genome, HIF1α only binds to approximately 1% of it (Schödel 
et al, 2011). In addition to the HRE, several HIF1α target genes contain a HIF anciliary 
sequence (HAS) 5’-CAGGT-3’, which is an imperfect inverted repeat of the HRE. Kimura et 
al showed that alteration of this sequence affects the HIF1α induced transcriptional activity of 
EPO (Kimura et al, 2000; 2001). Interestingly, HIF1α preferentially binds to HRE at regions 
of chromatin with DNaseI hypersensitivity, RNA polymerase II, basal transcriptional activity 
and histone modifications (Mole et al, 2009; Schödel et al, 2011; Xia & Kung, 2009). This 
may serve to explain why HIF1α has cell type specific activation of genes. 
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Oxygen independent stabilization of HIF1α 	
In addition to hypoxic conditions, several studies have shown that HIF1α can be stabilized 
under normoxic conditions by a variety of factors such as cytokines, growth factors and 
environmental stimuli. For example, insulin (Zelzer et al, 1998), insulin like growth factor I/II 
(IGF-I) (Zelzer et al, 1998; Feldser et al, 1999), interleukin-1β (IL1β), tumor necrosis factor α 
(TNFα) (Hellwig-Bürgel et al, 1999; Haddad & Land, 2001), thrombin, platelet derived 
growth factor AB (PDGF-AB) and transforming growth factor β1 (TGFβ1) (Görlach et al, 
2001) have all been shown to increase the transcriptional activity of HIF1α. IL1β works via by 
either inhibiting VHL dependent degradation of HIF1α or by activating NF-κβ through the 
PI3K/AKT/mTOR (Jung et al, 2003).  Interestingly, many of these pathways also stimulate the 
generation of reactive oxygen species (ROS).   
 Besides being an important effector of innate immune response, ROS has also been 
postulated to be an oxygen sensor. Several studies now suggest that ROS regulates the 
transcriptional activity of HIF1α under normoxic conditions. In human prostate cancer cells, 
this occurs in an adenosine monophosphate-activated protein kinase (AMPK) dependent 
manner (Jung et al, 2008). Bonello and colleagues demonstrated in pulmonary smooth muscle 
cells that thrombin treatment induced ROS production, which in turn led to the NF-κβ 
dependent increased transcription of HIF1α (Bonello et al, 2007). Conversely, other groups 
have reported contrary findings that ROS inhibits HIF1α activity (Fandrey et al, 1994). The 
mechanism of ROS stabilization or destabilization of HIF1α thus still remains controversial. 
Niecknig et al proposed that ROS induces a biphasic regulation of HIF1α, suggesting that 
shorter exposure to ROS increases HIF1α activity while longer exposures decreases it 
(Niecknig et al, 2012). NF-κβ, a key player in the innate immune system, has been implicated 
as a transcription factor of HIF1α. Using an in vivo mouse model, Rius and colleagues 
suggests that NF-κβ activity is required to maintain a concentration of HIF1α mRNA which 
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will enable the rapid accumulation of HIF1α protein under hypoxic conditions (Rius et al, 
2008).  
  There are several environmental regulators of HIF1α that have been exploited in in 
vitro experiments to study the role and function of the transcription factor. Iron is a key 
substrate for the activity of PHD to initiate the process of HIF1α degradation. Therefore 
decreasing cellular iron concentration with chemicals such as nickel (Ni2+) (Davidson et al, 
2005), cobalt (Co2+) (Yuan et al, 2003) and desferrioxamine (DFX) (Wang & Semenza, 1993c) 
will in turn result in its stabilization. Additionally, Co2+ and Ni2+ alternatively stabilizes HIF1α 
by downregulating the expression of FIH-1, ARD1 and depleting intracellular ascorbate (Ke et 
al, 2005).  
  While many oxygen independent factors have been shown to modulate HIF1α, the 
ability of proinflammatory cytokines and NF-κβ to induce HIF1α under normoxic conditions 
suggests that it may play a role in the immune responses and the inflammatory response.  
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HIF is the master regulator of the cellular hypoxic response. Under normoxic conditions (20% 
O2), HIF1α is hydroxylated in an oxygen dependent manner and tagged for degradation by 
VHL complexes. In low oxygen environments, HIF1α is stabilized due to the lack of O2, 
translocates to the nucleus and forms a heterodimer with HIF1β to activate transcription 
hypoxia inducible genes. Figure adapted from Simon, 2016 (Simon, 2016).   
  
Figure 1-13: The oxygen-sensing pathway of HIF.  
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1.4.4 HIF1α and the immune system 
 Immune cells traveling in the circulatory system are exposed to a gradient of oxygen 
concentrations in the blood, organs and areas of inflammation. HIF1α has been implicated in 
all facets of the immune response including inflammation, responses to bacterial and viral 
infections, immune cell metabolism, DC antigen presentation and lymphoid cell development 
(Palazon et al, 2014). It is therefore essential for immune cells such as monocytes, 
macrophages and dendritic cells to rapidly adapt to fluctuating oxygen microenvironments.      
 
Hypoxia / HIF1α role in monocytes 	
 In an attempt to elucidate the transcriptomic changes induced in monocytes exposed 
to hypoxia, Bosco et al performed a full genome microarray on monocytes obtained from 15 
independent donors cultured under hypoxic conditions (1% O2, 16h) (Bosco et al, 2006). As 
previously observed, genes involved in glycolytic metabolism and glucose transport were 
induced in hypoxia by HIF1α (Zhang et al, 1999; Wood et al, 2007). Gene ontology (GO) data 
mining determined biological processes relating to cell growth, protein metabolism and signal 
transduction were most enriched transcriptionally in both up and down regulated genes. 
Importantly, the profile from hypoxic monocytes revealed a trend towards immunity and 
inflammation. Enriched genes coded for response to external stimulus, immune response and 
cell-to-cell signaling (Bosco et al, 2006). The authors also showed that in monocytes, hypoxia 
modulates members of the toll-like receptor family (TLR5, TLR7), FcγR family (FcγRI, 
FcγRIIA, FcγRIIB) and CCL20, which play an important role in the immune response. Other 
studies have also observed the regulation of inflammatory genes such as COX-2(Demasi et al, 
2003).  
 Clinically, HIF1α activity in monocytes and macrophages has been implicated in 
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inflammatory diseases such as rheumatoid arthritis, atherosclerosis and sepsis. Recently, in a 
human sepsis model, it was suggested that HIF1α plays an immunosuppressive role in the 
functional re-programming of human monocytes. Exposure to endotoxins led to the 
stabilization and activation of HIF1α. This thus drives the cells into a endotoxin-tolerant state 
by increasing the expression of IRAKM (negative regulator of TLR) and downregulating the 
expression of proinflammatory cytokines (TNF, IL6) (Shalova et al, 2015).  
 While hypoxia and its major transcriptional factor HIF1α clearly plays a role in 
immune cell regulation, more studies are required to fully elucidate the impact of HIF1α 
activity.  
 
Hypoxia / HIF1α and human viral infections 	
Human viral infections are affected by oxygen in different ways. Generally, viruses that 
naturally infect and replicate in tissues with high oxygen content is impaired by hypoxia. 
Conversely, hypoxia has been shown to increase the infection of viruses that naturally infect 
organs with lower oxygen tensions.  
 For example, adenoviruses naturally infect well-oxygenated organs (Straus, 1984). In 
tumors, they are found in close proximity to vasculature (Sauthoff et al, 2004), which suggest 
that oxygen is required for its survival. Indeed significantly lower synthesis of adenovirus 
(Ad309) viral protein were observed when cells were cultured at 1% O2. This ultimately led to 
lower production of infectious Ad309 (Pipiya et al, 2005). Similar phenotypes were observed 
with oxygen dependent replication of influenza (Magill & Francis, 1936) and simian virus 40 
(SV40). Hypoxia blocks the unwinding of the SV40 origin, which is required for its 
replication, thus leading to abrogation of its replication (Riedinger et al, 1999).       
 Conversely, low oxygen levels are advantages to a number of viruses. For instance, 
hypoxia enhances the replication and promotes a sustained infection of hepatitis C virus 
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(HCV). This phenotype was observed to be independent of the HIF1α pathway and instead 
reliant on the activation of oncolytic genes such as AKT, FOS and Myc (Vassilaki et al, 2013). 
Uniquely, Kaposi’s sarcoma-associated herpesvirus (KSHV) was the first virus identified to 
have a functional HRE in its Rta gene. As activation of Rta results in induction of the lytic 
replication of the virus, this suggests that hypoxia can directly stimulate KSHV replication via 
HIF1α (Haque et al, 2003). In addition to taking advantage of the cellular hypoxic response, 
pathogens such as Vaccinia virus (Mazzon et al, 2013), Epstein-Barr virus (Wakisaka et al, 
2004) and Hepatitis B virus (Yoo et al, 2003) have been shown to stabilize HIF1α after 
infection to stimulate the transcription of hypoxia inducible genes in the absence of hypoxia.  
 Collectively, it is clear that hypoxia induced cellular changes play a role in viral 
infections and cellular host responses. 
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1.5 Gaps in knowledge in dengue pathogenesis under low oxygen environments 
Post-mortem analyses have found evidence of DENV replication in organs with low oxygen 
microenvironments. As shown in mice experiments, the first site of DENV replication occurs 
in the lymph nodes where the oxygen microenvironment is estimated to be approximately 3% 
O2, significantly lower than atmospheric 20% O2. There, FcγR beaing cells such as monocyes 
and macrophages are targets of infection and dissemination of DENV. Numerous studies have 
described hypoxia induced cellular changes that include immune responses to pathogens. Low 
oxygen concentrations modulate monocytes immunoregulatory and inflammatory pathways. 
Thus to accurately understand DENV infections, it is imperative to elucidate the molecular 
mechanisms of dengue pathogenesis under its physiological oxygen environment. In particular, 
the transcriptional changes in FcγR suggest that low oxygen environments may affect DENV 
neutralization and ADE. 
 However, how low oxygen induced modifications of host responses affect DENV 
neutralization, infection or ADE remains unknown as studies to date have been performed 
exclusively in atmospheric conditions. This thesis seeks to investigate if physiological oxygen 
concentrations (3% O2) modulate DENV neutralization and infections in monocytes.  
 The specific aims of this thesis are thus 
1. Explore the changes of DENV neutralization and enhancement in monocytes cultured at 
physiological oxygen environments; 
2. Elucidate the changes in mechanism of DENV internalization in monocytes under 3% O2;  
3. Explore how HIF1α independent changes can affect DENV internalization in monocytes 
under 3% O2 		
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Chapter 2: Materials and Methods 
2.1 Primary Samples 
Primary monocytes were derived from blood obtained from the Singapore Health 
Sciences Authority Blood Bank, under a protocol approved by the institutional review 
board (IRB 201406-01).  
 
2.2 Cells and viruses 
THP-1 cells, BHK-21 and Vero cells were obtained from American Type Culture 
Collection (ATCC).  
Primary monocyte isolation and culture was performed in collaboration with 
Summer Zhang. Blood was diluted with 2 volumes of 0.5% bovine serum albumin 
(BSA, Sigma Aldrich) diluted in phosphate buffer solution (PBS). Blood is then layered 
onto Ficoll-hypaque (GE Healthcare, Singapore) and subjected to centrifugation for 
30mins at 750 xg without brakes. Interphase consisting of peripheral blood mononuclear 
cell (PBMC) was aspirated, transferred to a clean tube, washed 3 times with 50ml of 
0.5%BSA/PBS and resuspended in growth media (100µg/ml streptomycin, 100U/ml 
penicillin, 10% fetal bovine serum in RPMI-1640). Cells were counted, seeded into T75 
flask at 5x107 cells per flask and incubated at 37oC, 5% CO2 for 2.5h to allow monocytes 
to adhere to the surface of the flask. Adhered cells were washed 5 times with PBS and 
replenished with fresh growth media. These adhered monocytes were allowed to recover 
overnight at 37oC, 5% CO2 before use. 
When required, THP-1 cells or primary moncoytes were adapted to 3% O2 in 
fully humidified incubators supplied with pure nitrogen gas to reduce oxygen levels as 
well as 5% CO2 for 24h prior to infection with DENV2. DENV2 (ST) is a clinical isolate 
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obtained from Singapore General Hospital.	D2ST was propagated in Vero cell line, 
harvested 96hpi and purified through a 30% sucrose gradient.  
 
2.3 Antibody-mediated dengue virus Infection  
Endotoxin free h3H5 and h4G2 chimeric human/mouse antibodies were constructed as 
previously described (Hanson et al, 2006) and shown to bind to DENV2 (Chan et al, 
2011). Briefly, mRNA and total cDNA from hybridoma cells were used as a template to 
amplify both variable heavy and light chain with specific primers. Additional recognition 
sites allowed for cloning into the human IgG1 constant region expression vector. 
Chimeric constructs were then transfected into 293-F cells and proteins were purified 
using Protein A beads (Amersham).  
To assess antibody-mediated DENV-2 infection in THP-1 cells, DENV2 was 
incubated with media, or 2 fold serial dilutions of antibodies or serum at 37oC for 1h 
before addition to THP-1 cells at multiplicity of infection (MOI) 10.   
 
2.4 Human sera 
Human sera used in this study was obtained from the early dengue infection and control 
study (EDEN) (Low et al, 2006), approved by the National Healthcare Group (NHG) 
Institutional Review Board (DSRB B/05/013). Upon consent, patients were grouped into 
DENV positive or DENV negative groups based on reverse transcription polymerase 
chain reaction (RT-PCR). Sera obtained from patients 3-4 weeks after illness were 
deemed as convalescent sera and used in this study.  
 
2.5 Quantifying DENV2 Internalization and Replication  
  58 
Internalization of DENV2 was assessed 2hpi by Alexa-flour labeled DENV with or 
without pronase treatment (1mg/ml) treated at 40C for 5 mins. Pronase treated cells were 
compared to non-pronase treated cells. Flow cytometry was performed with the 
LSRFortessa cell analyzer (Bectin Dickinson), data acquired with FACDiva Version 
6.1.3. Percentage of cells infected was compared against its matching non-infected cells. 
Virus replication was assessed at indicated time points of 2, 6, 18 and 24hpi 
by qPCR. Briefly, cells were washed thrice with ice cold PBS before lysis. RNA from 
cells was extracted using the RNeasy Kit (Qiagen) followed by cDNA synthesis (Biorad) 
and real-time aPCR (Roche) according to manufacturer’s protocol. Primer sequences 
were obtained from Origene. DENV primers used were: DENV-F 5’-
TTGAGTAAACYRTGCTGCCTGTAGCTC DENV-R 5’-
GAGACAGCAGGATCTCTGGTCTYTC. All RNA levels were measured relative to 
TATA-box binding protein (TBP), which was the housekeeping gene used for hypoxia 
studies. DENV2 RNA levels were measured relative to TBP. Infectious DENV2 
particles from culture supernatant were assessed via plaque assay 72hpi.   
 
2.6 Plaque Assays 
Virus plaque titers were quantified as previously described. Briefly, 10-fold serial 
dilutions of viruses were added to baby hamster kidney cells (BHK) in 24 well plates and 
incubated for 1h at 37oC. Virus was then aspirated and replaced with 0.8% methyl-
cellulose in RPMI media (RPMI-1640, 3% fetal calf serum, 25mM HEPES, penicillin). 
After 6 days, cells were fixed with 20% formaldehyde, washed with water and stained 
with 1% crystal violet.   
 
2.7 Fluorescent labeling of DENV-2 
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Labeling of DENV-2 with 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine,4- 
chlorobenzenesulfonate salt (DiD)-labeling (van der Schaar et al, 2007) and 
AlexaFluor488 is previously described in Zhang et al (Zhang et al, 2010). After labeling, 
fluorescent DENV-2 was stored in -80oC and retitered by plaque assay. Additionally, it 
was also tested for fluorescence using immunofluorescence infection assays on Vero 
cells prior to use. 
 
2.8 Flow cytometry 
After infection, primary monocytes and THP-1 cells were washed with phosphate buffer 
solution (PBS) and fixed with 3% paraformaldehyde at 4oC. Mouse anti-CD32 IV.3 
(1:300, Stem Cell Technologies 60012) and FcγRI (1:300, Abcam ab46679) was added 
for 0.5h at 4oC. After washing with PBS, anti-mouse AlexaFluor 488 (1:400) was added 
and incubated at 4oC for 0.5h prior to analysis with the BD LSRFortessa flow cytometer. 
Percentage of cells infected was compared against its matching non-infected cells. 
   
2.9 DFX treatment 
Desferrioxamine mesylate salt (DFX) was purchased from Sigma (D9533) and 
reconstituted in water. THP-1 cells were subsequently treated with a final concentration 
100µM or 200µM of DFX (diluted in RPMI) for 24h prior to infection with DENV or 
DENV opsonized with h3H5.  
 
2.10 Western blot 
Cells were washed once in PBS and resuspended in lysis buffer (1% Nonidet P-40, 
150mM NaCl, 50mM Tris pH8.0) in the presence of protease inhibitors (Sigma). 
Proteins in cells lysates were separated by SDS-PAGE, transferred to PVDF (Millipore) 
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and incubated with primary antibody followed by HRP-conjugated anti-rabbit (1:3000, 
Abcam 6721) or anti-mouse (1:1000, Dako P0447) antiserum. The primary antibodies 
used were LAMP-1 (1:1000, eBioscience 6721), FcγRI (1:300, Abcam ab46679), 
FcγRIIA (1:300, Stem Cell Technologies 60012), FcγRIIB (1:500, Abcam ab123240). 
Blots were developed by enhanced chemiluminescence detection reagents (Amersham). 




Antibodies against PrM (2H2, 1ug/ml) and E (4.8A, 1ug/ml) were coated in MaxiSorp 
plates overnight. BSA (0.5ug/ml) or PBS was used for negative controls. Blocking was 
done with 10% BSA in PBS at room temperature (RT) for 2h and washed three times 
with 0.05% tween PBS. Viruses were incubated for 1.5h and washed three times with 
0.05% tween PBS. Secondary antibodies and subsequently HRP were each incubated for 
1h at RT.  
 
2.12 Confocal Microscopy 
After infection with AF488 labeled DENV and fixation with 3% PFA for 0.5h, THP-1 
cells were subjected to cytospin at 800 x g for 3mins and washed with PBS. Mouse anti-
FcγRIIA (1:300, Stem Cell technologies 60012) was added and incubated for 1h at room 
temperature. After washing with PBS, anti-mouse AF568 (1:200) was added and 
incubated at room temperature for 45mins. Cells were washed with PBS and 
permeabalized with 0.1% saponin in 5% BSA for 30mins at room temperature. Anti-
CD32A was added for 1h at room temperature. After washing, anti-mouse AF647 was 
added and incubated at room temperature for 45mins. Thereafter, cells were fixed with 
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10% glycerol and 90% PBS before viewing under a Leica confocal microscope. 
Deconvolution (HuygensEssential) and Imaris analysis was performed at the Singhealth 
Advanced Bio Imaging Core. 
 
2.13 Imaris spot detection and colocalization analysis 
Confocal z stacks were analyzed with Imaris 8.1.2 spot detection. Plasma membrane was 
visualized using surface FcγRIIA stain prior permeabilization of the cell to identify 
intracellular FcγRIIA and DENV2 immune complexes. Using high-resolution 
microscopy at the Singhealth advanced bioimaging core, z stack images were taken of 
20% O2 and 3% O2 THP-1 cells infected with DENV-2 opsonized with enhancing levels 
of h3H5. FcγRIIA was visualized to a resolution of 200um and DENV2 to 50nm. Spots 
were then visualized at the centre of each protein. Intracellular FcγRIIA and DENV2 
spots interacting within 100nm were then identified. 
 
2.14 shRNA and siRNA Transfection 
siRNA transfection was performed with siAGPS  (s16248) and siHIF1α (s6539) at 50nM 
from Life Technologies were used. CD32A shRNA (sc-29992-v) was purchased from 
Santa Cruz Biotechnologies. Qiagen AllStars negative control siRNA (SI03650318) 
served as control siRNA. 
 
2.15 Microarray 
Following RNA extraction, microarray was performed at Duke-NUS Genome Biology 
Core Facility using Illumina human HT-12 beadchips. Data normalization was 
performed using Partek software and quantile normalized prior to analysis with Gene Set 
  62 
Enrichment Analysis. The microarray data were deposited in the Array Express database 
(www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-4692.  
 
2.16 Chromatin immunoprecipitation and sequencing (ChIP-Seq) 
 Chromatin immunoprecipitation was performed using SimpleChIP Enzymatic 
Chromatin IP Kit (CST #9003) according to the manutacturer’s protocol. After recovery 
of ChIP and input DNA, 30ng of DNA was used for each sequencing library preparation 
(New England Biolabs, E6240). 4 libraries were multiplexed (New England Biolabs, 
E7335) and sequenced on 1 lane of Hiseq2500 (Illumina) to an average depth of 20-30 
million reads per library. The quality of the sequencing reads was ascertained via the 
FASTQC tool (Li & Dewey, 2011).The average sequencing depth was 54.4 million reads 
per sample and the median per-base quality was >30 for all the samples. No further 
trimming of the bases was performed. Sequencing reads were then mapped to the human 
reference genome (hg19) using BWA-0.5.9 alignment tool (Li & Durbin, 2009). The 
average mapping rate was 99.5%. Peak calling were performed using MACS-1.4.2 
(Zhang et al, 2008b), resulting in the generation of potential HIF1α binding sites. 
 
2.17 Liquid-liquid extraction 
THP-1 membranes were prepared by incubation in 20mM Tris Buffer pH7.4. 
Chloroform:methanol (1:2) was added to cell suspension (after washing the cells with 1 
x PBS, reconstitute cells with 50µL of Milli-Q water). Known amounts of internal 
standards were spiked into the cell-solvent mixture prior to incubation. The mixture was 
incubated in a 4oC room for 2h with agitation at 600 rpm on a Thermomixer 
(Eppendorf). After incubation, 300µL of chloroform and 250µL of MQ water were 
added into the mixture and vortexed to mix. The mixture was centrifuged at 15,000 x g 
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for 5 min to break phase and the bottom organic phase which contain lipids was 
transferred into a clean tube. Re-extraction was performed by using another 500µL of 
chloroform and the organic phase obtained was pooled. The lipid extracts were then 
dried under nitrogen stream and kept at -80 oC until used. 
 
2.18 Lipids analysis using high performance liquid chromatography/mass spectrometry 
Lipids were analyzed on an Agilent 1290 HPLC system coupled with an Agilent 6460 
Triple Quadrupole mass spectrometer. Liquid chromatography was performed on a 
Zorbax Eclipse Plus, Rapid Resolution High Definition, 1.8µm reversed-phase C18 100 
Å, 50 × 2.1mm column (Agilent Technologies Corp, Santa Clara CA). HPLC conditions: 
injection volume 2µL; mobile phase A and B consisted of isopropanol: acetonitrile in the 
ratio of (60:40) and (90:10) (optima grade), respectively, both containing 10mM 
ammonium formate; flow rate 0.5 ml/min, 60% B for 2 min, then linearly changed to 
0.4mL/min in 2 min; solvent composition was then linearly switched to 100% B in 7 min 
and maintained for 2 min, and then linearly changed to 20% B in 9 min and maintained 
for 1.5 min. Then, the flow rate and the mobile phase were returned to the original ratio. 
Mass spectrometry was recorded under the positive ESI mode. Individual lipid species 
were quantified using spiked internal standards obtained from Avanti Polar Lipids 
(Alabaster, AL, USA). 
 
2.19 Statistical Analysis 
Experiments were repeated 3 times with at least 3 biological replicates. 2-tailed unpaired 
Student t test was performed to compare between 2 means using GraphPad Prism v7.0.	
  
  64 
Chapter 3: Results 	
3.1 Monocytes adapt to hypoxia 24h post oxygen adaptation 
For the scope of this thesis, primary moncoytes and THP-1 cells were cultured under 
20% and 3% O2 conditions for 24h prior to infection with DENV-2 immune complexes, 
gene expression studies and membrane lipid profiling (Figure 3-1).  To ensure that cells 
have indeed adapted to hypoxic environments, mRNA levels of hypoxia inducible genes 
such as vascular endothelial growth factor (VEFG) and adrenomedullin (ADM) (Bosco 
et al, 2006; Ng et al, 2014b) were assessed by qPCR. As expected, VEGF (Figure 3-
2a,c), ADM (Figure 3-2b,c) transcript levels were upregulated in both primary 
monocytes and THP-1 cells under 3% O2 conditions as compared to 20% O2 after 24h 
incubation.  
Previous studies have shown that apoptosis can be induced in response to long 
periods of hypoxia (Bellot et al, 2009; Lai et al, 2016). We therefore assessed for 
apoptosis marker Annexin V after culturing at 3% O2 for 24h. Annexin V binds 
phosphotidylserine (PS) that translocate from the inner to outer leaflet of the membrane 
during apoptosis. THP-1 cells cultured under hypoxic conditions for 24h showed a slight 
but non-significant difference in apoptosis as compared to cells cultured under normoxic 
conditions (Figure 3-2d).  
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Figure 3-1: Experimental Setup of THP-1 cells oxygen adaptation.  
THP-1 cells cultured under normoxic conditions were split into 20% and 3% O2 for 24h 
prior to infection with DENV-2 or DENV-2 opsonized with antibodies. DENV entry 
assessed with flow cytometry, replication with qPCR and plaque assays, gene expression 
analysis with microarray or qPCR and membrane lipid profiling with mass spectrometry.   
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Figure 3-2: Hypoxic response of THP-1 cells 24h post oxygen adaptation.  
a,b. mRNA gene expression of hypoxia inducible genes ADM (a) and VEGF (b) at 
various time points post oxygen adaptation. c. mRNA expression of hypoxia inducible 
genes 24h post oxygen adaptation expressed as fold change (3% / 20%). A positive 
fold change represents an increase in gene expression under hypoxic conditions. d. 
Percentage of cells stained with Annexin V assessed by flow cytometry. 
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3.2 Hypoxia mediated upregulation of FcγRIIA  
 
Low oxygen tensions have been shown, in human primary monocytes, to upregulate the 
transcription of FcγRs (Bosco et al, 2006), which plays a vital role in antibody mediated 
phagocytosis of pathogens (Chan et al, 2011; Chawla et al, 2013; Rodrigo et al, 2006). 
However, with highly regulated selective translation under hypoxic conditions 
(Koritzinsky et al, 2006; Young et al, 2008; Webb et al, 2015), not all increases in 
mRNA will result in changes in protein expression. Therefore we investigated if hypoxia 
alters the protein expression of FcγRs in monocytes.  
Consistent with the findings from Bosco and colleagues, human primary 
monocytes exposed to hypoxia for 24h showed increased mRNA expression of FcγRI, 
FcγRIIA and FcγRIIB (Figure 3-3a-c). However, only FcγRIIA showed an increase in 
protein expression as assessed by western blot (Figure 3-3d,e) and flow cytometry 
(Figure 3-3f,g). Similarly after 24h of oxygen adaptation, THP-1 cells showed increased 
mRNA and protein expression of FcγRIIA (Figure 3-3h-j) but not FcγRI or FcγRIIB 
(Figure 3-3i). These results suggest that hypoxia selectively regulates FcγRIIA 
expression in both primary monocytes and THP-1 cells.  
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Figure 3-3: Monocytes express higher levels of FcγRIIA under hypoxic conditions.  
a-c. FcγI (a), FcγRIIA (b) and FcγRIIB (c) RNA copy number in normoxic (blue) or 
hypoxic (red) primary monocytes at various time points (hours) post oxygen 
adaptation. d.  Protein expression of FcγRI, FcγRIIA and FcγRIIB in normoxic and 
hypoxic primary monocytes at 24h post oxygen adaption. LAMP1 served as loading 
control. Numbers shown below the blots indicate densitometry analysis of protein 
levels of FcγRs normalized to LAMP1. e. Protein abundance of FcγRIIA from 4 
donors in primary monocytes relative to LAMP1. f,g. Mean fluorescence intensity 
(MFI) of 4 biological replicates of FcγRIIA (f) and FcγRI (g) in normoxic (blue) and 
hypoxic (red) primary monocytes (n=4) at 24h post oxygen adaptation as assessed 
using flow cytometry. h. THP-1 FcγRIIA RNA copy number under normoxic (blue) 
and hypoxic (red) in THP-1 cells conditions at various time points post oxygen 
adaptation. i. Protein expression of FcγRI, FcγRIIA, and FcγRIIB in THP-1 cells at 
24h post oxygen adaptation. j. Protein abundance of FcγRIIA from 4 independent 
experiments in THP-1 cells relative to LAMP1 
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3.3 Hypoxia enhances antibody dependent infections 
To determine hypoxia’s effect on a monocytic cells susceptibility to DENV infections, 
we infected primary monocytes with DENV only or DENV opsonized with varying 
concentrations of DENV-2 specific human-mouse chimeric h3H5 (Hanson et al, 2006) 
(h3H5) or pan-serotype human-mouse chimeric 4G2 (h4G2) monoclonal antibody 
(mAb) (Hanson et al, 2006; Chan et al, 2011; Robinson et al, 2015). Hypoxic THP-1 
cells required more antibodies for neutralization as compared to THP-1 cells cultured 
under normoxic conditions (Figure 3-4a,b). In addition, plaque titers following antibody-
opsonized DENV infection at enhancing concentrations of h3H5 or h4G2 were higher in 
hypoxic conditions relative to infection under normoxic conditions (Figure 3-4a,b). 
Increase in plaque titers following DENV only infection was also observed in primary 
monocytes (Figure 3-4c) although this outcome was not observed universally across all 4 
primary monocyte donors (Figure 3-4e). In contrast, the increase in plaque titers with 
antibody opsonized DENV infection was consistently observed in primary monocyte 
from all donors (Figure 3-4d-f).  
Similar enhancement of infection was also observed when THP-1 cells were 
infected with DENV-2 opsonized with h3H5 (Figure 3-4g), h4G2 (Figure 3-4h), 
convalescent sera obtained from individuals previously infected with either DENV-2 
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Figure 3-4: Hypoxia modulates DENV infection in monocytes.  
a,b. Plaque titers of normoxic (blue) and hypoxic (red) primary monocytes (Donor 1) 
following infection with DENV-2 opsonized with varying concentrations of h3H5 (A) 
and h4G2 (B) at MOI of 10 at 72hpi. Using PRNT (PRNT50<1:10), Donor 1 was 
confirmed to have no pre-existing antibodies. c. Plaque titers of normoxic (blue) and 
hypoxic (red) primary monocytes from Donor 1 following DENV only infection.   
d-f. Plaque titers of normoxic (blue) and hypoxic (red) primary monocytes from 
Donor 2 (D), Donor 3 (E) and Donor 4 (F) when infected with DENV-2 opsonized 
with 0.391µg/ml h3H5 that permits maximal levels of ADE. Dashed lines represents 
plaque titers of normoxic (blue) and hypoxic (red) cells following DENV only 
infection in each individual donor g-h. Plaque titers of normoxic (blue) and hypoxic 
(red) THP-1 cells when infected with DENV-2 opsonized with varying concentrations 
of h3H5 (G) and h4G2 (H).  i,j. Plaque titers of normoxic (blue) and hypoxic (red) 
THP-1 cells when infected with DENV-2 opsonized with different levels of serotype-
specific (I) and cross-reactive (J) convalescent serum. k. Plaque tires of normoxic 
(blue) and hypoxic (red) THP-1 cells following DENV only infection.  
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3.4 Hypoxia results in increased internalization of antibody-opsonized DENV but not 
DENV only  
FcγRIIA is known to mediate phagocytosis after engagement by immune 
complexes (Chawla et al, 2013; Rodrigo et al, 2006). Therefore, to determine if FcγRIIA 
upregulation is responsible for the increase in internalization and infection of antibody-
opsonized DENV-2 under hypoxia, we performed a time course of viral infection over 
24h. The difference in antibody-opsonized and DENV only infection rate between 
hypoxic and normoxic THP-1 cells can be seen as early as 2 hours post-inoculation (hpi) 
(Fig 3-5a,b). However, treatment with pronase to remove plasma membrane-bound but 
uninternalized DENV abrogated any differences in RNA levels at 2hpi for virus only but 
not antibody-dependent infection (Figure 3-5c). Similar phenotypes were observed when 
antibody-opsonized and AF488 labeled DENV only were used to infect hypoxic and 
normoxic THP-1 cells. Increased internalization was observed under ADE infections but 
not after DENV only infections (Figure 3-5d,e). This suggests that an increase in the 
internalization of antibody-opsonized DENV under hypoxic condition may be due to the 
observed upregulation of FcγRIIA in monocytic cells cultured under hypoxic conditions.  
However, whether FcγR’s function to aid DENV immune complex binding to the 
cell surface or functionally mediate entry is a subject that is still controversial. To 
address this question, high-resolution confocal microscopy was used to assess 
interactions between FcγRIIA (250um) and Alexa-Fluor labeled DENV-2 (50nm) 
immune complexes 2hpi. Firstly, surface FcγRIIA was stained with anti-FcγRIIA and 
subsequently AF532 (blue) without permeabalization of the plasma membrane, thus 
enabling visualization of surface FcγRIIA. Thereafter cells were permeabalized and 
stained again with anti-FcγRIIA and AF647 (red) to label total FcγRIIA (surface and 
internalized). Using this strategy, surface FcγRIIA is labeled with both AF532 (blue) and 
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AF647 (red), whereas intracellular FcγRIIA would only be stained with AF647 (red). 
Intracellular interaction between FcγRIIA and DENV-2 was observed in THP-1 cells 1h 
post infection under hypoxic conditions (Figure 3-6a). In addition, Imaris spot 
colocalization analysis showed FcγRIIA and DENV-2 interacting within a distance of 
100nm (Figure 3-6b) suggesting that FcγRIIA potentially mediates the internalization of 
DENV-2 immune complexes. Furthermore, stable knockdown of FcγRIIA by shRNA 
results in decreased DENV titers 72hpi as compared to control THP-1 cells (Figure 3-
6c). 
Collectively these results suggest that hypoxia induced upregulation of FcγRIIA 








Figure 3-5: Hypoxia modulates DENV infection in monocytes.  
a,b. Time course of viral RNA copy numbers in normoxia (blue) and hypoxia (red) 
under ADE (a) or DENV-2 only (b) infection. c. Increase in DENV-2 RNA copy 
numbers 2hpi after pronase treatment under ADE and but not virus only infection. d,e. 
Percentage of hypoxic (red) and normoxic (blue) cells infected before and after pronase 
treament under ADE (d) and virus only infection (e) shows increase in ADE 
internalization but not in virus only infection.  **p<0.01, ***p<0.001, ****p<0.0001 
(unpaired t-test) 	  
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Figure 3-6: FcγRIIA upregulated under hypoxic conditions results in increased 
internalization of DENV immune complexes.  
a. FcγRIIA (red) interaction with DENV-2 (green) immune complexes (white arrow) 
in the cytoplasm 1hpi. b. Imaris spot detection was used to identify FcγRIIA (red) and 
DENV-2 (green) interacting within 100nm in the cytoplasm (white arrow). c. shRNA 
knockdown of FcγRIIA under hypoxic conditions show decreased enhancement. 
Numbers under  western blots indicate FcγRIIA protein levels normalized to LAMP1. 
****p<0.00001 (unpaired t-test).  
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3.5 HIF1α enhances FcγRIIA expression 
The upregulation of FcγRIIA in monocytic cells cultured under hypoxic conditions 
suggest that the transcription factor hypoxia-inducible factor (HIF1α or HIF2α) may play 
a role in regulating its expression. In oxygen rich environments, HIFs are degraded 
through O2 and iron-dependent reactions (Wang & Semenza, 1993b; 1993a). At low O2 
or iron levels, HIF binds the hypoxia-response element (HRE) to initiate transcription. 
To evaluate if the increase in FcγRIIA transcription is mediated by either HIFs, we 
cultured HIF1α or HIF2α silenced THP-1 cells under hypoxic conditions. As a control, 
we measured for the expected dose-dependent decrease in ADM mRNA expression, 
which has been previously shown to be regulated by HIFs (Keleg et al, 2007). Silencing 
HIF1α (Figure 3-7a) resulted in reduced expression of both ADM (Figure 3-7b) and 
FcγRIIA (Figure 3-7c,d).  However, HIF2α silenced cells (Figure 3-7e) showed no 
changes in FcγRIIA protein expression (Figure 3-7f) DENV internalization (Figure 3-7g) 
or DENV replication under ADE conditions (Figure 3-7h). Therefore, this suggests that 
HIF1α, and not HIF2α, plays a role in upregulating the expression of FcγRIIA under 
hypoxic conditions. Conversely, chemically stabilizing HIF by an iron chelator 
desferrioxamine (DFX) under normoxic conditions (Figure 3-8a) (Wang & Semenza, 
1993c) resulted in dose-dependent increase in ADM (Figure 3-8b) as well as both 
FcγRIIA mRNA (Figure 3-8c) and protein levels (Figure 3-8d). Collectively these results 
suggest that HIF1α regulates the transcription of FcγRIIA. 
Chromatin immunoprecipitation sequencing (ChIP-seq) analysis, however, did 
not reveal a HIF1α binding site in the promoter region of FcγRIIA. Instead, under 
hypoxic conditions, a binding site for HIF1α was identified approximately 5000 bases 
upstream of FcγRIIA (Figure 3-9a). Consistent with the rapid degradation of HIF1α 
under normoxia (Wang & Semenza, 1993b), ChIP-seq could not be carried out in cells 
  78 
cultured under 20% O2 conditions. However, upon HIF1α stabilization by DFX under 
normoxic conditions, a similar binding site for HIF1α was also observed (Figure 3-9b). 
These results suggest that HIF1α is able to bind to regulatory regions upstream of 
FcγRIIA to enhance its expression.  
Interestingly, knockdown of HIF1α and its resultant decrease in FcγRIIA 
expression only led to a modest decrease in infection of antibody-opsonized DENV 
(Figure 3-9c). No difference was observed in virus only control infection. These findings 
suggest that additional hypoxia-induced but HIF1α independent factors may act 
synergistically with FcγRIIA to increase ADE. To further investigate this, we infected 
hypoxic, normoxic and normoxic cells treated with 200uM of DFX simultaneously with 
antibody-opsonized DENV, with or without pronase treatment. The results showed 
increased DENV signal in both hypoxia (51%) and DFX treatment (47%) as compared to 
normoxic THP-1 cells (25%) as measured by flow cytometry (Figure 3-9d). However, 
pronase treatment showed that increased uptake of antibody-opsonized DENV remained 
high only in hypoxic cells (43%) as compared to normoxic cells (20%). In contrast, only 
25% of DFX treated THP-1 cells showed DENV internalization, which is only a 
marginal increase compared to normoxic, untreated cells.  
Collectively, these findings indicate that hypoxia-induced internalization of 
antibody-opsonized DENV requires HIF1α-independent changes in the cell to 
complement the induced FcγRIIA expression. 
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Figure 3-7: Stabilization of HIF1α increases expression of FcγRIIA.  
a. Protein expression HIFα after siRNA knockdown under hypoxic conditions. b. 
mRNA expression of ADM (b) and FcγRIIA (c) in HIFα silenced THP-1 cells under 
hypoxi conditions d. Protein expression FcγRIIA after siRNA knockdown of HIFα 
under hypoxic conditions. e,f. protein expression of HIF2α (e) and FcγRIIA (f) in 
HIF2α silenced cells under hypoxic conditions. g,h. No difference in infection of 
antibody-opsonized DENV in HIF2α silenced cells as assessed by flow cytometry (g) 
and plaque assay 72hpi (h). 
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Figure 3-8: Stabilizing HIF leads to an increase in FcγRIIA expression 
a. Protein expression of HIF1α under hypoxic, normoxic and increasing 
concentrations of DFX treatments under normoxic concentrations. LAMP1 served as 
a loading control. b,c. mRNA expression of ADM (b) and FcγRIIA (c) after DFX 
treatment. d. Protein expression of FcγRIIA 24h post DFX treatment. LAMP1 served 
as a loading control.  
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Figure 3-9: HIF1α enhances Fc𝛄RIIA expression for binding but not internalization of 
antibody-opsonized DENV. 
a.	HIF1α	binding	site	upstream	of	the	FcγRIIA	gene	under	hypoxic	conditions	as	determined	using	ChIP-Seq.	b.	HIF1α	binding	site	upstream	of	the	FcγRIIA	gene	in	THP-1	treated	with	200µM	of	DFX	under	normoxic	conditions	determined	using	ChIP-Seq.	c.	Control	and	HIF1α	silenced	THP-1	cells	cultured	under	hypoxic	conditions	and	infected	with	AF488	labeled	DENV-2,	without	or	with	opsonization	with	enhancing	levels	(0.391mg/ml)	of	h3H5.	Cells	were	treated	with	pronase	at	2hpi	to	assess	DENV	internalization	by	MFI.	d.	Percentage	of	THP-1	cells	infected	with	AF488	labeled	DENV-2	opsonized	with	enhancing	levels	of	h3H5,	without	or	following	pronase	treatment.	THP-1	cells	were	cultured	under	hypoxic	conditions	or	under	normoxic	conditions	without	or	with	200µM	of	DFX.	Percentage	infection	was	determined	by	flow	cytometry.			  
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3.6 Transcriptomic differences in hypoxic and normoxic cells  
To analyze host responses to hypoxia that would aid in increasing DENV immune 
complex internalization independent of HIF1α, we profiled mRNA transcripts in THP-1 
cells exposed to hypoxia and normoxia for 24h. Quantile normalization of the data was 
performed in Partek and fold change was determined by comparing hypoxic versus 
normoxic cells.  
 Using GSEA to analyze for enriched pathways, we observed significant enrichment in 
lipid synthesis genes such as acyl chain remodeling of PE, cholesterol biosynthesis and 
membrane trafficking genes (Figure 3-10). This result suggests that there may be 
alterations to the lipid compositions in THP-1 cells under hypoxic conditions. As lipid 
composition of cellular membranes have been shown to be important in membrane 
fluidity and phagocytosis, we hypothesized that changes in cellular lipid compositions 
may contribute to increased ADE under hypoxic conditions. 
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Figure 3-10: Pathways enriched under hypoxic conditions 
Lipid metabolism pathways significantly enriched in hypoxic THP-1 cells as identified by 
GSEA analysis.  
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3.7 Hypoxic cells have increased levels of ether linked PE  
Modifications in membrane lipid compositions may affect DENV phagocytosis. 
Hence, we isolated membrane of hypoxic and normoxic THP-1 cells and analyzed 
their respective lipid profiles. In general, hypoxic and normoxic THP-1 cells are 
highly enriched in PC, with modest concentrations of PE and SM. LPE and LPC 
make up less than 1% of both hypoxic and normoxic THP-1 cells (Figure 3-11). 
Most lipids species such as ceremides (Figure 3-12a,b), phosphoinostitides 
(PI) (Figure 3-12c), phosphotidylserine (PS) (Figure 3-12d), sphingomyelin (SM) 
(Figure 3-12e), lysophosphotidylethanolamine (LPE) (Figure 3-13a), 
lysophosphotidylcholine (LPC) (Figure 3-13b) and phosphotidylcholine (PC) (Figure 
3-13c,d) showed no difference between hypoxic and normoxic cells.  
While phosphoethanolamine (PE) lipid species were slightly upregulated 
under normoxic conditions, interestingly, ether PE’s were upregulated 2-4 fold in 
hypoxic cells (Figure 3-14a) (Table 3-1, 3-2). To determine if the changes in ether PE 
were HIF1α dependent or independent, we analyzed the ether PE lipid profile of DFX 
treated cells. DFX treated cells showed no difference in PE concentrations as 
compared to normoxic cells, suggesting that ether PE upregulation is independent of 
HIF1α (Figure 3-14b). In addition, silencing HIF1α in hypoxic THP-1 cells (Figure 3-
15a) had no significant effect on concentration of PE lipids (Figure 3-15b-d); further 
suggesting that upregulation of ether PE lipids is independent of HIF1α. 
To test if elevated levels of ether PE were required for increased DENV 
internalization, we silenced an enzyme required in the synthesis of ether PE, 
acylglycerone phosphate synthase (AGPS) (Figure 3-16a). As expected, knockdown 
of AGPS significantly reduced ADE of DENV infections (Figure 3-16b) and 
enhancement profiles (Figure 3-16c) under hypoxic conditions. Double knockdown of 
  86 
both AGPS and FcγRIIA resulted in further decrease in antibody-opsonized DENV 
internalization as compared to silencing only AGPS or FcγRIIA (Figure 3-16d,e). 
 Collectively these findings suggest that enhanced infection typically observed 
in secondary infections is both antibody dependent and hypoxia induced. Therefore, 
under physiological oxygen tensions, FcγRIIA upregulation and changes in 
membrane lipid compositions work synergistically to increase ADE (Figure 3-17).  
  




Figure 3-11: Overview of hypoxic and normoxic THP-1 membrane lipid profiles 
a,b.	Composition	of	different	lipid	classes	in	normoxic	(a)	and	hypoxic	(b)	THP-1	cells	expressed	as	percentages.	Data obtained in collaboration with Dr. Markus 
Wenk.  		
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Figure 3-12: Lipid profiles of THP-1 cells after 24 of oxygen adaptation  
a-e. Lipid profiles of ceramide (Cer) (a) dihexosylceramide (DHCer), 
monohexosylceramide (MHCer) (b) phosphatidylinositol (PI) (c) phosphotidylserine 
(PS) (d) and sphingomyelin (SM) (e) in hypoxic and normoxic THP-1 cells. In all 
graphs, normoxia is represented in blue and hypoxic is represented in red. Data 
obtained in collaboration with Dr. Markus Wenk 
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Figure 3-13: Lipid profiles of THP-1 cells post oxygen adaptation 
a-f. Lipid profiles of lysophosphotidylethaloamine (LPE) (a) lysophosphotidylcholine 
(LPC) (b) phosphotidylcholine (PC) (c) plasmologen (PC(-P)) and ether 
phosphotidylcholine (PC(-O)). For all graphs normoxia is represented in blue and 
hypoxic is represented in red. *P<0.05 (unpaired t-test). Data obtained in 
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Figure 3-14: Hypoxia modulates cellular lipid composition  
a. THP-1 cells adapted to 3% O2 for 24h exhibits an increase in ether linked PE. 
Individual lipid species and fold changes are listed in Table 1-1 and 1-2. Dotted lines 
represents a 1.5 fold change. b. DFX treated THP-1 cells do not exhibit the same 
increase in ether linked PE. *P<0.05 (unpaired t-test). Data obtained in collaboration 
with Dr. Markus Wenk. 
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Figure 3-15: Upregulation of ether lipids under hypoxic conditions is HIF1α  
independent 
a. Knockdown efficiency of HIF1α in control and HIF1α silenced THP-1 cells 
assessed by western blot. LAMP1 served as a loading control. b-d. No significant 
changes in ether linked PE (b), PE (c) or plasmalogen PE (d) in control and HIF1α 
silenced cells cultured under hypoxic conditions. Data obtained in collaboration with 
Dr. Markus Wenk. 
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Figure 3-16: Upregulation of ether lipids and FcγRIIA synergistically result in 
increased internalization of antibody opsonized DENV 
a.	Knockdown	efficiency	of	AGPS	in	THP-1	cells.	LAMP1	served	as	a	loading	control	and	numbers	below	western	blot	indicate	the	levels	of	AGPS	normalized	to	LAMP1.	b.	Percentage	of	AGPS	(black)	and	control	(red)	THP-1	silenced	cells	infected	under	ADE	conditions	2hpi.	c.	Plaque	titers	following	infection	of	AGPS	(black)	and	control	(red)	cells	with	DENV-2	opsonized	with	decreasing	concentrations	of	h3H5	under	hypoxic	conditions.	d.	Knockdown	efficiency	of	AGPS	and	FcγRIIA	in	THP-1	cells.	LAMP1	served	as	a	loading	control	and	numbers	below	western	blot	indicate	the	levels	of	AGPS	and	FcγRIIA	normalized	to	LAMP1.	e.	Percentage	of	FcγRIIA and AGPS silenced THP-1 cells infected under 
hypoxic conditions. 	
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Table 3-1: List of PE lipids in Figure 2-16a. 
 
Lipid Species Fold Change  
PE 
PE 32:2 -1.7459 
PE 32:1 -1.3925 
PE 32:0 -1.5746 
PE 34:3 -1.3399 
PE 34:2 -1.4315 
PE 34:1 -1.5029 
PE 34:0 -1.5943 
PE 36:5 -1.4185 
PE 36:4 -1.2842 
PE 36:3 -1.2904 
PE 36:2 -1.4817 
PE 36:1 -1.6803 
PE 38:6 -1.2714 
PE 38:5 -1.3118 
PE 38:4 -1.2652 
PE 38:3 -1.5109 
PE 38:2 -1.6514 
PE 40:7 -1.3983 
PE 40:6 -1.4862 
PE 40:5 -1.3479 
PE 40:4 -1.5681 
PE 40:3 -1.4451 
PE 40:2 -1.8935 
PE 40:1 -1.9311 
PE 42:2 -2.0270 
PE 42:1 -1.8937 
Fold change was calculated by (mean hypoxia / mean normoxia). Genes upregulated 
in hypoxia is expressed as a positive value and genes upregulated in normoxia is 
expressed as a negative value. Data obtained in collaboration with Dr. Markus Wenk 
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Table 3-2: List of ether and plasmalogen PE lipids in Figure 2-16a.  
 
Lipid Species Fold Change  
Ether PE 
PE(O-32:1)/oddPE 31:1 2.8134 
PE(O-32:0)/oddPE 31:0 1.1186 
PE(O-34:2)/oddPE 33:2 4.2384 
PE(O-34:1)/oddPE 33:1 2.3325 
PE(O-36:5)/oddPE 35:5 3.2295 
PE(O-36:4)/oddPE 35:4 2.8498 
PE(O-36:3)/oddPE 35:3 3.2612 
PE(O-36:2)/oddPE 35:2 3.0171 
PE(O-38:6)/oddPE 37:6 1.1546 
PE(O-38:5)/oddPE 37:5 2.3505 
PE(O-38:4)/oddPE 37:4 2.4332 
PE(O-40:7)/oddPE 39:7 1.4622 
PE(O-40:6)/oddPE 39:6 1.1898 



















PE(P-20:0/20:4 ) -1.5000 
PE(P-18:0/22:4 ) -2.0019 
Fold change was calculated by (mean hypoxia / mean normoxia). Genes upregulated 
in hypoxia is expressed as a positive value and genes upregulated in normoxia is 
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Figure 3-17: Schematic of postulated mechanism in which ADE infection of 
DENV is modulated under hypoxia.  
Exposure of THP-1 cells to 24hours of 3% O2 results in the stabilization of 
transcription factor HIF1α which in turn enhances the transcription of FcγRIIA. The 
increase in FcγRIIA results in increased binding of DENV immune complexes to the 
surface of the cell. Hypoxia induced but HIF1α independent changes to cellular ether 
PE lipid concentrations results in increased internalization of the DENV immune 
complexes mediated directly by FcγRIIA. 
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3.8 DENV only infection results in more infectious DENV production  
Results shown in section 3.4 had indicated that DENV only infection does not result in 
increased internalization of the virus (Figure 3-5c,e). However at 72hpi, increase in 
plaque titers was observed in DENV only infections in hypoxic primary monocytes and 
THP-1 cells as compared to normoxic conditions (Figure 3-4c,k). Curiously, no changes 
in the ratio of E (mature) and PrM (immature) DENV virus progeny from both hypoxic 
and normoxic THP-1 cells were observed 24 and 48hpi as assessed by both western blot 
and ELISA (Figure 3-18a,b). In addition, no difference in total mature and immature 
DENV progeny from both hypoxic and normicox conditions was observed 24hpi (Figure 
2-18a). However more mature, but not immature DENV, was observed under hypoxic 
conditions 48hpi (Figure 2-18c). This suggests that that increased egress of mature 
DENV occurs after the first round of replication, between 24-48hpi.   
One possible explanation for the increased DENV progeny titers may be due to 
changes in DENV progeny infectivity under hypoxic conditions after the first round of 
replication. This could be attributed to either mutations in the genome acquired during 
replication in hypoxic cells or, as suggested by cellular lipidomic analysis, changes in the 
lipid profiles of progeny DENV in hypoxia. Firstly, to investigate if hypoxic DENV 
progeny are indeed more infectious than normoxic DENV progeny, DENV produced 
from normoxic and hypoxic THP-1 cells were harvested, concentrated and used to infect 
normoxic HEK293T cells. DENV RNA was then measured at 2 and 22 hours post 
infection. Internalization of normoxic or hypoxic DENV occurred at the same rate as no 
difference was observed in the levels of RNA 2hpi. However, more DENV RNA from 
hypoxic DENV progeny was produced as compared to RNA from normoxic DENV 
progeny at 22hpi (Figure 2-18d). This suggests that hypoxic DENV progeny is more 
infectious than normoxic DENV progeny from THP-1 cells. 
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Figure 3-18: DENV only infection modulated by hypoxia.  
a. No changes in PrM/E ratio in normoxic or hypoxic progeny DENV as assessed by 
western blot 24hpi 4.8A antibody was used to probe for E protein and 2H2 for PrM. 
b. No difference was observed in PrM/E ratio of DENV progeny from hypoxic and 
normoxic THP-1 cells 48hpi. c. No difference in immature viruses (PrM) but more 
mature (E) DENV progeny in hypoxia as compared to normoxia as assessed by 
ELISA. d. DENV grown in hypoxic and normoxic conditions were concentrated and 
used to infect HEK293T cells. mRNA of DENV was then assessed by qPCR 2hpi and 
22hpi.  
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3.9 Genome sequence of 20% O2 and 3% O2 progeny DENV 
Changes in DENV genome have been shown to affect the fitness of the virus 
(Manokaran et al, 2015; Quiner et al, 2014) and could explain for the differences 
observed in 20% O2 and 3% O2 DENV progeny. Therefore, to determine if any 
mutations are present in 3% O2 DENV progeny, next generation sequencing was 
performed to identify any changes in the genome as compared to 20% O2 DENV 
progeny. 
 NGS libraries for both normoxic and hypoxic progeny virus were constructed 
to approximately 500bp (Figure 3-19a) and reads were mapped to a reference genome 
and aligned (Figure 3-19b,c). In total 7 alleles variant were identified between 
normoxic and hypoxic DENV progeny. However, these changes are negligible as 
allele frequency for each variant was less than 1% (Table 3-3). As the consensus 
sequence between DENV produced under 20% O2 and 3% O2 conditions were 
similar, this suggests that the increase in replication of hypoxic DENV is independent 
of any changes to the DENV genome.  
  
  99 
 
Figure 3-19: Next generation sequencing of normoxic and hypoxic DENV progeny.  
a. DNA from normoxic (20%) and hypoxic (3%) NGS library construction was 
prepared to approximately 500bp prior to sequencing. c,d. Genome coverage at each 
position is generally higher than 10^5 and is represented in red for both normoxic (b) 
and hypoxic (c) progeny DENV virus. Data obtained in collaboration with Dr. 
October Sessions. 
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Table 3-3: Allele changes in 20% and 3% progeny DENV 
 
Positions (Column 1) and allele changes in 20% (Column 2) and 3% (Column 3) 
DENV progeny viruses as compared to the consensus sequence. AF represents allele 
frequency. Numbers in brackets represent allele frequencies of each change. Column 
4 indicates if the mutation resulted in an amino acid change. Gene in which the 
mutation occurred is represented in column 5. Data obtained in collaboration with Dr. 
October Sessions.  
Position 20% (AF) 3% (AF) Change Gene 
2223  T (0.0011) Phe (F) Silent E 
3942 T (0.0054)   Val (V), silent NS2A 
7242  A (00058) Ala (A) silent NS4B 
9209  A (0.0050) Leu (L) à Glu (Q) NS5 
10633  C (0.0050)  3’UTR 
10659  C (0.0052)  3’ UTR 
10662 C (0.0085)   3’ UTR 
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3.10 Lipid profiles of DENV under hypoxic and normoxic conditions 
As previously shown, the lipid profile of hypoxic THP-1 cells differs from normoxic 
cells. This potentially has significant impact on viral maturation and egress from cells 
as DENV progeny packages host membrane for the formation of its own membrane, 
thus possibly changing the infectivity of the resultant virion. We hence investigated if 
the lipid profile of DENV progeny in hypoxia differs from DENV progeny under 
normoxic conditions. DENV progeny from hypoxic and normoxic THP-1 cells were 
harvested and purified prior to analysis by mass spectrometry. In general, hypoxic and 
normoxic DENV-2 progeny virions are highly enriched in LPC, with modest 
concentrations of PC and SM. PE and LPE make up less than 1% of both virions 
(Figure 3-20). 
 Hypoxic DENV-2 generally showed a slight increase in PC profiles (Figure 3-
21a) but not for ether linked or plasmalogen PC (Figure 3-21b,c). No trend was 
observed for PE and plasmalogen PE (Figure 3-22a,c). In contrast to hypoxic THP-1 
cells, hypoxic DENV-2 show a decrease in the levels of ether linked PE (Figure 3-
22b). In addition, there is a decrease in LPE, an increase in LPC lipids (Figure 3-
23a,b) and a significant decrease in SM in hypoxic DENV-2  (Figure 3-24).  
The enrichment of LPC in hypoxic DENV is particularly interesting. Due to 
its conical shape, the increase of LPC lipids in hypoxic DENV suggests a more 
compact but circular DENV structure due to LPC positive curvature. The increase in 
LPC however may result in packing defects making the viral membrane more 
unstable. This could possibly result in more efficient fusion of viral membranes with 
host endosomes, leading to increased infection. However, further investigations are 
required to show how these changes in hypoxic DENV membrane lipid compositions 
functionally affect viral infectivity.  




Figure 3-20: Overview of hypoxic and normoxic DENV progeny lipid profiles 
a,b.	Composition	of	different	lipid	classes	in	normoxic	(a)	and	hypoxic	(b)	DENV	progeny	expressed	as	a	percentages	of	the	total	concentration	of	lipids.	Data 
obtained in collaboration with Dr. Markus Wenk 		
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Figure 3-21: Lipid PC profiles of hypoxic vs normoxic DENV-2 progeny.  
a,b,c. Fold changes of PC (a) ether PC (b) and plasmalogen PC (c) in DENV-2 
progeny. Positive fold change represents an increase in hypoxic DENV-2 as 
compared to normoxic DENV-2. Data obtained in collaboration with Dr. Markus 
Wenk 
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Figure 3-22: Lipid PE profiles of hypoxic vs normoxic DENV progeny.   
a,b,c. Fold changes of PE (a) ether PE (b) and plasmalogen PE (c) in DENV-2 
progeny. Positive fold change represents an increase in hypoxic DENV-2 as 
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Figure 3-23: Lipid LPC and LPE profiles of hypoxic vs normoxic DENV-2 progeny.  
a,b. Fold changes of LPE (a) and LPC (b) in DENV-2 progeny. Positive fold change 
represents an increase in hypoxic DENV-2 as compared to normoxic DENV-2. Data 
obtained in collaboration with Dr. Markus Wenk 
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Figure 3-24: Lipid SM profiles of hypoxic vs normoxic DENV-2 progeny. Fold	changes	of	SM	in	DENV	2	progengy	derived	from	hypoxic	and	normoxic	THP-1	cells.	Positive	fold	change	represents	an	increase	in	hypoxic	DENV-2	progeny	as	compared	to	normoxic	DENV-2.	Data obtained in collaboration with Dr. 
Markus Wenk 		
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Chapter 4: Discussion 
4.1 Factors that impact monocytes affect DENV pathogenesis 
 Physiologically low oxygen tensions have been shown to modulate a host 
cellular response that potentially enhances or inhibits viral replication (Bosco et al, 
2006). Since early DENV infection and replication occurs in lymphoid organs with 
low oxygen tensions, this thesis focused on how DENV infections are affected by 
hypoxia.  
Studies have shown that FcγR-bearing monocytes are one of the main targets 
of DENV infection and dissemination	(Sun et al, 2011); therefore any factor that 
possibly impacts a monocytes response to pathogens could potentially impact DENV 
pathogenesis. One factor that has been consistently overlooked during the study of 
dengue pathogenesis is the tissue microenvironment in which monocytic cells 
congregate. A cell’s interaction with its environment can affect key regulatory 
processes including signaling cascade, gene regulation, the fate of a cell and how it 
responds to foreign antigens. Factors such as vascularization (oxygen pressure), 
interaction with surrounding cells and even physical 3 dimensional environments 
have been shown to have drastic effects on cells. For example, cell adhesion 
properties have been shown to be more stable in a 3D matrix as compared to a 2D flat 
surface. By adjusting the in vitro environment to better resemble in vivo physiology, 
the authors were able to reveal novel findings on cancer cell motility (Doyle et al, 
2015; Kam et al, 2008)  
In addition to physical interactions in tissues, cells have also to adapt to the 
tissue oxygen microenvironment. Cellular responses, and viral infections, under low 
oxygen tensions in tissues and tumor microenvironments have been intensively 
studied in cancer. Hypoxia is associated with increased occurrence of metastasis, 
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confers tumor resistance to standard chemotherapy or radiation and is thus associated 
with poor survival outcomes (Brizel et al, 1997; Bush et al, 1978; Tannock & 
Guttman, 1981). This creates an obstacle for the effectiveness of antitumor therapy 
such as oncolytic viruses that must be engineered to overcome the inhibition of DNA, 
RNA and protein synthesis that occurs during hypoxic stress. By lowering the oxygen 
environment in which cells are cultured in in vitro, Fong et al was able to show that 
herpes simplex virus (HSV) can be engineered to take advantage of the tumor hypoxic 
environment and preferentially replicate in tumor cells. Using the same in vitro 
experimental strategy, others have shown that another oncolytic virus candidate, 
vesicular stomatitis virus (VSV), has an inherent ability to adapt and replicate in 
hypoxic environments (Connor et al, 2004). In addition, conditionally replicating 
adenoviruses (CRAd) regulated by two promoters, one of which is the hypoxia 
response element (HRE), showed better tumor-selective oncolysis in vivo (Wang et al, 
2008). Collectively, these studies emphasize how physiological oxygen 
microenvironments can modulate pathogenesis of viruses and should therefore be a 
consideration in in vitro experiments. 
 In our study, we explored the effect of physiological oxygen tensions on 
DENV neutralization and enhancement. This thesis is the first study to provide a 
mechanistic view of the role of physiological oxygen environment on cellular 
functions that impacts dengue pathogenesis.  
 
4.2 Selective hypoxia-mediated inhibition of protein translation 
One of the key cellular responses to hypoxia is the control of mRNA 
translation to maintain energy homeostasis (Koumenis et al, 2002; Koritzinsky et al, 
2005; Pettersen et al, 1986). The transcription profiles of a multitude of genes are 
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altered under hypoxic conditions, but translation efficiency is highly gene specific 
(Koritzinsky & Wouters, 2007; Koritzinsky et al, 2006). With general inhibition of 
DNA synthesis and selective translation, the increase in mRNA does not necessarily 
result in changes in protein abundance. The findings of this thesis show that hypoxia 
induced increase in FcγRIIA protein expression partly but significantly contributes to 
increased internalization of antibody-opsonized DENV in hypoxic THP-1 cells. In 
addition to FcγRIIA, hypoxia also increases the mRNA expression of FcγRI and 
FcγRIIB although difference in the levels of protein expression was not detected. This 
suggests that hypoxia results in additional regulatory mechanisms on differential 
mRNA translation that impacts FcγR translation.  
 Inhibition of translation in hypoxic conditions is a general condition that has 
been observed in multiple cells lines in vitro including gliablastoma, kidney and lung 
carcinoma cells (Liu et al, 2006; Koumenis et al, 2002; Kaper et al, 2006).Several 
studies have explored the mechanisms regulating the selective translation in hypoxia. 
Koritzinsky and colleagues showed a biphasic inhibition of mRNA synthesis under 
hypoxic conditions in HeLa cells. The transient phosphorylation of eIF2α resulted in 
initial rapid inhibition, whereas prolonged inhibition is associated with the subsequent 
disruption of the mRNA cap binding complex eIF4F. Interestingly, differences in 
mRNA distribution within polysomes also revealed fundamental differences in the 
mechanism of translation inhibition in acute and prolonged hypoxia. A substantial 
decrease in the number of ribosomes to each transcript was observed in acute 
hypoxia. In contrast, prolonged hypoxia results in the decrease in the amount of 
mRNA found within polysomes (Koritzinsky et al, 2006). Therefore for mRNA (such 
as FcγRIIA) to be preferentially transcribed, it could be less dependent on eIF2α and 
eIF4F during acute and prolonged hypoxia respectively. 
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    While it is advantageous for cells to conserve energy under hypoxic 
conditions, translation of proteins encoding for adaptive functions to hypoxia is still 
required. Several groups have postulated that internal ribosome entry sites (IRES) 
play a role in regulating translation of hypoxia inducible genes. IRES are responsible 
for the translation of 3-5% of cellular mRNA’s, but its role in regulating translation in 
hypoxic condition has been controversial (Young et al, 2008; Lang et al, 2002). Lang 
and colleagues, using a dicistronic vector assay, identified that the HIF1α internal 
IRES site in its 5’ untranslated region (UTR) regulates its translation. As IRES 
translation is maintained under hypoxic conditions, when hypoxia reduces cap-
dependent translation, the internal IRES mediating cap-independent translation is 
utilized instead (Lang et al, 2002; Stein et al, 1998). However, a few years after their 
discovery, it was suggested that the dicistronic reporter containing the eukaryotic 
IRES elements only produced a positive signal due to cryptic promoter activity 
activated by the SV40 enhancer (Bert et al, 2006). Young et al, using a dicistronic 
vector with SV40 removed, observed low levels of IRES activity in HIF1α, HIF2α or 
VEGF under acute severe hypoxic stress (Young et al, 2008). While HIF1α 
translation in hypoxia may not be driven by IRES, a recent study concluded that the 
epidermal growth factor receptor (EGFR) expression under hypoxic conditions is 
driven by an IRES within its 5’ UTR (Webb et al, 2015). Thus, it is possible that 
different proteins use disparate mechanisms to regulate translation under hypoxic 
conditions, resulting in the contrasting observations between studies.  
 In addition, microRNA (miRNA) have been implicated in the post-
transcriptional regulation of the cellular hypoxic response by repressing mRNA 
translational efficiency (Gorospe et al, 2011).  For example, miR-210 expression is 
upregulated under hypoxic conditions in a HIF1α dependent manner. In response, 
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miR-210 aids in the metabolic transition from oxidative phosphorylation to glycolysis 
by downregulating Iron-Sulfur Cluster Scaffold Homolog (ISCU) (Tong & Rouault, 
2006), NADH dehydrogenase ubiquinone 1α  subcomplex 4 (NDUFA4) 
(Giannakakis et al, 2008), succinate dehydrogenase complex subunit D (SDHD)	
(Puissegur et al, 2011) and cytochrome c oxidase (COX10)	(Chen et al, 2010).  
Additionally, miR-21 has been shown to inhibit hypoxia-induced apoptosis by 
suppressing programmed cell death protein 4 (PDCD4) expression (Dong et al, 2009). 
By inhibiting the translation of Cdc25A, miR-21 is postulated to induce cell cycle 
arrest (de Oliveira et al, 2009).  
 While the literature does contain clues on how FcγRIIA is preferentially 
translated compared to FcγRI and FcγRIIB, further studies are required to determine 
which mechanism operate in this instance specifically. Moreover, as FcγRIIA and 
FcγRIIB share the same promoter and are differentially spliced	(Brooks et al, 1989), it 
remains to be investigated how hypoxia skews splicing efficiency towards FcγRIIA.  
  
4.3 HIF1α inhibitors as a potential anti-viral strategy 
The identification of HIF1α as a potential enhancer of FcγRIIA, which in part 
leads to increase in DENV enhancement, suggests a unique opportunity for HIF1α 
inhibitors to be used as anti-viral treatments against DENV. HIF1α has been proposed 
as a master regulator of innate immunity and its activity can be observed under both 
low oxygen concentrations and during infection (Zarember & Malech, 2005). To date, 
HIF1α inhibitors have been developed primarily for cancer tumor therapy. According 
to HIF1α’s mechanism (Figure 1-15), inhibitors can be broadly classified into 5 
different mechanisms for modulation (Onnis et al, 2009),  
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(1) HIF1α mRNA expression;  
(2) HIF1α protein translation;  
(3) HIF1α protein degradation;  
(4) HIF1α DNA binding and  
(5) HIF1α transcriptional activity.   
While an increase in mRNA expression does not necessarily equate an increase in 
protein expression, HIF1α mRNA levels have been suggested to be a rate-limiting 
factor for its translation (Young et al, 2008). A highly specific RNA antagonist EZN-
2968 is an antisense oligonucleotide that has been shown to bind to HIF1α mRNA to 
reducing its translation both in vitro and in vivo. This then resulted in the reduction of 
HIF1α transcriptional targets (Greenberger et al, 2008). Phase I clinical trials showed 
safety in patients and further studies are required to investigate EZN-2968 modulation 
of HIF1α transcriptional targets (Jeong et al, 2014; Patnaik et al, 2009).  
 To inhibit HIF1α protein translation and accumulation in cells, agents such as 
inhibitors of topoisomerases I and II, receptor tyrosine kinase, cyclin dependent 
kinases and signaling pathways are all possible candidates. As studies have shown 
that mTOR plays a role in HIF1α translation, inhibiting mTOR signaling would lead 
to downregulation of HIF1α. Indeed mTOR inhibitors such as temsirolimus (Del 
Bufalo et al, 2006), everolimus (Vandamme et al, 2016) and MLN0128 (Ingels et al, 
2014) have all been shown to inhibit HIF1α protein translation. Stabilization of 
HIF1α in the cytosol requires interaction with the chaperone protein HSP90. In the 
presence of HSP90 inhibitors, HIF1α undergoes proteasomal degradation (Isaacs et 
al, 2002). Therefore HSP90 inhibitors such as 17-AAG and 17-DMAG are currently 
in development for cancer therapy. In addition, small molecules may also 
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downregulate the activity of HIF1α by inhibiting its ability to bind to HRE and 
initiate transcription of target genes. Recently, a compound DJ12 was identified from 
a screen of 15000 compounds to inhibit HIF1α activity by blocking its binding to 
HRE sequences (Jones & Harris, 2006). Examples of HIF1α inhibitors and their 
targets are summarized in Table 3-1.  
  HIF1α inhibitors may be effective against viral (Haeberle et al, 2008; Hwang 
et al, 2006), bacterial (Rius et al, 2008; Peyssonnaux et al, 2005), protozoan (Werth et 
al, 2010) and fungal (Werth et al, 2010) infections that have exhibited the ability to 
induce and thrive under HIF1α activity. Pathogens such as Murid herpesvirus 4 
(Polcicova et al, 2008) and EBV (Jiang et al, 2006) use HIF1α levels to sense the 
optimal time to exit a stressed and dying host cell. Other viruses such as HCV 
(Vassilaki et al, 2013), HBV (Yoo et al, 2003) and KSHV (Haque et al, 2003) all take 
advantage of the activation of HIF1α for its survival. These findings collectively 
suggest that inhibiting HIF1α could potentially serve as an anti-viral treatment 
strategy.  
 
HIF1α activity during immune responses   
 Conversely, as HIF1α controls multiple facets of cellular metabolism and 
immune responses, inhibiting it as a strategy for treating disease does pose 
conundrums. In healthy tissues, oxygen is generally consumed during oxidative 
phosphorylation and at sufficient concentrations to meet metabolic requirements. 
Recent studies observed that tissue hypoxia is associated with inflammatory diseases 
such as arthritis, atherosclerosis, inflammatory bowel disease, obesity, infections and 
cancer (Eltzschig & Carmeliet, 2011). Regions of inflammation result in hypoxic 
environments due to the high density of inflammatory cells and an increase in 
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metabolic activity, which leads to the increase in oxygen consumption. For example, 
neutrophils are able to create a state of hypoxia for neighboring cells during its 
oxidative burst activities (Campbell et al, 2014).  
HIF1α expression aids in anti-viral activity by promoting the recruitment and 
migration of immune cells to sites of infection. Hypoxia induces dendritic cells to 
upregulate chemo-attractants such as chemokine (motif CXC) ligand CXCL2, 
CXCL3, CXCL5 and CXCL8 which attract neutrophils (Winning & Fandrey, 2016). 
HIF1α  also increases the life span of neutrophils by inhibition of apoptosis 
(Walmsley et al, 2005). Additionally, macrophages increase its expression of CXC 
chemokine receptor (CXCR) such as CXCR4, and decreases CXCR5 resulting in 
macrophage retention (Sun et al, 2015; Fang et al, 2009). Similar to our study, HIF1α 
activation resulted in increased phagocytosis of bacteria in macrophages (Anand et al, 
2007). In mouse models, knockout of HIF1α in myeloid cells decreases its ability to 
combat pathogens (Peyssonnaux et al, 2005). 
Adding to the complexity, myeloid (monocytes and macrophages) and 
lymphoid cells (such as T cells) react differently to HIF1α stabilization. For example, 
hypoxia reduces T cell’s survival (Larbi et al, 2010) and proliferation (Conforti et al, 
2003; Larbi et al, 2010), whereas HIF1α has recently been shown to be essential for 
myeloid cell activity (Cramer et al, 2003a). This difference may be due to the 
disparate metabolism in which myeloid and lymphoid cells exhibit. Myeloid cells 
tend to rely on glycolysis for energy production, whereas lymphoid leans towards 
oxidative phosphorylation. As hypoxia and HIF1α promotes glycolysis in the absence 
of oxygen for the production of ATP, this enables myeloid cells to thrive but is 
considerably less effective for lymphoid cells (Kominsky et al, 2010).  
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 Collectively, in light of the conflicting roles HIF1α plays, further exploration 
is required to determine if augmenting or inhibiting HIF1α could be used to combat 
infections such as dengue.  
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4.4 Cellular membrane lipids modulate virus infections 
In addition to the increased FcγRIIA expression, our results also indicate that 
hypoxia causes HIF1α independent modulation of cellular lipid membranes (Figure 3-
14, 3-15). Synergistically, these changes result in the increased internalization and 
hence infection of antibody opsonized DENV (Figure 3-16). Hypoxia mediated 
changes to cellular lipid composition potentially affects membrane fluidity 
(Braverman & Moser, 2012) and aids in phagocytosis. This observation could explain 
why overexpression of FcγRIIA in cells under atmospheric oxygen tensions failed to 
result in increased FcγR-mediated entry (Chotiwan et al, 2014). 
 
Role of cellular lipids in viral internalization  
Cellular lipids play a role in almost every step of the virus life cycle including 
phagocytosis, facilitating virus binding, viral genome replication, modifying 
intracellular structures for replication and virus assembly (Chan et al, 2010; Martín-
Acebes et al, 2016; Lorizate & Kräusslich, 2011; Aloia et al, 1993). For example, 
lipid rafts have been shown to play important roles in the efficiency of entry of both 
enveloped and non-enveloped virus (Mercer & Schelhaas, 2010; Marsh & Helenius, 
2006; Ewers & Helenius, 2011). During internalization, many viruses subvert pre-
existing cellular lipids for entry and trafficking.  
 Lipids are also used as entry receptors for viruses; gangliosides serve as 
receptors for the polyomavirus family (Smith et al, 2003; Tsai et al, 2003) and 
phosphotidylserine (PS) is used by vesicular stomatitis virus (VSV) (Carneiro et al, 
2002). Ganglioside GM1 binds specifically to SV40 and subsequently recruits 
cholesterol for the generation of a lipid raft. This association is sufficient to result in 
inducing membrane curvatures leading to the formation of plasma membrane 
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invaginations (Ewers et al, 2010). Apart from SV40, this mode of entry has also been 
shown for cholera (Wolf et al, 2008) and shiga toxins (Römer et al, 2007). 
Lipoproteins, such as cholesteryl esters and apolipoproteins, on the surface of HCV 
binds to low-density lipoproteins receptors to facilitate its entry into hepatocytes 
(Targett-Adams et al, 2010; Alvisi et al, 2014). In addition, blocking cholesterol-
sensing receptors Niemann-Pick C1 (NPC1) blocks HCV entry, thus suggesting that 
cholesterol is also necessary for HCV uptake into liver cells (Sainz et al, 2012). 
For DENV, membrane lipid composition is also important for ADE as FcγR 
has been shown to associate with lipid rafts when engaged by IgG and depletion of 
cholesterol in these regions resulted in the decrease of ADE (Puerta-Guardo et al, 
2010). Under physiological oxygen conditions, our results suggests ether PE lipids are 
generally increased in monocytes cellular membranes, which contribute to increased 
DENV immune complex internalization. While to date there is no literature on the 
effect of ether PE lipids on DENV phagocytosis, the influence of lipid composition on 
membrane curvature and fluidity has been described.  
Membrane fluidity is promoted by lipids with short unsaturated fatty acids that 
lowers the packing density of membranes due to the presence of the double bonds 
(Koynova & Caffrey, 1998). Addition of sterols to membranes interferes with packing 
of fatty acid chains, thus resulting in increased membrane fluidity. Curvature however 
is dependent on lipid shape, which is determined by the area ratio of its polar head 
and acyl chains. Viral membrane fusion can be modulated by the addition of lipids, in 
either host cells or the virion, that affect the curvature of membranes. PC has a 
cylindrical shape with an equal head to chain ratio and thus induces neutral membrane 
curvature. PE on the other hand has a small head as compared to its acyl chain which 
creates a cone shape and induces negative curvature on membranes (Holthuis & 
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Menon, 2014). Increase in acyl chain unsaturation increases the propensity of PE to 
be in a non-bilayer state, resulting in packing defects that aids in membrane fusion 
(Marsh, 2007). It is therefore possible that an increase in ether-PE concentration 
results in membranes favorably for phagocytosis.     
 
Role of cellular lipids in viral fusion 
Interestingly, virus fusion activity can also be influenced by the composition 
and molecular shape of endosomal lipids. Studies have shown that alphavirus (Kielian 
et al, 2010) and West Nile virus (Moesker et al, 2010) requires either cholesterol or 
cholesterol and sphingolipids for fusion, respectively. Fusion of DENV in endosomes 
is modulated by the endosomal membrane lipid composition. This comes from the 
observation that DENV particles do not fuse with plasma membranes of cells 
(Zaitseva et al, 2010), and even with appropriately low pH, DENV viruses do not fuse 
in early endosomes (Guirakhoo et al, 1993). Mammalian late endosomal membrane 
are rich in anionic lipids (AL) such as PS (Coil & Miller, 2004) and 
bis(monoacylglycero)phosphate (BMP) (Kobayashi et al, 2002). Previous studies 
suggest that DENV fusion requires the presence of the AL, as intracellular 
membranes that do not support DENV fusion becomes fusion-competent after the 
addition of PS and BMP (Zaitseva et al, 2010). The reliance on AL to be present in 
membranes for fusion to occur allows the virion to determine the timing and cytosolic 
location of the release of its genome.  
Conversely, host cells can modulate endosomal membrane fluidity to restrict 
viral fusion. For example, interferon-induced transmembrane protein 3 (IFITM3) has 
been shown to inhibit influenza virus fusion by altering the properties of endosomal 
membranes and blocking the formation of viral fusion pores (Desai et al, 2014). 
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IFITM3 was characterized as a restriction factor against DENV and WNV (Brass et 
al, 2009) and was recently reported to inhibit DENV by upregulating interferons 
(IFN) in both infected and neighboring non-infected cells (Zhu et al, 2015).  
 It is clear that lipids play an important role in viral infections. This thesis 
shows that the increase of ether PE lipids in host cellular membranes in part 
contributes to the increase in DENV immune complexes under hypoxic conditions. 
Our results thus suggest that the hypoxia-induced changes in cellular lipid 
composition create a more favorable environment for viral infection or replication.  
 
Role of cellular lipids in viral replication 
In addition to internalization and fusion, modulation of cellular lipid content has been 
shown to affect viral replication in other ways. How viruses enter host cells and hijack 
cellular functions for their benefit have been intensively studied. From the literature, 
it seems that viruses subjugate and reprogram host lipids for its own advantage 
(Mazzon & Mercer, 2014). Pathogenesis of viruses such as picornoviruses (Fricks & 
Hogle, 1990), parvoviruses (Zádori et al, 2001), polyomaviruses (Tsai et al, 2014), 
adenoviruses (Maier et al, 2010), and reoviruses (Liemann et al, 2002) has been 
shown to require lipid interactions for successful replication. Double stranded DNA 
viruses and positive stranded viruses tend to create replication sites in the cytosol by 
reorganizing cellular membranes to form replication complexes (RC).  These sites 
serve to concentrate viral and cellular factors that are required for efficient replication 
of the viral genome. Additionally, RC induced during WNV is able to provide partial 
protection for the virus from cellular surveillance and anti-viral activity (Hoenen et al, 
2007). Positive-strand RNA such as HCV and DENV epitomizes the ability to shape 
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intracellular membranes in the host cell to favor its own replication (Mazzon et al, 
2013).  
 During infection, HCV viral proteins accumulate and hijack lipid droplets for 
the assembly of its progeny virions (Miyanari et al, 2007). Intracellular levels of fatty 
acids such as cholesterol are able to influence HCV replication in membranous webs 
(MW), which are virus induced, endoplasmic reticulum (ER)-derived vesicles (Egger 
et al, 2002). HCV NS4B induces the formation of the MW enriched with PI lipids 
(Hsu et al, 2010) in a yet to be identified mechanism (Egger et al, 2002). Importantly, 
the enrichment of PI together with cholesterol rich lipid rafts has been postulated to 
directly trigger the curvature of the membrane (McMahon & Gallop, 2005; Aizaki et 
al, 2004). Microarray and lipidomic analysis of HCV infected cells highlighted 
upregulation of lipid metabolism pathways, in particular cholesterol, phospholipid and 
sphingolipid biosynthesis to account for the elevated demands of the virus 
(Woodhouse et al, 2010).   
 Similarly, DENV infection results in invagination in the host ER membrane 
together with convoluted membranes (CM) that contain double stranded RNA 
(dsRNA) and viral proteins respectively (Welsch et al, 2009). Heaton and colleagues 
showed that viral NS3 recruits fatty acid synthase to replication sites to increase the 
rate of fatty acid biosynthesis required for its RC (Heaton et al, 2010). This suggests 
that DENV is able to manipulate host lipids to create sites of active replication, store 
its translated viral proteins and produce de novo fatty acids, all of which are essential 
for the efficient DENV life cycle.  
These studies show that lipid compositions of subcellular membranes can 
influence DENV replication post fusion. As our study did not characterize the lipid 
compositions of subcellular organelles, it is possible that hypoxia influences changes 
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in replication complexes or subcellular organelles that impacts DENV replication. 
This may in part explain our observation of an increase of DENV replication in under 
DENV infections in the absence of antibodies.  
 
Role of lipids in viral egress 
Lastly, enveloped virus progeny acquire their envelope membrane from the host cell 
during budding and exocytosis. Retroviruses, paramyxoviruses, and 
orthomyxoviruses typically bud at the plasma membrane, flaviviruses from the ER, 
HSV from the nuclear envelope, cytomegalovirus (CMV) from the golgi and 
subsequently released through the secretory pathway (Martín-Acebes et al, 2016). 
Membrane microdomains have been postulated to play a role in virus budding and 
exocytosis as viral proteins have been observed to colocalize with raft markers as 
visualized by immunofluorescence (Briggs et al, 2003). However, when virus proteins 
(HIV and Ebola) are expressed in the same cells, no colocalizations of viral proteins 
are observed on cellular membranes (Leung et al, 2008). This is strong evidence that 
enveloped viruses preferentially bud at different domains of membranes thus resulting 
in distinct viral lipid and protein composition.  
 Thus, as this thesis suggests that lipid compositions are altered under hypoxic 
conditions, it is possible that changes in the ER and golgi may impact DENV egress 
and progeny lipid compositions.  
 
4.5 Lipid composition of virions affect infectivity  
All viral membranes are derived from host cellular membranes. From our results, we 
show that DENV grown in hypoxic THP-1 cells either fuses or replicates more 
efficiently as compared to DENV grown in normoxic THP-1 cells. While there were 
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no genetic changes between DENV progeny from normoxic and hypoxic moncoytes, 
lipidomic analysis showed differences in the viral lipid profiles.  
 Between exocytosis and subsequent infection, the membranes of viruses 
protect it from chemical and mechanical damages. Therefore viral lipid envelopes 
play an important role in both protecting the virion and facilitate subsequent infection. 
Analysis of the HIV lipid profile found enrichment of plasmalogen PE molecules 
which is postulated to aid in fusion activity (Chan et al, 2008; Brügger et al, 2006; 
Glaser & Gross, 1994). In addition, viral envelopes of VSV (Fong et al, 1976), 
Newcastle disease virus (Quigley et al, 1971), Rous sarcoma virus (Quigley et al, 
1971) and Sendai virus (Barnes et al, 1987) all showed enrichment in PE content. As 
the presence of cone shaped PE enhances fusion activity, it is possible the lipid 
composition of viral membranes can result in less challenging cellular entry (Chan et 
al, 2010).  
However, results of the analysis of the lipid compositions shown in this thesis 
identified enrichment in LPC and reduction in SM and LPE in hypoxic DENV2 as 
compared to normoxic DENV2 (Figure 3-23,24). Interestingly, LPCs are a minority 
phospholipid in mammalian membranes but are enriched in DENV lipid membranes. 
LPCs are formed by the hydrolysis of the Sn2 acyl chain of PC by phospholipase A2, 
thus resulting in an inverted cone shape with a large head compared to its chain. 
Several studies have suggested that the additional of LPC in membranes inhibits 
fusion (Chernomordik et al, 1995; Yeagle et al, 2002; Vogel et al, 1993; Günther-
Ausborn & Stegmann, 1997).	In	addition,	SM	and	cholesterol	has	been	shown	to	be	required	for	fusion	of	Sindbis	virus	to	endosomal	membranes	(Wessels	et	al,	2007).	From	these	studies,	the	increase	of	LPC	and	decrease	of	SM	in	hypoxic	DENV	progeny	points	towards	inefficient	viral	fusion.	 
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In	contrast,	our	results	show	that	although	there	is	no	change	in	internalization	of	hypoxic	and	normoxic	DENV	progeny,	there	is	significantly	more	hypoxic	DENV	mRNA	22hpi	(Figure	3-18d).	Therefore	it	remains	to	be	defined	if	the	change	in	hypoxic	DENV	lipid	composition	acts	to	facilitate	viral	fusion.		
4.6 Implication for DENV assays 
In our study, we have shown that hypoxia affects DENV internalization 
through the modifications of FcγRIIA and cellular membrane lipid compositions. This 
is important, as the gradient of oxygen tensions exists in sites of in vivo dengue 
replication and in vitro experiments. In vitro measurements of neutralizing antibody 
titers needed to confer protection are important to determine vaccine immunogenicity. 
The results in this thesis may in part explain the disconnect between in vitro and 
clinical observations from the recent Sanofi dengue vaccine phase III trials. In vitro, 
plaque reduction neutralization test (PRNT) is currently the most widely used method 
of measuring the neutralizing and protective antibodies against DENV and in 
assessing the immunogenicity of dengue vaccines (Roehrig et al, 2008). Phase IIB 
trials data showed strong immunogenicity in vitro, but incomplete protection against 
the four antigenically distinct DENV serotypes clinically (Sabchareon et al, 2012).  
One possible explanation for this discord is the lack of FcγR in cells used for 
PRNT assays. Using PRNT assays in BHK cells, Moi et al demonstrated neutralizing 
activity in 18 serum samples from patients with acute secondary DENV to the 
infecting serotype. However the same neutralizing activity was not observed when 
FcγR-expressing cells were used (Moi et al, 2012). In addition, Wu and colleagues 
using acute and convalescent sera showed that heterologous antibodies could not 
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neutralize in the presence of FcγR mediated phagocytosis (Wu et al, 2012). This 
suggests that for complete humoral protection, antibodies need to prevent viral 
uncoating after FcγR mediated phagocytosis. As cross-reactive antibodies are 
generally poorly neutralizing as compared to serotype specific antibodies, depleting 
cross-reactive antibodies in sera prior to neutralization assays may also improve the 
accuracy of determination of vaccine immunogenicity (de Alwis et al, 2014; Henein 
et al, 2016).   
 As FcγR bearing cells are one of the main targets of dengue infection in vivo, 
using these cells may allow researchers to better assess the neutralizing capabilities of 
antibodies in vitro. In addition, our observations of hypoxia-induced expression of 
FcγRIIA in monocytic cells suggest that, due to oxygen conditions, assays conducted 
under atmospheric conditions in FcγR bearing cells potentially underestimates the 
amount of antibodies required for complete protection in vivo. Thus oxygen 
concentration is a factor that should be considered in in vitro assays conditions.  
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Chapter 5: Conclusion and future directions 
5.1 Concluding statements 
This thesis provides new insights into DENV infections in monocytes under 
physiological tissue microenvironments. Previous studies have shown that FcγR-
bearing monocytes play important roles in both protection and pathogenesis of DENV 
infections, therefore any factor that changes a monocytes behavior has the potential to 
impact DENV pathogenesis. This thesis adds to this knowledge by showing that the 
physiological oxygen concentration in lymphoid organs, which is lower (~3% O2) 
compared to atmospheric air (~20-21% O2), significantly alters monocytic cells’ 
susceptibility to antibody-dependent DENV infection.  
The findings reported here show that monocytic cells cultured at 3% O2 
demonstrated three distinct phenotypes  
(1) Increased requirement of antibodies for neutralization; 
(2) Increase in DENV progeny under ADE infection and 
(3) Increase in DENV progeny under virus only infection 
In summary, hypoxia induced increase in FcγRIIA expression results in the changes 
in antibody stoichiometry required for neutralization in hypoxic monocytic cells. 
Simultaneously ether PE lipids enriched in hypoxic cellular membranes 
synergistically increases the internalization of DENV immune complexes, thus in part 
leading to increased viral load and enhancement. In conclusion, our findings suggest 
that enhanced infection often observed in secondary dengue is antibody-dependent 
and hypoxia induced. A schematic to illustrate these findings is demonstrated in 
Figure 2-20. In addition to these changes, we also determined that hypoxic DENV 
progeny is more infectious compared the DENV progeny from normoxic THP-1 cells. 
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Collectively this thesis provides a first mechanistic view of the contributory role of 
low oxygen environments on cellular functions that impact dengue pathogenesis.  
 
5.2 Future studies 
 Our findings indicate an increase in the replication efficiency of hypoxic 
DENV progeny. It is possible that this phenotype is due to changes in the lipid 
composition of DENV progeny from hypoxic monocytes. As low oxygen tension is a 
better representation of in vivo tissue microenvironments of DENV replication, 
further studies are therefore required to determine if hypoxic DENV progeny better 
reflects DENV in a clinical setting. Furthermore, lipid analysis should be performed 
on different serotypes of DENV grown in hypoxic conditions to assess if the changes 
observed are applied across serotypes and compared to clinical isolates. If true, 
perhaps DENV virus stocks used for in vitro experiments should be grown under low 
oxygen tensions.  
 Independently, the difference in lipid compositions of hypoxic DENV progeny 
could be an interesting area of investigation on the role viral membrane lipids play in 
DENV fusion. Further studies to determine if the lipid membrane of hypoxic DENV 
changes its fusion efficiency could include labeling the virion with DiD and assess 
lipid mixing with the endosomal or liposome membranes.  
Increased replication of DENV under hypoxic conditions may in part be due 
to hypoxia induced cellular factors. We recently discovered a significant increase of 
autophagy flux in hypoxic THP-1 cells. Studies have shown that DENV infection 
induces autophagy, thus enabling viral replication without triggering cellular 
apoptosis(Datan et al, 2016). Whether increasing autophagy flux in hypoxia aids in 
DENV replication can be determined by knockdown of key autophagy related genes 
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(ATG) such as ATG5 or Beclin 1. Inhibitors of PI3-kinase and acid proteases, which 
are essential for autophagosome formation and lysosome activity, can also be used to 
determine the role of autophagy in the increase of DENV replication under hypoxic 
conditions(Yang et al, 2013).  
In addition, our results showed that DENV only infection in hypoxic 
monocytes resulted in increase binding of the virion but not internalization. This 
observation points towards a hypoxia induced increase in the expression of DENV 
binding factors. Co-immunoprecipitation and subsequent mass-spectometry analysis 
may reveal novel cellular receptors for DENV under physiological oxygen tensions. 
Investigations into these factors could be instrumental in our understanding of the 
DENV infections under physiological oxygen conditions.  
This thesis reveals novel insights into how tissue oxygen microenvironments 
affect DENV pathogenesis. Our findings have clear implications on preclinical 
evaluations on potential therapeutic antibodies against dengue and would thus 
contribute to the design of vaccines and therapeutics to better protect against the 
scourge of dengue.   	  
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	Abstract 
 
Dengue virus (DENV) has been found to replicate in lymphoid organs such as the lymph 
nodes, spleen and liver in post mortem analysis. These organs are known to have low 
oxygen levels (~0.5-4.5% O2) due to the vascular anatomy. However, how 
physiologically low levels of oxygen affect DENV infection via hypoxia-induced 
changes in the immune response remains unknown. Here we show that monocytes 
adapted to 3% O2 show greater susceptibility to antibody-dependent enhancement of 
DENV infection. Low oxygen level induces HIF1α-dependent upregulation of fragment 
crystalizable gamma receptor IIA (FcγRIIA) as well as HIF1α-independent alterations in 
membrane ether lipid concentrations. The increased FcγRIIA expression operates 
synergistically with altered membrane composition, possibly through increase membrane 
fluidity, to increase uptake of DENV immune complexes for enhanced infection. Our 
findings thus indicate that the increased viral burden associated with secondary DENV 
infection is antibody-dependent but hypoxia-mediated and suggest a role for targeting 
hypoxia-induced factors for anti-dengue therapy.  
 
Keywords 
Antibody-dependent enhancement / Cellular lipids / Dengue / Fc Receptors / Hypoxia  
	Introduction 
 
Dengue is a mosquito-borne viral infection that affects approximately 390 million people 
worldwide annually (Bhatt et al, 2013). There is currently no therapy for DENV and the 
recently licensed vaccine provides incomplete protection against the four antigenically 
distinct DENV serotypes (Sabchareon et al, 2012; Capeding et al, 2014; Villar et al, 
2015). Infection by any of these four serotypes (DENV1-4) leads to a wide spectrum of 
clinical outcome that includes severe circulatory shock, internal hemorrhage and organ 
dysfunction.  If not properly managed, mortality rates can be as high as 30% in severe 
dengue patients.  
Severe disease has been associated with secondary infection, where non-
neutralizing antibodies from prior infection with any of the 4 DENV serotypes bind to the 
remaining 3 heterologous DENV. Fragment crystallizable gamma receptor (FcγR)-
mediated uptake of these non-neutralized viral immune complexes result in viral entry 
that, along with other host (Ubol et al, 2010; Chareonsirisuthigul et al, 2007; Yang et al, 
2001; Halstead et al, 2010; Khor et al, 2011) and viral factors (Manokaran et al, 2015; 
Quiner et al, 2014), contributes to increased risk of severe dengue. This is uniquely 
demonstrated in infants, born to dengue-immune mothers, who develop severe disease 
after a primary infection as a result of sub-neutralizing levels of maternal antibodies that 
enhance infection (Kliks et al, 1988; Simmons et al, 2007). Antibody-dependent 
enhancement (ADE) of infection in cells such as monocytes, macrophages and dendritic 
cells results in increased pro-inflammatory and possibly toxic effects of viral antigens 
that exacerbates disease (Beatty et al, 2015; Modhiran et al, 2015). Indeed, ADE has 
recently been demonstrated clinically where cross reactive antibodies were shown to 
	enhance live attenuated yellow fever virus vaccination infection and corresponding pro-
inflammatory response for improved immunogenicity (Chan et al, 2016).  
Post mortem analyses have found evidence of active DENV replication in 
myeloid-derived cells in the lymph nodes, spleen and liver (Nisalak et al, 1970; Balsitis 
et al, 2009; Basílio-de-Oliveira et al, 2005). In mice, infection of monocytes and 
macrophages in lymph nodes is an early event as DENV is trafficked from the site of 
inoculation by dendritic cells where subsequent rounds of infections occur (Prestwood et 
al, 2012). In vivo, the oxygen microenvironments of these lymphoid organs (~0.5% - 
4.5% O2) are substantially lower than atmospheric O2 levels (~20% O2) (Caldwell et al, 
2001). Low oxygen levels are known to result in differential expression of a number of 
genes, including those that regulate the inflammatory and immunoregulatory responses in 
monocytes (Bosco et al, 2006; 2011). How such hypoxia-induced modifications in host 
response affect DENV infection or ADE remain unknown, as mechanistic studies to date 
have been exclusively performed at atmospheric O2 levels.  
In this study, we demonstrate that low oxygen levels induce FcγRIIA protein 
abundance via hypoxia-inducible factor 1 alpha (HIF1α), which possibly acts as a 
transcriptional enhancer. With increased FcγRIIA expression, internalization of DENV 
immune complexes is increased and higher concentration of antibodies are required for 
complete DENV neutralization. Furthermore, under hypoxic conditions, infection with 
DENV opsonized with enhancing levels of antibodies resulted in increased in production 
of infectious DENV progenies. While HIF1α stabilization by hypoxia can explain 
increased FcγRIIA expression, it alone is insufficient for enhanced infection as chemical 
stabilization of HIF1α in cells cultured at atmospheric O2 levels showed increased 
	FcγRIIA expression but not viral entry. Instead, hypoxia-induced but HIF1α-independent 
change in membrane lipid compositions is also necessary for increased FcγRIIA-
mediated uptake of DENV immune complexes, which is a key first step for antibody-




Hypoxia upregulates FcγRIIA expression 
Low oxygen tensions have been shown, in human primary moncoytes, to upregulate the 
transcription of FcγR which play a vital role in phagocytosis of antibody-opsonized 
pathogens (Bosco et al, 2006). However, with general inhibition and selective translation 
under hypoxic conditions, not all upregulated mRNAs necessarily results in changes in 
protein abundance in the cell (Koritzinsky et al, 2006; Young et al, 2008; Pettersen et al, 
1986).To investigate how hypoxia affects the expression of FcγRs on monocytes, we first 
determined if primary monocytes cultured at 20% and 3% O2 (herein refered to as 
normoxia and hypoxia, respectively) for 24 hours exhibited changes in FcγR expression. 
To ensure that data obtained from cell lines can be representative of an ex vivo system, 
response to hypoxia was tested in an acute monocytic leukemia cell line (THP-1) and 
primary monocytes. Both approaches showed the expected increase in hypoxia induced 
genes such as adrenomedullin (ADM) and vascular endothelial growth factor (VEGF) 
after 24 hours of adaptation to hypoxia (Fig EV1, Appendix Table S1). Consistent with 
previously reported observations (Bosco et al, 2006), exposure to hypoxia increased 
FcγRI, FcγRIIA and FcγRIIB mRNA levels as early as 6 hours post oxygen exposure and 
persisted at least up to 24 hours post oxygen exposure in primary monocytes (Fig 
	1A,B,C). However, only FcγRIIA but not FcγRI or FcγRIIB, showed increased amounts 
of protein expression 24 hours post hypoxia exposure as assessed by both western blot 
(Fig 1D,E) and flow cytometry (Fig 1F,G, Appendix Fig S1). Similarly, both the increase 
in FcγRIIA mRNA and protein expression 24 hours post hypoxia adaptation was 
observed in THP-1 cells (Fig 1H-J).  
 
Hypoxia enhances antibody dependent DENV infections 
To determine the effect hypoxia on the susceptibility of monocytic cells to DENV 
infections, primary monocytes were infected with DENV only or DENV opsonized with 
varying concentrations of DENV-2 specific human-mouse chimeric 3H5 (Hanson et al, 
2006) (h3H5) or pan-serotype human-mouse chimeric 4G2 (h4G2) monoclonal antibody 
(mAb) (Hanson et al, 2006; Chan et al, 2011; 2014; Robinson et al, 2015). Hypoxic cells 
required more antibodies for neutralization as compared to cells cultured under normoxic 
conditions (Fig 2A,B). In addition, plaque titers following DENV only infection or 
infection with enhancing concentrations of h3H5 or h4G2 mAbs under hypoxic 
conditions were higher relative to infection under normoxia (Fig 2A-F). The increase in 
enhancement was observed with primary monocytes from 3 other donors (Fig 2D-F) 
using DENV opsonized with enhancing concentrations of h3H5. However, the increase in 
plaque titers following DENV only infection was not universal across all 4 primary 
monocyte donors (Fig 2D).  
Similar enhancement phenotypes were observed when THP-1 cells were infected 
with DENV-2 opsonized with h3H5 (Fig 2G), h4G2 (Fig 2H), convalescent sera obtained 
from individuals previously infected with either DENV-2 (Fig 2I) or DENV-1 (Fig 2J) 
	(Low et al, 2006) as well as DENV only (Fig 2K). Increased DENV replication was also 
observed at lower oxygen concentrations (0.5% O2), suggesting that this phenotype is not 
constrained to 3% O2 environments (Appendix Figure S2).  
 
Hypoxia results in increased internalization of antibody-opsonized DENV but not 
DENV only 
The difference in infection rate can be seen as early as 2 hours post-inoculation 
(hpi) of DENV onto THP-1 cells cultured under hypoxia compared to normoxia (Fig 3A, 
B). However, treatment with pronase to remove plasma membrane-bound but 
uninternalized DENV abrogated any differences in RNA levels at 2hpi for virus only but 
not antibody-dependent infection (Fig 3C). This suggests that an increase in the 
internalization of antibody-opsonized DENV under hypoxic condition may be due to the 
observed upregulation of FcγRIIA in monocytic cells cultured under hypoxic conditions. 
In contrast, the effect of hypoxia on DENV only infection is probably mediated through 
post-viral entry mechanisms.  
Next, we determined if FcγRIIA functionally mediated the observed increase in 
entry of antibody-opsonized DENV or serves only to aid viral attachment to the plasma 
membrane (Ayala-Nunez et al, 2016; Mady et al, 1991; Chotiwan et al, 2014). We used 
high-resolution confocal microscopy and subsequent deconvolution analysis to visualize 
antibody-opsonized, AF488-labeled DENV-2 with FcγRIIA at resolutions of 
approximately 200 and 50nm, respectively (Fig 3D). Using Imaris spot detection and co-
localization analysis, spots were placed at center points of DENV-2 and FcγRIIA.  This 
enabled the identification of FcγRIIA interacting with individual antibody-opsonized 
	DENV to within a distance of 100nm of each other and at a distance of more than 500nm 
inside the plasma membrane (Fig 3E). Similar results were obtained when we used 
ImarisCell to reconstruct the plasma membrane with a highly conservative thickness and 
identified FcγRIIA-DENV-2 interacting spots within the cytoplasm (Appendix Video 
S1). These findings indicate that FcγRIIA directly mediated uptake of DENV immune 
complex during antibody-dependent infection under hypoxic conditions.  
Concordant to the microscopy data, stable knockdown of FcγRIIA expression using 
shRNA resulted in significantly decreased DENV plaque titers under hypoxic conditions 
(Fig 3F).  
 
HIF1α  enhances FcγRIIA expression 
The upregulation of FcγRIIA under hypoxic conditions suggest that the transcription 
factor hypoxia-inducible factor (HIF1α or HIF2α) may play a role in regulating its 
expression. Under oxygen rich environments, HIFs are degraded through O2- and iron-
dependent reactions (Semenza, 2004). At low O2 or iron levels, HIF binds the core penta-
nucleotide sequence, or hypoxia-response element (HRE), to initiate transcription. To 
evaluate if the increase in FcγRIIA transcription is mediated by either HIFs, we cultured 
HIF1α or HIF2α silenced THP-1 cells under hypoxic conditions. As a control, we 
measured for the expected dose-dependent decrease in ADM mRNA expression, which 
has been previously shown to be regulated by HIFs (Keleg et al, 2007). HIF2α silenced 
cells (Fig EV2A) showed no changes in FcγRIIA protein expression (Fig EV2B) DENV 
internalization (Fig EV2C) or DENV replication under ADE conditions (Fig EV2D). 
	However, silencing HIF1α (Fig 4A) resulted in reduced expression of both ADM (Fig 
4B) and FcγRIIA (Fig 4C, D).   
Likewise, chemically stabilizing HIF1α by an iron chelator desferrioxamine 
(DFX) under normoxic conditions (Fig 4E) (An et al, 1998) resulted in dose-dependent 
increase in ADM (Fig 4F) as well as both FcγRIIA mRNA (Fig 4G) and protein levels 
(Fig 4H). This stabilization of HIF1α and subsequent increase in FcγRIIA expression 
resulted in increased immunofluorescence signal of DENV immune complexes, which 
was abrogated upon knockdown of FcγRIIA (Fig 4I). These results suggest that FcγRIIA 
transcription is regulated by HIF1α.  
Chromatin immunoprecipitation sequencing (ChIP-seq) analysis, however, did 
not reveal a HIF1α binding site in the promoter region of FcγRIIA. ChIP-seq could not be 
carried out at 20% O2 tension due to the rapid degradation of HIF1α (Appendix Table 
S2). However, under hypoxic conditions, a binding site for HIF1α was identified 
approximately 5000 bases upstream of FcγRIIA (Fig 5A). A similar binding site for 
HIF1α was also observed upon HIF1α stabilization by DFX under normoxic conditions 
(Fig 5B). These results suggest that HIF1α is not a promoter but potentially an enhancer 
of FcγRIIA expression although further work will be needed to confirm the latter notion.  
Curiously, however, knockdown of HIF1α and its resultant decrease in FcγRIIA 
expression only led to a modest decrease in infection of antibody-opsonized DENV (Fig 
5C). No difference was observed in virus only control infection. These findings suggest 
that additional hypoxia-induced but HIF1α may act synergistically with FcγRIIA to 
increase ADE. To further investigate this, we infected hypoxic, normoxic and normoxic 
cells treated with 200uM of DFX simultaneously with antibody-opsonized DENV, with 
	or without pronase treatment. This allows us to ascertain if other hypoxia-induced but 
HIF1α-independent factors contribute to the increase in internalization of antibody-
opsonized DENV observed in hypoxic monocytes. The results showed increased DENV 
signal, as measured by flow cytometry, in both hypoxia (51%) and DFX treatment (47%) 
as compared to normoxic THP-1 cells (25%) (Fig 5D). However, pronase treatment 
showed that increased uptake of antibody-opsonized DENV remained high only in 
hypoxic cells (43%) as compared to normoxic cells (20%). In contrast, only 25% of DFX 
treated THP-1 cells showed DENV internalization, which is only a marginal increase 
compared to normoxic, untreated cells. Collectively, these findings indicate that hypoxia-
induced internalization of antibody-opsonized DENV requires HIF1α-independent 
changes in the cell to complement the induced FcγRIIA expression. 
 
Increased membrane ether-linked PE aids internalization of DENV immune 
complexes 
To identify HIF1α-independent host cell response to hypoxia that could act in 
concert with FcγRIIA for increased ADE, we profiled mRNA transcripts in THP-1 cells 
cultured under normoxia and hypoxia for 24 hours. Gene set enrichment analyses 
(GSEA) comparing hypoxic to normoxic cells identified lipid metabolic pathways such 
as phosphotidylethaloamine (PE), phosphotidylserine (PS), cholesterol and 
glycosphingolipid metabolism to be enriched under hypoxic conditions (Fig 6A).  
Lipids, especially phospholipids, are important in maintaining cellular membrane 
integrity and proper function of membrane proteins (Dowhan, 1997). To identify the 
membrane lipid composition modification that alters the efficiency of FcγR-mediated 
phagocytosis (Ebbesen et al, 1991), we compared the lipid profile of cells cultured under 
hypoxia against normoxia. Our results showed that ceramides (Cer), phosphotidylserine 
(PS), sphingomyelin (SM), phosphatidylinositol (PI) (Fig EV3A-E), phosphotidylcholine 
(PC), lyso-phosphotidylcholine (LPC), lyso-phosphotidylethanolamine (LPE) (Fig 
EV4A-D) were not significantly different between hypoxic and normoxic cells. While 
cholesterol also showed no difference (Fig EV4E), cholesterol esters were marginally 
upregulated in hypoxic cells (Fig EV4F). Significant differences, however, were 
observed in a subset of phosphotidylethanolamine (PE) lipids. Ether linked PEs were 
upregulated up to 4-fold in hypoxic compared to normoxic cells (Fig 6B). In contrast, 
DFX treated cells showed no change in ether PE concentration as compared to normoxic 
cells (Fig 6C). Furthermore, silencing HIF1α (Fig EV5A) had no significant effect on 
concentration of PE lipids (Fig EV5B-D), suggesting that upregulation of ether PE is 
HIF1α-independent.  
PE is one of the major structural lipids in eukaryotic membranes and assumes a 
conical molecular geometry due to the relatively small size of its polar headgroup 
(Holthuis & Menon, 2014). Any subtle change in PE composition could thus affect cell 
membrane fluidity (Braverman & Moser, 2012) that alters FcγR-mediated uptake of 
antibody-opsonized DENV. To test this possibility, we used siRNA to silence 
alkylglycerone phosphate synthase (AGPS), a requisite enzyme for ether lipid synthesis 
(Fig 7A) (Benjamin et al, 2013). As expected, reduced AGPS expression significantly 
reduced uptake of antibody-opsonized DENV (Fig 7B) and the resultant plaque titers 
produced (Fig 7C) under hypoxic conditions. Furthermore, double knockdown of AGPS 
and FcγRIIA (Fig 7D) resulted in further decrease in uptake of antibody-opsonized 
DENV compared to silencing only either AGPS or FcγRIIA (Fig 7E). Collectively, our 
data indicates that upregulation of ether-linked PE complements the increased FcγRIIA 
expression to increase susceptibility to antibody-dependent infection under hypoxic 
conditions.  
Discussion 
Monocytes that traffic to lymph nodes and the spleen ultimately function in low 
O2 environments. While low O2 alters FcγR expression transcriptionally (Bosco et al, 
2006), it is unknown how FcγR protein levels and other cellular functions that are 
affected can impact DENV infection. This study thus provides a first molecular view of 
the contributory role of low oxygen environments on cellular functions that impact 
dengue pathogenesis. 
Oxygen level is known to affect viral pathogenesis in different ways. Generally, 
hypoxia impairs viruses that naturally infect tissues with high atmospheric oxygen 
concentration such as influenza virus (Magill & Francis, 1936), adenovirus (Pipiya et al, 
2005) and simian virus 40 (Riedinger et al, 1999). In contrast, hypoxia has been shown to 
increase the infection of viruses, such as hepatitis C virus (HCV) (Vassilaki et al, 2013) 
and sendai virus (Ebbesen et al, 1991), which naturally target organs with low oxygen 
concentrations such as the liver, spleen and lymph nodes, as does DENV. We show in 
this study that hypoxia increases DENV infection through both increased uptake of 
antibody-opsonized DENV and hitherto undefined post-uptake mechanism for DENV 
only inoculation. Antibody-dependent infection is augmented by hypoxia through 
FcγRIIA induction, through a possible enhancer role of HIF1α as well as HIF1α-
independent alteration in membrane ether linked PE levels. Both changes act 
synergistically for increased internalization of DENV immune complexes. Indeed, these 
findings could explain why overexpression of FcγRIIA in cells cultured at atmospheric 
oxygen levels had, on some occasions, failed to show increased FcγR-mediated entry 
(Chotiwan et al, 2014).  Hypoxia also appears to induce FcγRI and FcγRIIB mRNA 
levels without detectable differences in the protein levels, suggesting additional 
regulatory mechanisms on translation by hypoxia that remain to be fully identified. 
Nonetheless, hypoxia-driven effects on cells targeted by DENV could be an essential 
factor in dengue pathogenesis, especially in individuals with pre-existing DENV 
antibodies from a previous infection with a heterologous DENV serotype.  
Interestingly, virus internalization during DENV only infection in the absence of 
antibodies was not affected by the changes in cellular lipid composition, despite 
increased replication and production of DENV progeny in both primary monocytes and 
THP-1 cells. This difference suggests that cellular lipid composition may impact the 
efficiency of FcγR-mediated phagocytosis differently from other receptor-mediated 
endocytosis or macropinocytosis, the cellular entry pathway used by DENV only 
infection (Ayala-Nunez et al, 2016). Additional studies to define how hypoxia affects 
DENV only infection will be needed to confirm these possibilities. 
Adaptation to hypoxia results in a multitude of changes in the cell, ranging from 
metabolic pathways (Masson & Ratcliffe, 2014; Eales et al, 2016), autophagy (Bellot et 
al, 2009; Heaton & Randall, 2011; Lai et al, 2016) to host immune responses (Bosco et 
al, 2006; Nizet & Johnson, 2009). It is clear that hypoxia-driven changes for DENV 
production remain to be fully elucidated and cellular autophagy, which has previously 
been shown to enhance DENV replication (McLean et al, 2011; Heaton & Randall, 2011) 
may also be important for antibody-enhanced infection. The observations reported here 
suggest that these mechanisms could be productive areas of investigation to understand 
dengue pathogenesis. 
Besides pathogenesis, the role of hypoxia in DENV infection also raises other 
important questions that need to be explored urgently. In vitro measurements of 
neutralizing antibody titers required to confer protection is especially vital to determine 
vaccine immunogenicity or dose of therapeutic antibodies required against dengue. Our 
findings suggest that assays conducted at atmospheric oxygen tensions potentially 
underestimate the amount of antibodies required for complete protection in vivo under 
physiological oxygen tensions due to hypoxia-induced increases in FcγRIIA.  Sub-
neutralizing levels antibodies, increases the risk of triggering antibody-enhanced 
infection, which may result in severe disease. Development of assays using cells that 
express the relevant repertoire of FcγR cultured under hypoxic conditions could provide a 
fresh layer of information on protective immunity following vaccination. 
In conclusion, our findings suggest that the enhanced infection often observed in 
secondary dengue is antibody-dependent and hypoxia-induced.  Developments in drugs 
that target hypoxia-induced factors as anti-neoplastic therapy could thus also have 
antiviral efficacy. 
Materials and Methods 
Primary Samples: Primary monocytes were derived from blood obtained from the 
Singapore Health Sciences Authority Blood Bank, under a protocol approved by the 
institutional review board (IRB 201406-01). Donor 1 was tested for pre-existing DENV 
antibodies by PRNT and was found to be negative for antibodies against the four DENV 
serotypes. 
Cells: THP-1 cells were obtained from ATCC. Primary moncoytes were isolated from 
healthy donors and cultured as described (Chan et al, 2011). When required, cells were 
adapted to 3% O2 in fully humidified incubators supplied with pure nitrogen gas to 
reduce oxygen levels as well as 5% CO2 for 24 hours prior to infection with DENV-2. 
Cells tested negative for mycoplasma.  
Virus Infection: DENV-2 (ST) is a clinical isolate obtained from Singapore General 
Hospital. Endotoxin free h3H5 and h4G2 chimeric human/mouse antibodies were 
constructed as described (Hanson et al, 2006). DENV-2 was incubated with media, 
antibodies or serum at 37oC for 1 hour before inoculation onto THP-1 cells at MOI of 10. 
Internalization of virus was assessed by Alexa-488 labeled DENV 2hpi as described 
(Zhang et al, 2014) or by qPCR. Viral progenies produced 72 hpi were assessed by 
plaque assay 72hpi.  
DFX treatment: Desferrioxamine mesylate salt (DFX) was purchased from Sigma 
(D9533) and reconstituted in water. DFX (Sigma D9533) was diluted in water to a stock 
concentration of 500µM. THP-1 cells were subsequently treated with 100µM or 200µM 
of DFX (diluted in RPMI) for 24h prior to infection with DENV at MOI of 10.  
Virus assessment with qPCR: RNA from cells was extracted using the RNeasy Kit 
(Qiagen) followed by cDNA synthesis (Biorad) and real-time aPCR (Roche) according to 
manufacturer’s protocol. Primer sequences were obtained from Origene. DENV primers 
used were: DENV-F 5’-TTGAGTAAACYRTGCTGCCTGTAGCTC DENV-R 5’ 
GAGACAGCAGGATCTCTGGTCTYTC. All RNA levels were measured relative to 
TATA-box binding protein (TBP). 
Plaque Assays: Virus plaque titers were quantified as previously described (Chan et al, 
2011). 
Flow cytometry: After infection, primary monocytes and THP-1 cells were washed with 
phosphate buffer solution (PBS) and fixed with 3% paraformaldehyde at 4oC. Blocking 
of FcγRIIA was performed with goat polyclonal CD32A (1:100, R&D Systems AF1875) 
for 30min at 4oC. After washing with PBS, mouse anti-CD32 IV.3 (1:300, Stem Cell 
Technologies 60012) was then added for 30min at 4 oC. After further washing with PBS, 
anti-mouse AlexaFluor 488 (1:400) was added and incubated at 4oC for 30min prior to 
analysis with the BD LSRFortessa flow cytometer. In a separate experiment, primary 
monocytes and THP-1 cells cultured at 20% O2 and 3% O2 for 24h were washed with 
PBS and fixed with 3% PFA. Mouse anti-FcγRI (1:300, Abcam ab46679) and mouse 
anti-CD32 IV.3 (1:300, Stem Cell Technologies 60012) antibodies were added for 30min 
at 4oC. After washing with PBS, anti-mouse AlexaFluor 488 (1:400) was added and 
incubated at 4oC for 30min prior to analysis with the BD LSRFortessa flow cytometer.  
Western blot: Cells were washed once in PBS and resuspended in lysis buffer (1% 
Nonidet P-40, 150mM NaCl, 50mM Tris pH8.0) in the presence of protease inhibitors 
(Sigma). Proteins in cells lysates were separated by SDS-PAGE, transferred to PVDF 
(Millipore) and incubated with primary antibody followed by HRP-conjugated anti-rabbit 
(1:3000, Abcam 6721) or anti-mouse (1:1000, Dako P0447) antiserum. Primary 
antibodies for LAMP1 (1:1000, eBioscience 6721), FcγRI (1:300, Abcam ab46679), 
FcγRIIA (1:300, Stem Cell Technologies 60012), FcγRIIB (1:500, Abcam ab123240), 
AGPS (1:250, Sigma HPA030209), HIF1α (1:1000, Abcam 2158) and HIF2α (1:1000, 
Abcam 8365) were used. Blots were developed using enhanced chemiluminescence 
detection reagents (Amersham). Data shown is representative of 3 independent 
experiments. Quantification of protein densitometry was performed with ImageJ 1.47v.  
Confocal Microscopy: After infection with AF488 labeled DENV and fixation with 3% 
PFA for 30min, THP-1 cells were subjected to cytospin at 800 x g for 3mins and washed 
with PBS. Mouse anti-CD32A (1:300, Stem Cell technologies 60012) was added and 
incubated for 1h at room temperature. After washing with PBS, anti-mouse AF568 
(1:200) was added and incubated at room temperature for 45mins. Cells were washed 
with PBS and permeabalized with 0.1% saponin in 5% BSA for 30min at room 
temperature. Anti-CD32A was added for 1h at room temperature. After washing, anti-
mouse AF647 was added and incubated at room temperature for 45mins. Thereafter, cells 
were fixed with 10% glycerol and 90% PBS before viewing under a Leica confocal 
microscope. Deconvolution (HuygensEssential) and Imaris analysis was performed at the 
SingHealth Advanced Bio Imaging Core. 
shRNA and siRNA Transfection: siRNA transfection was performed as previously 
described(Chan et al, 2014). siAGPS  (s16248), siHIF1α (s6539) and siHIF2α (s4698) 
from Life Technologies were used. CD32A shRNA (sc-29992-v) was purchased from 
Santa Cruz Biotechnologies. Qiagen AllStars negative control siRNA (SI03650318) 
served as control siRNA. 
Microarray: Following RNA extraction, microarray was performed at Duke-NUS 
Genome Biology Core Facility using Illumina human HT-12 beadchips. Data 
normalization was performed using Partek software and quantile normalized prior to 
analysis with Gene Set Enrichment Analysis. The microarray data were deposited in the 
Array Express database (www.ebi.ac.uk/arrayexpress) under accession number E-
MTAB-4692.  
ChIP-Seq: Chromatin immunoprecipitation was performed using SimpleChIP Enzymatic 
Chromatin IP Kit (CST #9003) according to the manutacturer’s protocol. After recovery 
of ChIP and input DNA, 30ng of DNA was used for each sequencing library preparation 
(New England Biolabs, E6240). 4 libraries were multiplexed (New England Biolabs, 
E7335) and sequenced on 1 lane of Hiseq2500 (Illumina) to an average depth of 20-30 
million reads per library. The quality of the sequencing reads was ascertained via the 
FASTQC tool (Li & Dewey, 2011).The average sequencing depth was 54.4 million reads 
per sample and the median per-base quality was >30 for all the samples. No further 
trimming of the bases was performed. Sequencing reads were then mapped to the human 
reference genome (hg19) using BWA-0.5.9 alignment tool (Li & Durbin, 2009). The 
average mapping rate was 99.5%. Peak calling were performed using MACS-1.4.2 
(Zhang et al, 2008), resulting in the generation of potential HIF1α binding sites. 
Liquid-liquid extraction: THP-1 membranes were prepared by incubation in 20mM Tris 
Buffer pH7.4. Chloroform:methanol (1:2) was added to cell suspension (after washing 
the cells with 1 x PBS, reconstitute cells with 50µL of MQ water). Known amount of 
internal standards were spiked into the cell-solvent mixture prior to incubation. The 
mixture was incubated in a 4oC room for 2 hours with agitation at 600 rpm on a 
Thermomixer (Eppendorf). After incubation, 300µL of chloroform and 250µL of MQ 
water were added into the mixture and vortexed to mix. The mixture was centrifuged at 
15,000 x g for 5 min to break phase and the bottom organic phase which contain lipids 
was transferred into a clean tube. Re-extraction was performed by using another 500µL 
of chloroform and the organic phase obtained was pooled. The lipid extracts were then 
dried under nitrogen stream and kept at -80 oC until used. 
Lipids analysis using high performance liquid chromatography/mass spectrometry: 
Lipids were analyzed on an Agilent 1290 HPLC system coupled with an Agilent 6460 
Triple Quadrupole mass spectrometer. Liquid chromatography was performed on a 
Zorbax Eclipse Plus, Rapid Resolution High Definition, 1.8µm reversed-phase C18 100 
Å, 50 × 2.1mm column (Agilent Technologies Corp, Santa Clara CA). HPLC conditions: 
injection volume 2µL; mobile phase A and B consisted of isopropanol: acetonitrile in the 
ratio of (60:40) and (90:10) (optima grade), respectively, both containing 10mM 
ammonium formate; flow rate 0.5 ml/min, 60% B for 2 min, then linearly changed to 
0.4mL/min in 2 min; solvent composition was then linearly switched to 100% B in 7 min 
and maintained for 2 min, and then linearly changed to 20% B in 9 min and maintained 
for 1.5 min. Then, the flow rate and the mobile phase were returned to the original ratio. 
Mass spectrometry was recorded under the positive ESI mode. Individual lipid species 
were quantified using spiked internal standards obtained from Avanti Polar Lipids 
(Alabaster, AL, USA). 
Statistical Analysis 
Experiments were replicated 3 times (unless stated otherwise), each with 4 biological 
replicates. Mean of 1 representative experiment and its standard deviation (SD) is shown 
in each figure. Primary monocytes obtained from 4 different donors were used, with each 
dataset representing 4 replicates from a single donor obtained from a single experiment. 
2-tailed unpaired t-test was performed to compare between the means of 2 conditions of
the same donor using GraphPad prism v7.0. A 2-tailed paired t-test was performed using 
GraphPad prism v7.0 when multiple donors were included in a single analysis.  
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Main Figure Legends 
Figure 1: Monocytes express higher levels of FcγRIIA under hypoxic conditions. 
A-C. FcγI (A), FcγRIIA (B) and FcγRIIB (C) RNA copy number in normoxic (blue) or
hypoxic (red) primary monocytes at various time points (hours) post oxygen adaptation. 
D. Protein expression of FcγRI, FcγRIIA and FcγRIIB in normoxic and hypoxic primary
monocytes at 24h post oxygen adaption. LAMP1 served as loading control. Numbers 
shown below the blots indicate densitometry analysis of protein levels of FcγRs 
normalized to LAMP1.  
E. Protein abundance of FcγRIIA from 4 donors in primary monocytes relative to
LAMP1. 
F,G. Mean fluorescence intensity (MFI) of 4 biological replicates of FcγRIIA (E) and 
FcγRI (F) in normoxic (blue) and hypoxic (red) primary monocytes (n=4) at 24h post 
oxygen adaptation as assessed using flow cytometry.  
H. THP-1 FcγRIIA RNA copy number under normoxic (blue) and hypoxic (red) in THP-
1 cells conditions at various time points post oxygen adaptation. 
I. Protein expression of FcγRI, FcγRIIA, and FcγRIIB in THP-1 cells at 24h post oxygen
adaptation. 
J. Protein abundance of FcγRIIA from 4 independent experiments in THP-1 cells relative
to LAMP1 
Data information: In (A-C,F-H), data are presented as mean ± SD. *P<0.05, **P<0.01, 
***P<0.001 (Unpaired t-test). In (E,J), data are presented as mean ±SEM. *P<0.05, 
**P<0.01. (Paired t-test)  
Figure 2: Hypoxia modulates DENV infection in monocytes.  
A,B. Plaque titers of normoxic (blue) and hypoxic (red) primary monocytes (Donor 1) 
following infection with DENV-2 opsonized with varying concentrations of h3H5 (A) 
and h4G2 (B) at MOI of 10 at 72hpi. Using PRNT (PRNT50<1:10), Donor 1 was 
confirmed to have no pre-existing antibodies.  
C. Plaque titers of normoxic (blue) and hypoxic (red) primary monocytes from Donor 1
following DENV only infection.  
D-F. Plaque titers of normoxic (blue) and hypoxic (red) primary monocytes from Donor
2 (D), Donor 3 (E) and Donor 4 (F) when infected with DENV-2 opsonized with 
0.391µg/ml h3H5 that permits maximal levels of ADE. Dashed lines represents plaque 
titers of normoxic (blue) and hypoxic (red) cells following DENV only infection in each 
individual donor 
G-H. Plaque titers of normoxic (blue) and hypoxic (red) THP-1 cells when infected with
DENV-2 opsonized with varying concentrations of h3H5 (G) and h4G2 (H).  
I,J. Plaque titers of normoxic (blue) and hypoxic (red) THP-1 cells when infected with 
DENV-2 opsonized with different levels of serotype-specific (I) and cross-reactive (J) 
convalescent serum.  
K. Plaque tires of normoxic (blue) and hypoxic (red) THP-1 cells following DENV only
infection.  
Data information: In (A-K), data are presented as mean ± SD. *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001 (Unpaired t-test). 
Figure 3: Hypoxia induced Fc!RIIA expression increases uptake of antibody-
opsonized DENV.  
A,B. Viral RNA copy numbers at 2hpi with DENV-2 opsonized with h3H5 (ADE) (A) or 
DENV-2 only (B). Blue and red bars represent cells cultured in normoxia and hypoxia, 
respectively. 
C. Viral RNA copy numbers after pronase treatment at 2hpi under ADE or DENV-2 only
conditions. 
D. Immunofluorescence microscopy of surface FcγRIIA (blue, AF532), total FcγRIIA
(red, AF647) with DENV (green, AF488). Co-localization of internalized FcγRIIA with 
DENV in the cytoplasm of THP-1 is indicated by the white arrows.  
E. Imaris spot detection of FcγRIIA (red, AF647) and DENV-2 (green, AF488)
interaction. White arrow indicates red and green spots within 100nm in the cytoplasm. 
Images were acquired at 100x magnification using a Leica TCS SP8 confocal, DMI6000 
Microscope and hybrid detectors (HyD). Images were acquired and processed with the 
Leica Application Suite X 2.0.1.14392 (LAS X). Subsequent deconvolution and analysis 
was performed with the Huygens Professional v15.05 and Imaris x64 8.1.2 software. 
Scale bar represent 4µM. 
F. Plaque titers following ADE infection in shControl and shFcγRIIA THP-1 cells at
72hpi. FcγRIIA silencing efficiency was assessed by western bolt with LAMP1 as a 
loading control. Numbers under western blot indicate levels of FcγRIIA normalized to 
LAMP1.
Data information: In (A-C,F), data are presented as mean ± SD. *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001 (Unpaired t-test). 
Figure 4: Increased Fc!RIIA expression is modulated by HIF1α. 
A. HIF1α proteins levels in control and HIF1α silenced THP-1 cells. LAMP1 served as a
loading control. Numbers indicate levels of HIF1α normalized to LAMP1. 
B-D. Expression of ADM (B), FcγRIIA mRNA (C) and FcγRIIA protein expression (D)
24h after siRNA control (siC) treatment or knockdown of HIF1α in THP-1 cells under 
hypoxic conditions. Numbers below the western blot (D) indicate levels of HIF1α 
normalized against LAMP1. 
E. HIF1α proteins levels in THP-1 cells treated with DFX and cultured at 20% and 3%
O2 for 24h. Numbers indicate levels of HIF1α normalized against LAMP1. 
F-H Levels of ADM (F), FcγRIIA (G) mRNA and protein expression of FcγRIIA (H).
All three figures show levels at 24h post HIF1α stabilization using media only, 100µM or 
200µM DFX in THP-1 cells under normoxic conditions. Numbers below the western blot 
(H) indicate levels of HIF1α normalized against LAMP1.
I. Percentage of control or FcγRIIA silenced THP-1 cells positive for AF488 labeled
DENV-2 upon treatment with 100µM or 200µM of DFX compared to untreated cells. 
Proportion of infected cells was measured using flow cytometry at 2hpi.  
Data information: In (B,C,F,G,I), data are presented as mean ± SD. *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001 (Unpaired t-test). 
Figure 5: HIF1α enhances Fc!RIIA expression for binding but not internalization of 
antibody-opsonized DENV. 
A. HIF1α binding site upstream of the FcγRIIA gene under hypoxic conditions as
determined using ChIP-Seq. 
B. HIF1α binding site upstream of the FcγRIIA gene in THP-1 treated with 200µM of
DFX under normoxic conditions determined using ChIP-Seq. 
C. Control and HIF1α silenced THP-1 cells cultured under hypoxic conditions and
infected with AF488 labeled DENV-2, without or with opsonization with enhancing 
levels (0.391µg/ml) of h3H5. Cells were treated with pronase at 2hpi to assess DENV 
internalization by MFI. 
D. Percentage of THP-1 cells infected with AF488 labeled DENV-2 opsonized with
enhancing levels of h3H5, without or following pronase treatment. THP-1 cells were 
cultured under hypoxic conditions or under normoxic conditions without or with 200µM 
of DFX. Percentage infection was determined by flow cytometry.  
Data information: In (A, B), HRE sequence in peak region is denoted by #. In (C, D), 
data are presented as mean ± SD. *P<0.05, **P<0.01, ***P<0.001 (Unpaired t-test). 
Fig 6: Hypoxia increases membrane ether PE concentrations independent of HIF1α  
A. Lipid metabolism pathways enriched in hypoxic THP-1 cells as identified by GSEA
analysis. 
B. PE concentrations in THP-1 cells following incubation in 3% O2 and 20% O2 for 24
hours. Ether PE lipid concentrations increased under hypoxic conditions. No changes 
were observed in other PE or plasmalogen lipid species. Individual lipid species and fold 
changes are listed in Appendix Table S3 and Appendix Table S4. Dotted lines represent a 
fold change of 1.5.  
C. Ether linked PE concentrations in hypoxic compared to normoxic, DFX-treated
(200µM) THP-1 cells. 
Data information: In (B,C), data are presented as mean ± SD. *P<0.05 (Unpaired t-test). 
Figure 7: Upregulation of ether lipids and FcγRIIA synergistically increased uptake 
of antibody-opsonized DENV. 
A. Knockdown efficiency of AGPS in THP-1 cells cultured at 20% and 3% O2 assessed
by western blot. LAMP1 served as a loading control. Numbers below western blot 
indicate levels of AGPS normalized to LAMP1. 
B. Percentage of control and AGPS silenced THP-1 cells infected under ADE conditions
at 2hpi in 20% and 3% O2. 
C. Plaque titers following infection of control (red) and AGPS silenced (black) THP-1
cells with DENV-2 opsonized with varying concentrations of h3H5 under hypoxic 
conditions at 72hpi.  
D. Knockdown efficiency of AGPS in shControl and shFcγRIIA THP-1 cells cultured at
3% O2 assessed by western blot. LAMP1 served as a loading control. Numbers under 
western blot indicate levels of AGPS or FcγRIIA normalized to LAMP1. 
E. Percentage of AGPS and or FcγRIIA silenced THP-1 cells internalized under hypoxic
conditions. 
Data information: In (B,C,E), data are presented as mean ± SD. *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001 (Unpaired t-test). 
Expanded	View	Datasets	
Figure EV1: Incubation at 3% oxygen upregulates expression of known hypoxia-
inducible genes in human primary monocytes and THP-1 cells.  
A,B. Vascular endothelial growth factor (VEGF)(A) and adrenomedulin (ADM) mRNA 
(B) expression in primary monocytes 24h post culture in 3% O2.
C,D. Vascular endothelial growth factor (VEGF) (C) and adrenomedulin (ADM) mRNA 
(D) expression in THP-1 cells 24h post culture in 3% O2.
Data information: Data is presented as mean ± SD. *P<0.05, ***P<0.001 (Unpaired t-
test) in all figures. 
Figure EV2: Hypoxia induced increase in FcγRIIA expression and DENV infection 
is independent of HIF2α .   
A. Knockdown efficiency of HIF2α in control and HIF2α silenced THP-1 cells cultured
at 3% O2 assessed by western blot. LAMP1 served as a loading control. Numbers under 
western blot indicate levels of AGPS normalized to LAMP1. 
B. Protein levels of FcγRIIA in control and HIF2α silenced THP-1 cells cultured at 3%
O2 assessed by western blot showed no difference in FcγRIIA expression. LAMP1 served 
as a loading control. Numbers under western blot indicate levels of AGPS normalized to 
LAMP1.  
C. Control and HIF2α silenced THP-1 cells cultured at 3% O2 were infected with DENV-
2 opsonized with enhancing concentrations of h3H5 (0.391µg/ml). Internalization was 
assessed at 2hpi by flow cytometry revealing no changes in internalization in HIF2α 
silenced THP-1 cells as compared to control cells. 
D. Control and HIF2α silenced THP-1 cells cultured at 3% O2 infected with DENV-2
opsonized with varying concentrations of h3H5 antibody showed no significant 
difference in both neutralization and enhancement profiles.   
Data information: In (C,D), data is presented as mean ± SD (Unpaired t-test). 
Figure EV3: Lipid profile of THP-1 cells after 24h of oxygen adaptation 
A-E. No significant differences were observed in lipid profiles of ceramide (Cer) (A)
dihexosylceramide (DHCer), monohexosylceramide (MHCer) (B) phosphatidylinositol 
(PI) (C) phosphotidylserine (PS) (D) and sphingomyelin (SM) (E) in hypoxic and 
normoxic THP-1 cells. Blue and red bars indicate normoxia and hypoxia, respectively, in 
all figures.  
Data information: Data is presented as mean ± SD (Unpaired t-test) in all figures. 
Figure EV4: Lipid profiles of THP-1 cells post oxygen adaptation 
A-F. No significant differences were observed in lipid profiles of
lysophosphotidylethaloamine (LPE) (A) lysophosphotidylcholine (LPC) (B) 
phosphotidylcholine (PC) (C) plasmalogen (PC(-P)) and ether phosphotidylcholine (PC(-
O)) (D) cholesterol (E) 24h post hypoxic and normoxic adaptation. Cholesterol esters (F) 
were slightly upregulated under hypxoic conditions. Blue and red bars indicate normoxia 
and hypoxia, respectively, in all figures. 
Data information: Data is presented as mean ± SD. *P<0.05 (Unpaired t-test) in all 
figures. 
Figure EV5: Hypoxia induced increase in ether PE lipids is independent of HIF1α  
A. Knockdown efficiency of HIF1α in control and HIF1α silenced THP-1 cells cultured
at 3% O2 assessed by western blot. LAMP1 served as a loading control. Numbers under 
western blot indicate levels of AGPS normalized to LAMP1. 
B. No significant differences in ether linked PE concentrations in control and HIF1α
silenced THP-1 cells cultured at 3% O2 for 24h. 
C. No significant differences in PE concentrations in control and HIF1α silenced THP-1
cells cultured at 3% O2 for 24h. 
D. No significant differences in plasmalogen PE concentrations in control and HIF1α
silenced THP-1 cells cultured at 3% O2 for 24h. 
Data information: Data is presented as mean ± SD (Unpaired t-test) *P<0.05 (Unpaired t-
test) in all figures.  
Figure 1: Monocytes express higher levels of FcγRIIA under hypoxic conditions. 
Figure 2: Hypoxia modulates DENV infection in monocytes. 
Figure 3: Hypoxia induced Fc!RIIA expression increases uptake of 
antibody-opsonized DENV. 
Figure 4: Increased Fc!RIIA expression is modulated by HIF1α. 
Figure 5: HIF1α enhances Fc!RIIA expression for binding but not internalization 
of antibody-opsonized DENV. 
Fig 6: Hypoxia increases membrane ether PE concentrations independent of HIF1α 
Figure 7: Upregulation of ether lipids and FcγRIIA synergistically increased 
uptake of antibody-opsonized DENV. 
Figure EV1: Incubation at 3% oxygen upregulates expression of known 
hypoxia-inducible genes in human primary monocytes and THP-1 cells.  
Figure EV2: Hypoxia induced increase in FcγRIIA expression and DENV 
infection is independent of HIF2α .   
Figure EV3: Lipid profile of THP-1 cells after 24h of oxygen adaptation 
Figure EV4: Lipid profiles of THP-1 cells post oxygen adaptation 











Appendix Table S3: List of PE lipids in Fig 5a.  
Fold change was calculated by (mean hypoxia / mean normoxia). Genes upregulated 
in hypoxia is expressed as a positive value and genes upregulated in normoxia is 
expressed as a negative value. 
Appendix Table S4: List of ether and plasmalogen PE lipids in Fig 5a.  
Fold change was calculated by (mean hypoxia / mean normoxia). Genes upregulated 
in hypoxia is expressed as a positive value and genes upregulated in normoxia is 
expressed as a negative value. 
Appendix Video S1: FcγRIIA directly mediates internalization of DENV immune 
complexes.  
Hypoxic THP-1 cells were infected with DENV immune complexes and imaged 1-
hour post infection. Imaris imaging software was used to reconstruct the plasma 
membrane (blue) and identify internalized FcγRIIA (red) interacting with DENV 
(green).  
Appendix Figure S1: FcγRIIA antibody for flow cytometry is specific to 
FcγRIIA. 
Appendix	Figure	S2:	Increase	in	DENV	RNA	observed	at	0.5%	O2	
Appendix Table S1: TBP mRNA levels at various time points post O2 adaptation 
 












Appendix Table S2: HIF1α 	ChIP-Seq	unable	to	enrich	DNA	under	normoxic	
conditions	
	
Conditions Concentration (ng/µ l) 
2% Input 4.98 
Histone H3 (D2B12) 16 
Rabbit IgG - 
HIF1α 20% O2 - 
  
Appendix Table S3: List of PE lipids in Fig 5a.  
 
 
Lipid Species Fold Change  
PE 
PE 32:2 -1.7459 
PE 32:1 -1.3925 
PE 32:0 -1.5746 
PE 34:3 -1.3399 
PE 34:2 -1.4315 
PE 34:1 -1.5029 
PE 34:0 -1.5943 
PE 36:5 -1.4185 
PE 36:4 -1.2842 
PE 36:3 -1.2904 
PE 36:2 -1.4817 
PE 36:1 -1.6803 
PE 38:6 -1.2714 
PE 38:5 -1.3118 
PE 38:4 -1.2652 
PE 38:3 -1.5109 
PE 38:2 -1.6514 
PE 40:7 -1.3983 
PE 40:6 -1.4862 
PE 40:5 -1.3479 
PE 40:4 -1.5681 
PE 40:3 -1.4451 
PE 40:2 -1.8935 
PE 40:1 -1.9311 
PE 42:2 -2.0270 
PE 42:1 -1.8937 
  




PE(O-32:1)/oddPE 31:1 2.8134 
PE(O-32:0)/oddPE 31:0 1.1186 
PE(O-34:2)/oddPE 33:2 4.2384 
PE(O-34:1)/oddPE 33:1 2.3325 
PE(O-36:5)/oddPE 35:5 3.2295 
PE(O-36:4)/oddPE 35:4 2.8498 
PE(O-36:3)/oddPE 35:3 3.2612 
PE(O-36:2)/oddPE 35:2 3.0171 
PE(O-38:6)/oddPE 37:6 1.1546 
PE(O-38:5)/oddPE 37:5 2.3505 
PE(O-38:4)/oddPE 37:4 2.4332 
PE(O-40:7)/oddPE 39:7 1.4622 
PE(O-40:6)/oddPE 39:6 1.1898 



















PE(P-20:0/20:4 ) -1.5000 
PE(P-18:0/22:4 ) -2.0019 	
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REVIEW
The mechanistic role of antibodies to dengue virus in protection and disease
pathogenesis
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ABSTRACT
Introduction: Dengue is a prevalent disease in tropical and subtropical countries with an estimated
400 million people infected annually. While significant advancement has been made in the chase for an
effective dengue vaccine, the recently licensed Sanofi vaccine was, in contrast to in vitro data, only
partially protective.
Areas covered: This suggests that our understanding of the serological correlates for dengue is
currently inadequate. With growing evidence supporting the role of fragment crystalizable gamma
receptors (FcγRs) in antibody-mediated neutralization or antibody-dependent enhancement (ADE) of
dengue virus (DENV) infection, FcγR-expressing cells have been increasingly used for measuring
neutralizing antibody responses elicited by dengue vaccines. Here, we review the mechanisms of
how FcγRs modulates both DENV neutralization and enhanced infections via its interactions with
antibodies.
Expert commentary: This review provides insights on the importance of factoring FcγRs for in vitro
neutralization assays. Bridging the gap between in vitro and clinical observations would allow research-
ers to more accurately predict in vivo vaccine efficacy.
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Dengue is the most common mosquito-borne viral disease,
which spreads in over 100 countries and represents a serious
threat to global community. The disease results from infection
with dengue virus (DENV), which is a single positive-stranded
RNA virus that belongs to Flavivirus genus. DENV consists of
four antigenically distinct serotypes, namely DENV-1, DENV-2,
DENV-3, and DENV-4. While infection with DENV can be
asymptomatic, disease manifestation can range from dengue
fever (DF) to severe, life-threatening dengue hemorrhagic
fever (DHF), or dengue shock syndrome (DSS). Based on the
new World Health Organiztion (WHO) classification system,
severe dengue is characterized by either severe plasma leak-
age, severe bleeding, or severe organ involvement [1–4]. Using
cartographic approaches, a recent study estimates that DENV
infects more than 390 million people every year with
96 million exhibiting clinically apparent diseases [5].
According to estimation by WHO, half a million of severe
dengue cases require hospitalizations every year [6].
Human activities such as urbanization, migration, and tra-
velling have resulted in geographical expansion of DENV and
its primary mosquito vector, Aedes aegypti. Furthermore, resi-
dential environments have been proven to be an effective
breeding habitat for the Aedes aegypti as its larvae has been
frequently found in common areas such as ant traps, earth-
enware jars, bowls, tanks, tin cans, and drums [7]. A current
promising entomological strategy to combat the spread of
mosquito vectors is to release modified Aedes aegypti infected
with the intracellular bacterium Wolbachia, which have been
shown to have a reduction in its ability to transmit dengue [8].
However, it will take several years post implementation to
assess the effectiveness of these methods in disrupting the
transmission of DENV. Furthermore, effective vector control
can be difficult especially for developing countries as such
programs depend on availability of resources and trained
personnel for execution [9,10]. Given the challenges with vec-
tor control, the development of a safe and potent tetravalent
dengue vaccine is necessary to eradicate dengue. Among all
the potential dengue vaccines, only Sanofi Pasteur’s tetrava-
lent chimeric yellow-fever dengue (CYD) vaccine passed the
phase IIb and phase III vaccine trials. Although the CYD vac-
cine showed clinical efficacy against DENV-3 and DENV-4,
efficacies against DENV-1 and DENV-2 were found to be sig-
nificantly weaker in the clinical trials [11,12]. Interestingly,
these observations are in contrast to preclinical studies in
mice and monkeys, where protection against DENV-1 and
DENV-2 were observed after administration of the CYD vaccine
[13].
The discrepancies observed in the pre-clinical studies and
clinical evaluation is still largely unknown. A possibility is that
DENV-1 and DENV-2 are genetically more diverse compared to
the other DENV serotypes [14]. Another possibility is the lack
of a good surrogate of protection, indicating a requirement to
better define dengue immune correlates of protection, so as
to identify the relevant parameters required for future vaccine
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potency tests. Besides dengue, the recent Zika outbreak that
resulted in an associated increase in Guillain–Barre syndrome
(GBS) [15–17] and microcephaly [18,19] also warrants the need
of a Zika vaccine that prevents these adverse reactions. The
knowledge gained from the understanding of immune corre-
lates of vaccine protection would therefore aid in accelerating
development vaccine candidates for dengue and other medi-
cally important flaviviruses.
1.1. Antibodies – friend or foe?
Similar to many viruses, the measurement of neutralizing anti-
body responses is one of the most relevant endpoints when
testing for efficacy of a dengue vaccine. However, antibodies
against DENV is potentially a double-edge sword. While ser-
otype-specific neutralizing antibodies can confer life-long pro-
tection [12], cross-reactive antibodies targeted against the
other DENV serotypes only protect for approximately 3–-
6 months [13]. Moreover, as levels of cross-reactive antibodies
wane with time, these antibodies can potentially result in
increased pathogenicity. The most widely accepted hypothesis
to explain for this phenomenon is the antibody-dependent
enhancement (ADE), where sub-neutralizing levels of antibo-
dies can form immune complexes that interact with FcγRs in
monocytes, macrophages and dendritic cells, leading to
increased uptake and infection [20]. In addition to dengue,
ADE has been shown in vitro with other viruses such as
influenza virus [21], coxsackievirus B virus [22], respiratory
syncytial virus (RSV) [23], ebola virus [24], human immunode-
ficiency virus (HIV) [25], and zika virus [26]. Despite a wealth of
in vitro studies [27–29] and an elegant mice study proving the
existence of ADE using maternal transferred antibodies [30],
the role of ADE has only been recently authenticated clinically,
where cross-reactive antibodies can result in enhanced live-
attenuated vaccine infection, resulting in prolonged viraemia
[31]. Given the significance of FcγRs in mediating neutraliza-
tion and ADE, a better understanding of the molecular
mechanisms involved in these processes could potentially
lead to the development of tools to assess neutralizing and
non-neutralizing antibody responses produced by vaccines.
This review hence focuses on describing the current knowl-
edge of the key mechanisms involved in antibody-dependent
neutralization and enhancement of DENV infection in
FcγR-bearing cells, which would be necessary for interpreta-
tion of antibody responses following administration of dengue
candidate vaccines in humans.
1.2. Antibody responses to dengue virus infection
The viral envelope of DENV consists of three main proteins –
envelope (E) membrane (M), and pre-membrane (prM). During
infection, the E protein facilitates DENV binding to cellular
receptors and mediates intracellular fusion of DENV and host
membranes [32]. Following replication, immature virions con-
sisting of E and prM are assembled in the endoplasmic reticu-
lum (ER) and subsequently pass through the trans-golgi
network (TGN) [33]. In the acidic environment of the TGN, an
endoprotease furin cleaves prM to M [34,35]. Peptide pr then
dissociates from the virion upon secretion of the virus.
However, cleavage of prM to M is not efficient [36], thus
resulting in the secretion of high levels of prM-immature
viruses. Although fully immature viruses are unable to cause
infection due to its inability to present the E protein for host
cell attachment, studies have shown that antibodies targeting
prM can rescue their infectious properties via ADE [37]. Thus,
potent neutralizing antibodies must prevent ADE by either
blocking viral attachment to cells or prevent fusion of viral
and host membranes.
The main surface antigen on DENV, the E protein, which
consists of three domains (EDI, EDII, and EDIII), is a major
target of neutralizing antibodies [38]. Antibodies that target
E protein or its quaternary epitopes can neutralize by inhibit-
ing virus attachment or preventing viral uncoating. While
humans can produce neutralizing antibodies to epitopes simi-
lar to those recognized by murine EDIII antibodies, in a natural
primary infection, only a small subset of the antibody reper-
toire produced presents serotype specificity and potent neu-
tralizing properties [39–41]. Anti-EDIII antibodies, for instance
1H9, 14A4, and 8A1 have been shown to neutralize DENV
infections [42–45]. Broadly neutralizing anti-EDIII monoclonal
antibodies such as 1A1D-2 can also potently neutralize DENV-
1, DENV-2, and DENV-3 at 37°C by inhibiting attachment of
DENV to host cells [46]. Furthermore, using the structural
framework of EDIII, Robinson et al. developed a unique EDIII
potent neutralizing antibody that binds to the epitope–para-
tope interface on EDIII of all DENV serotypes and potently
neutralizes DENV by preventing viral fusion [47], reinforcing
the notion that EDIII antibodies can be highly neutralizing. In
addition, antibodies that target complex quaternary structures
of DENV can be highly neutralizing. For instance, antibodies
such as 5J7 and 2D22 that binds across E proteins are highly
neutralizing and can neutralize DENV by inhibiting viral fusion
[48,49]. In contrast, cross-reactive antibodies that target the
EDII fusion peptide are predominantly non-neutralizing [50],
and can potentially lead to ADE of DENV and ZIKV infections
[26]. Nonetheless, a broadly neutralizing human antibody
1C19 that targets a unique cross-reactive epitope of EDII has
been shown to be a potent neutralizing antibody across all
four DENV serotypes [51]. Altogether, these studies suggest
that although neutralizing monoclonal antibodies have been
mapped to all three domains, antibodies that target the EDIII
and the complex quaternary epitopes (such as the hinge) are
likely to be most neutralizing in humans [39,52–55].
While high levels of EDIII targeting antibodies can be
potentially neutralizing, these antibodies would be most sui-
table for therapeutic use, as EDIII targeting antibodies are only
induced at low levels following a natural infection. This is
clearly demonstrated in depletion experiments, where studies
have shown that depletion of EDIII antibodies did not signifi-
cantly change the neutralization potency of sera [56,57]. On
the other hand, antibodies that target the complex quaternary
epitopes are generated following a natural infection and are
highly neutralizing. Therefore, besides assessing antibody
titers, the epitopes that the human antibodies target should
be an important consideration when assessing for neutralizing
antibody responses against DENV. With the knowledge that
cross-reactive antibodies neutralizes poorly in humans, a
method that employs depleting the sera of cross-reactive
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antibodies with other DENV serotypes before assessing the
amount of serotype-specific antibodies present in the sera by
ELISA or PRNT will likely be informative in the assessment of
the levels of neutralizing antibodies induced by potential
dengue vaccine candidates [39,58].
1.3. Determinants of neutralization or enhancement of
dengue virus infection
Two models exist to understand the mechanisms of neutralizing
antibodies; the (1) ‘single hit’ and (2) ‘multiple hit’ hypothesis.
The ‘single hit’ hypothesis posits that a critical neutralization site
exists on a virion, thus suggesting that blocking of these func-
tionally important regions will result in neutralization [59].
However, with the diversity of virion structures and the complex-
ity of viral fusion, to expect neutralization with a single binding
event is unlikely. The ‘multiple hit’ hypothesis posits that neu-
tralization requires binding of antibodies to the virion with a
stoichiometry that exceeds the threshold required for virus neu-
tralization. In this model, both antibody affinity and epitope
accessibility are important determinants to assessing the con-
centrations of antibodies needed to bind and neutralize the
virion. Antibody affinity correlates strongly with neutralizing
activity. However, affinity alone is insufficient as binding sites
must be available for docking of antibodies, as not all epitopes
may be accessible for antibody binding. Steric constraints, struc-
tural dynamics and changes in virion surface conformation that
affects epitope accessibility has also been demonstrated to affect
the stoichiometric requirements for DENV neutralization [60,61].
To assess if antibodies meet the stoichiometry require-
ments for antibody neutralization, plaque reduction neutrali-
zation test (PRNT) on baby hamster kidney (BHK-21) or Vero
cells are traditionally used. PRNT measures an antibody’s abil-
ity to inhibit infection either by blocking virus entry or pre-
venting virus uncoating [62,63]. However, fibroblast and
epithelial cells are not the primary targets of dengue infection.
Moreover, they do not express FcγRs, which are abundantly
expressed in human monocytes; the primary targets of DENV
infection [64,65]. Given the role of FcγRs in modulating neu-
tralization and enhancement of DENV immune complexes,
stoichiometric requirements for antibody neutralization
should be determined in FcγR-bearing cells.
1.4. FcγRs and their role in antibody-dependent uptake
of dengue immune complexes
The association of severe disease and ADE was uniquely
demonstrated in young infants who developed DHF due to
waning concentrations of maternal antibodies to DENV
[66,67]. Ventura and colleagues were the first to observe
DENV antibodies crossing the placenta barrier either through
the placenta via neonatal Fc receptor (FcRn) or through
breast-feeding [68]. As neonatal and adult monocytes exhibit
similar expression of FcγRI and FcγRIIA [69], DENV opsonized
with sub-neutralizing levels of maternal DENV antibodies can
result in ADE of dengue infection. T-cells, on the other hand,
cannot directly pass through the placenta barrier, suggesting
that T-cells are unlikely to be involved in severe disease of
young infants. Hence, besides viral factors [70,71], ADE of
dengue infection can potentially explain for the epidemiolo-
gical observations of severe disease in young infants. On the
other hand, the contribution of ADE in severe disease in adults
is less clear, as cytotoxic T-cells that are partially protective
may lead to release of cytokines that leads to enhanced
inflammation and tissue damage [72]. Nonetheless, we have
clinically demonstrated that the levels of pre-existing cross-
reactive antibodies can directly affect vaccine viraemia and
subsequent immunogenicity of live-attenuated vaccines [31].
Taken together, these studies emphasize the need to consider
the involvement of FcγR when assessing for antibody-
mediated neutralization and enhancement of DENV infection.
Monocytes are the FcγR bearing cells that have been
shown to be a major reservoir for DENV infection and replica-
tion [64,65]. Primates have a complex FcγR system consisting
of FcγRI family (FcγRIA, FcγRIB, FcγRIC), FcγRII family (FcγRIIA,
FcγRIIBI, FcγRIIBII, FcγRIIBIII, FcγRIIC), and FcγRIII family
(FcγRIIIA, FcγRIIIB). Each FcγR subtype has its own distinct
properties and thus have different effects on DENV neutraliza-
tion or enhancement [73]. As the majority of the monocytes
express FcγRI, FcγRIIA, and FcγRIIB, these are the main FcγRs
that have an impact on antibody-opsonized DENV infection or
neutralization (Table 1). Kwissa et al. recently suggested that
DENV infection induces the expansion of FcγRIII expressing
monocytes to stimulate plasmablast differentiation [74].
FcγRIII bearing monocytes can also play an important pro-
inflammatory role during disease, stimulating the release of
Table 1. FcγRs effects on antibody-dependent dengue neutralization and enhancement.
Neutralization Enhancement
FcγRI Overexpression of FcγRI and γ-chain reduces stoichiometric requirement for
DENV neutralization [77]
Overexpression of FcγRI and γ-chain increases ADE of DENV infection [28]
Knockdown of FcγRI in monocytes increases stoichiometric requirement for
DENV neutralization [29]
Abrogation of γ-chain signaling of FcγRI or blocking FcγRI in monocytes
significantly impairs phagocytosis and infectivity of antibody-opsonized
DENV [28]
Preferentially binds and phagocytose DENV immune complexes that are
neutralized by potent neutralizing antibodies to the late endosomal or
lysosomal compartments [29,78,79]
FcγRIIA Overexpression of FcγRIIA increases stoichiometric requirement for DENV
neutralization [77]
Overexpression of FcγRIIA increases ADE of DENV infection [28] [80]
Knockdown of FcγRIIA in monocytes reduces stoichiometric requirement for
DENV neutralization [29]
Swapping of ITAM motifs in FcγRIIA, blocking or knockdown of FcγRII in
monocytes reduces ADE of DENV infection [29,80]
FcγRIIB Engagement of FcγRIIB is required for neutralization of DENV cross-reactive
antibodies. Knockdown of FcγRIIB affects stoichiometric requirement for
DENV neutralization mediated by cross-reactive antibodies [78]
Overexpression of FcγRIIB in monocytes reduces ADE of DENV infection [78]
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cytokines such as TNFα, CCL2, CCL3, and CCL4 [75]. However,
since FcγRIII is only present on 10% of monocytes under
healthy conditions and has little impact on DENV neutraliza-
tion or enhancement [76], this review will focus on FcγRI,
FcγRII and their impact on the assessment of neutralizing
antibody efficiency against DENV.
FcγRIA has high affinity to monomeric IgG and immune
complexes while FcγRIIA and FcγRIIIA have higher affinity to
immune complexes but not monomeric IgG. Both FcγRIA and
FcγRIIIA are activating FcγRs and have an accessory immunor-
eceptor tyrosine-based activation motif (ITAM) bearing
gamma-chain for signal transduction. By contrast, FcγRIIA has
an ITAM motif in its own cytoplasmic domain, thereby elim-
inating the need for a gamma chain. Compared to FcγRIIA,
FcγRI requires lesser antibodies to neutralize DENV, suggesting
that FcγRI plays a more predominant role in DENV neutraliza-
tion. This could be attributed to its role in internalization of
neutralized immune complexes when both FcγRs are
expressed [29]. On the other hand, although both activating
FcγRs can mediate ADE, FcγRIIA has been shown to be more
effective compared to FcγRI [28] (Table 1).
The physiological role of activating FcγRs in professional
phagocytes is to internalize immune complexes via
FcγR-mediated endocytosis or phagocytosis to clear immune
complexes in blood circulation [81]. IgG engagement to FcγRs
initiates a signaling cascade beginning with the phosphoryla-
tion of tyrosines within its ITAM [82]. This results in the recruit-
ment and activation of protein and lipid kinases such as proto-
oncogene tyrosine-protein kinase (Src) and spleen tyrosine
kinase (Syk) [83]. Members of the Src tyrosine-kinase family
(Fyn, Hck, Lyn, Yes, Src), is postulated to be important for early
phosphorylation events after initial engagement of FcγRs [84–
86] along with increased synthesis of signaling molecules
phosphatidylinositol (3,4,5)-trisphosphate (PIP3), phosphatidy-
linositol 4,5-bisphosphate (PI(4,5)P2) and diacylglycerol (DAG).
However, a degree of redundancy is likely present, as Src–/–
macrophages exhibited no alternations in phagocytosis.
Phosphorylated ITAMs allows for docking, phosphorylation
and activation of Syk, which subsequently stimulates multiple
signaling cascades such as phosphoinositide 3-kinase (PI3K),
phosphoinositide phospholipase C (PLCγ), phospholipase D
(PLD), and protein kinase C (PKC) [87,88]. In addition, engage-
ment of FcγRs triggers membrane ruffling and the formation
of actin protrusions [89], resulting in FcγR-mediated phagocy-
tosis of immune complexes.
However, whether FcγRs functionally mediates DENV entry
or serves only to aid in DENV attachment to the cell surface
remains an unsolved question [90]. Using DENV with triple
mutations in its E protein, Chotiwan et al. showed that DENV
opsonized with monoclonal antibody 4G2 was unable to
bypass the viral attachment defect [91]. This suggests that
post-FcγR engagement and interactions with other cellular
receptors are required for successful entry of the DENV
immune complexes [91]. Hence, FcγRs can enhance uptake
of DENV immune complexes via FcγR-phagocytosis or
improved interaction with DENV receptors (Figure 1).
Given the role of activating FcγRs in uptake of immune
complexes, potent neutralizing antibodies against DENV
must be able to neutralize DENV intracellularly by inhibiting
viral fusion. In contrast, non-neutralizing antibodies against
DENV would result in enhanced DENV uptake via activating
FcγRs and intracellular fusion, thus leading to ADE. Through
mechanisms that are largely unclear, these virions bound by
sub-neutralizing concentrations of antibodies are able to
evade degradation in the phagolysosme and are unable to
prevent E-protein mediated fusion of the virion. This allows
the release of its genome in the host cytosol and subsequently
establishes a productive infection. Indeed, we have previously
shown that weakly cross-reactive antibodies can only neutra-
lize at concentrations high enough to form viral aggregates
that co-ligate the lowly expressed inhibitory Fc-receptor,
FcγRIIB [78]. FcγRIIB has an immunoreceptor tyrosine-based
inhibition motif (ITIM), which can recruit and activate phos-
phatases Src homology region 2 domain containing phospha-
tase-1 (SHP-1) and phosphatidylinositol-3,4,5-trisphosphate
5-phosphatase 1 (SHIP-1) to shut down signaling mediated
by activating FcγRs, thereby inhibiting FcγR-mediated phago-
cytosis [78,92]. As the mode of neutralization mediated by
Figure 1. Hypothesized mechanisms of extrinsic ADE. (1) DENV immune complexes internalization is mediated by the engagement of activating Fc?Rs (red) on the
cell surface triggering the phosphorylation of cytosolic ITAM by Src kinases. This subsequently leads to the phosphorylation of Syk and PI3 K that triggers a signaling
cascade for Fc?R-mediated phagocytosis. (2) Alternatively, activating Fc?Rs (red) can concentrate immune complexes on the surface of the cell. The virion is then
able to bind to its receptor to enter the cell via receptor-mediated endocytosis. These processes result in increased internalization of the virus, thus resulting in ADE.
Full color available online.
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serotype-specific and cross-reactive antibodies differs funda-
mentally in FcγR-expressing cells monocytes, these cells can
be used to assess the type of antibodies that are induced by
DENV. Indeed, using 30 blinded convalescent sera, Wu et al.
observed that this method correctly identifies DENV serotype
of infection in 93.3% of the cases as compared to 76.7% with
PRNT [79]. These studies support that neutralizing antibodies
against DENV would be able to inhibit viral fusion even in the
presence of FcγR-mediated phagocytosis and this can poten-
tially be used to assess antibody responses triggered by future
dengue vaccines.
1.5. FcγRs and their role in modification of antiviral
pathways
Activating FcγR signaling is known to induce interferon-
stimulated genes (ISGs) production unless co-ligated with an
inhibitory receptor such as FcγRIIB [93]. However, under ADE
conditions, antibodies are not present at sufficiently high
levels to form immune complex aggregates that facilitates co-
ligation of FcγRIIB [78]. For ADE of DENV infection to occur, we
have recently elucidated that DENV immune complexes can
co-ligate the inhibitory receptor leukocyte-immunoglobulin
like receptor B1 (LILRB1) that activates phosphatase SHP-1 to
downregulate antiviral responses triggered by Syk phosphor-
ylation from activating FcγR signaling [27] (Figure 2).
Furthermore, as postulated by Halstead et al., after Fc-
receptor mediated phagocytosis [94], DENV immune com-
plexes is thought to induce innate immune responses sup-
pression by driving a bias toward a T-helper-2 (Th2) response,
repress IL12, IFNγ, and TNF-α [95,96] and induce IL10 [97] and
suppressor of cytokine signaling 1 (SOCS-1) [98], thus leading
to increased production of infectious particles in infected cells
(Figure 2). Other downstream intracellular signaling, including
signal transducer and activator of transcription 1 (STAT-1) and
interferon regulatory factor 1 (IRF1) have also been observed
to be suppressed after infection with DENV opsonized with
antibodies [96], creating an immunosuppressive intracellular
environment that is considered favorable for DENV replication.
However, it is important to note that in human primary mono-
cytes, suppression of IFN under ADE conditions is not
observed [99], suggesting that there could be involvement
of other intrinsic factors that accounts for the increased
DENV replication observed during ADE. Interestingly, a recent
study by Flipse et al. showed using primary human macro-
phages that entry of DENV immune complexes does not affect
binding, internalization, or immunosuppressive signaling but
instead, appeared to have enhanced fusion activity per cell,
leading to increased viral progeny production [100]. While the
exact mechanism remains to be determined, it is likely that
antibody-opsonized DENV traffics DENV into cellular compart-
ments different from DENV only infection. Altogether, these
studies suggest that the success of ADE infection relies on the
immune complexes ability to increase binding, internalization,
fusion and evasion of host cell immune responses during the
early course of infection. Future dengue vaccine candidates
should hence aim to induce neutralizing antibody responses
that would inhibit DENV fusion, thereby circumventing DENV
replicate even if the immune complexes are internalized via
FcγR-mediated phagocytosis.
1.6. Considerations when assessing antibody responses
in fcγR-bearing cells
There are many FcγR-bearing cell lines that can be used to
assess neutralization and ADE of DENV infection. However, of
the FcγR-bearing cell lines available, THP-1, K562 and U937 are
most commonly used. Others have also used HEK-293, COS or
BHK-21 cell lines transfected with FcγRs required for ADE. For
example, Moi et al. used 18 secondary dengue patients’ sera
and compared PRNT results in both FcγR-negative BHK-21
cells and FcγR-positive BHK-21 cells. Neutralization titers
obtained using FcγR-negative BHK-21 cells were found to be
significantly higher than BHK-21 cells that over-express of FcγR
[101]. However, the limitation to using transfected cells is the
differences in the expression of activating and inhibitory FcγRs
in these cells compared to monocytes, which may cause dif-
ferences in the stoichiometric requirement for DENV neutrali-
zation (Table 1). To potentially reduce these variabilities,
FcγR-bearing monocytic cell lines can be used to assess neu-
tralization (Table 2). In such cases, the important consideration
when using these cell lines are the types and the expression
Figure 2. Hypothesized mechanisms of intrinsic ADE. Immune complexes engage activating Fc?R (red) that results in the phosphorylation of Syk. This subsequently
leads to the activation of STAT1 that drives the transcription of interferon-stimulated genes (ISG). However, co-ligation of LILRB1 mediated by DENV immune
complexes under ADE conditions can reduce ISG responses by phosphorylation of SHP-1 that attenuates Syk and STAT-1 signaling. At longer time periods, co-
ligation of Fc-gamma receptor can also signal for IL-10 induction that inhibit IFN and subsequent STAT-1 and ISG induction. Besides intracellular signaling for
evasion of host immune responses, virus fusion activity can be increased under ADE conditions. Together, these intrinsic pathways lead to suppression of the anti-
viral responses thus resulting in enhanced DENV infection. Full color available online.
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levels of FcγRs that are present in these cell lines, which could
influence outcome of DENV neutralization or enhancement.
For instance, as K562 is FcγRI deficient, the stoichiometric
requirement required for DENV neutralization in K562 is four-
fold higher than what is obtained for THP-1, where both FcγRI
and FcγRII are present [29]. In our experiment, we have
observed that antibody neutralization titer observed in THP-1
closely mimics the antibody titers in primary monocytes.
However, due to heterogeneity in cancer cell lines, it is always
recommended to validate results obtained from cell lines with
primary monocytes.
Although human primary monocytes are known to express
FcγRs, the single-nucleotide polymorphism (SNPs) and expres-
sion of FcγRs can influence outcome of antibody-mediated
neutralization. Therefore, detection of FcγR SNPs in human
monocytes is recommended for accurate interpretation of
neutralization titers. An important consideration is the SNPs
present in FcγRIIA. Common single-nucleotide polymorphisms
in FcγRIIA gene at position 131 (rs1801274) changes the amino
acid at position 131 (His131Arg). This site is polymorphic for
binding of human IgG2 but not IgG1, with H131 form of
FcγRIIA the only class of FcγRs that interacts well with IgG2.
Thus His131Arg potentially leads to significant reduction in
binding to IgG, which could potentially account for the
reduced ADE and reduced risk of dengue severity associated
with this polymorphism [103,104]. The frequency of rs1801274
varies between ethnic groups as Osborne et al. found that
Japanese and Chinese have an increased frequency of H131 as
compared to Caucasians [105]. Polymerase chain reaction with
confronting two-pair primers method can be used to access
polymorphism of the receptors [27].
Expression of FcγRs in primary monocytes can vary
between individuals. For instance, differential levels of cyto-
kines can influence FcγR expression. FcγRI expression has been
shown to be upregulated by interferon γ (IFNγ) which can
affect stoichiometry required for DENV neutralization
[73,106,107]. In contrast, interleukin-4, interleukin-10 and
transforming growth-factor-B (TGB-B) downregulate activating
FcγRs but enhances the inhibitory FcγRIIB [108,109] which can
potentially impact on the neutralization of immune complexes
mediated by cross-reactive antibodies [102]. Expression of
FcγRs can also vary between ethnic and age groups. It has
been previously shown that groups of African descents have
increased expression of FcγRI [110]. Seidler et al. suggest that
monocytes subsets changes considerably with age, with
CD14+CD16+ subset increasing with age [111]. Therefore, for
consistency, we should take into consideration FcγR SNPs and
expression when accessing the stoichiometric requirements
for DENV neutralization and enhancement in human mono-
cytes. Alternatively, primary monocytes obtained from
different donors can be used to reduce the effects from
these confounding factors.
2. Conclusion
Defining correlates of protection induced by dengue vaccines
can be potentially challenging. However, it is crucial that anti-
body responses elicited by dengue vaccines should neutralize
all four DENV serotypes without increasing the risk of ADE,
which highlights the relevance of using FcγR-bearing cells for
the assessment of humoral responses generated by these
vaccines.
3. Expert commentary
The inconsistencies observed clinically compared to in vitro
data has highlighted the necessity for assays that reliably
predicts either immunity or the increased susceptibility to
severe disease. Given the different neutralization efficiency
mediated by different types of antibodies, it is essential to
develop neutralization assays that can differentiate between
serotype-specific antibodies that result in long-term protec-
tion from cross-reactive antibodies that can cause ADE of
dengue infection, for accurate assessment of protective
immune responses elicited by dengue vaccines. With the cur-
rent knowledge of the role of FcγRs in neutralization and
enhancement of DENV, it has become increasingly clear that
traditional methods of measuring DENV neutralization and
protective antibodies are inadequate in predicting vaccine
efficacy. We hence reason that neutralizing antibody titers
obtained from FcγR-expressing cells will likely be more indica-
tive of protection in humans.
4. Five-year view
Neutralizing antibody responses depend on multiple para-
meters, including antibody titer, antibody avidity index, and
antibody–antigen stoichiometry. In addition, with increasing
evidence clarifying the importance of FcγRs in DENV neutrali-
zation and enhancement, antibody assays that reliably assess
the neutralization capacity of antibodies in FcγR-expressing
cells will be instrumental to determine the level of protection
elicited by future candidate dengue vaccines.
Key issues
● Dengue is disease of global significance. The current Sanofi
vaccine provides only partial protection against DENV-1 and
DENV-2.
● Traditional methods of assessing immunogenicity do not
accurately predict in vivo protection.
● Antibodies targeting EDIII and the complex quaternary epi-
topes (such as the hinge) of DENV are neutralizing, as
compared to anti-EDII antibodies that target near the fusion
loop.
● FcγRs are essential for antibody-mediated DENV neutraliza-
tion and ADE of DENV infection
Table 2. FcγR-expressing cell lines commonly used to assess antibody-dependent
enhancement and neutralization of dengue infection.
Cell line
FcγR subtypes
ReferencesFcγRI FcγRIIA FcγRIIB FcγRIIIA FcγRIIIB
THP-1 + + + – – [102]
K562 – + + – – [76]
U937 + + + – – [76,102]
+: Expression; –: not found.
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● The type and levels of FcγRs expressed affect the stoichio-
metric requirement of DENV neutralization Neutralizing
antibodies inhibit DENV infections by preventing virus
fusion.
● Non-neutralizing antibodies enhance DENV infection by
increasing virus entry, fusion and evasion of host immune
responses.
● Neutralizing antibody responses determined in
FcγR-expressing cells will likely be more indicative of vac-
cine protection than in traditional assays, which uses
epithelial cells.
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Cross-reactive antibodies enhance live attenuated
virus infection for increased immunogenicity
Kuan Rong Chan1, Xiaohui Wang1, Wilfried A. A. Saron1, Esther Shuyi Gan1, Hwee Cheng Tan1,
Darren Z. L. Mok2, Summer Li-Xin Zhang1, Yie Hou Lee3,4, Cui Liang3, Limin Wijaya5, Sujoy Ghosh6,
Yin Bun Cheung7,8, Steven R. Tannenbaum3,9, Soman N. Abraham1,10, Ashley L. St John1,
Jenny G. H. Low5* and Eng Eong Ooi1,2,3*
Vaccination has achieved remarkable successes in the control of childhood viral diseases. To control emerging infections,
however, vaccines will need to be delivered to older individuals who, unlike infants, probably have had prior infection or
vaccination with related viruses and thus have cross-reactive antibodies against the vaccines. Whether and how these
cross-reactive antibodies impact live attenuated vaccination efﬁcacy is unclear. Using an open-label randomized trial
design, we show that subjects with a speciﬁc range of cross-reactive antibody titres from a prior inactivated Japanese
encephalitis vaccination enhanced yellow fever (YF) immunogenicity upon YF vaccination. Enhancing titres of cross-
reactive antibodies prolonged YF vaccine viraemia, provoked greater pro-inﬂammatory responses, and induced adhesion
molecules intrinsic to the activating Fc-receptor signalling pathway, namely immune semaphorins, facilitating immune cell
interactions and trafﬁcking. Our ﬁndings clinically demonstrate antibody-enhanced infection and suggest that vaccine
efﬁcacy could be improved by exploiting cross-reactive antibodies.
Viral infections that spread rapidly and transcontinentally havebecome increasingly prevalent. The ﬁrst 16 years of thiscentury, alone, have already witnessed the pandemic spread
of the severe acute respiratory syndrome (SARS) coronavirus,
swine origin H1N1 inﬂuenza, ebola and zika viruses, all of which
caused global health emergencies1–3. Of the strategies that can be
employed to prevent viral spread, vaccination—especially with live
vaccines—has undoubtedly the most remarkable track record4,5.
Vaccination has eradicated smallpox and has now eliminated polio
from most parts of the world. Most recently, a cluster-randomized
trial demonstrated that ring vaccination of contacts of ebola cases vir-
tually eliminated any secondary spread of the virus6. Measures that
are able to effectively prevent the spread of such viruses in susceptible
populations should thus be a top research priority.
During development, the immunogenicity of candidate vaccines
is frequently evaluated in animals and humans immunologically
naive to the pathogen of interest. This has been a reasonable
approach as vaccines are most likely to be given to infants and
young children to prevent childhood diseases. With emerging
viruses, however, vaccines will have to be delivered to both children
and adults, many of whom will probably have had prior infection or
vaccination with cross-reactive viruses that are antigenically related
to the vaccine strain. Indeed, the endemicity of human corona-
viruses globally implies that any SARS or Middle East respiratory
syndrome (MERS) coronavirus vaccination must be effective
despite the presence of anti-coronavirus antibodies. Similarly, the
control of yellow fever by vaccination, or even zika virus when a
vaccine becomes available, will probably be conducted in popu-
lations with a high prevalence of dengue antibodies, because these
viruses are transmitted by the same mosquito vector. However,
whether and how cross-reactive antibodies modify live vaccination
outcome remains unclear. Some reports suggest that cross-reactive
antibodies reduce vaccine efﬁcacy7,8. In contrast, recent Phase 3
trials of a chimaeric dengue vaccine showed that subjects with
prior ﬂavivirus infection experienced signiﬁcantly better efﬁcacy than
individuals immunologically naive to ﬂaviviruses9–11.
The efﬁcacy of live attenuated virus (LAV) vaccination may be
inﬂuenced by antibody-dependent enhancement (ADE) of infection,
which is a popular hypothesis to explain the increased risk of severe
disease upon secondary dengue virus infection. This hypothesis
posits that cross-reactive or sub-neutralizing levels of antibodies that
develop from prior infection with a heterologous but antigenically
related virus enhance viral entry into target cells via Fc gamma recep-
tors (FcγRs). It is thus possible that cross-reactive antibodies augment
immunogenicity by enhancing LAV infection of antigen presenting
cells (APCs) and triggering host responses intrinsic to activating
FcγR signalling12. Indeed, demonstrating increased immunogenicity,
infection and activation of pathways intrinsic to FcγR activation
would also authenticate the ADE hypothesis clinically, which until
now has only been demonstrated in experimental systems.
Results
Clinical trial features. To investigate how cross-reactive antibodies
affect live attenuated vaccination, we examined, through an open
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label and randomized clinical trial, the effects of sequential
vaccination with two ﬂaviviral vaccines: the inactivated Japanese
encephalitis (JE) vaccine and live attenuated yellow fever (YF)
vaccine. These licensed ﬂaviviral vaccines were selected because of
their safety proﬁles and are known to generate cross-reactive
antibodies that bind ﬂaviviruses, including dengue, West Nile and
zika viruses. A total of 84 healthy volunteers that tested negative
for anti-dengue immunoglobulins (IgGs) by enzyme-linked
immunosorbent assay (ELISA) were randomized, upon receipt of
written informed consent, to receive JE followed by YF vaccine or
YF vaccine alone (Fig. 1a and Supplementary Table 1). To achieve
a gradient of cross-reactive antibodies before YF vaccination, we
further subdivided the subjects into three groups based on the
time interval between JE and YF vaccination: one (Group 1), four
(Group 2) and nine months (Group 3) between vaccinations.
Group 4 subjects served as controls (only YF vaccine was
administered; Fig. 1b and Supplementary Table 2). Adverse events
(AEs) following JE and YF vaccination did not differ among the
different groups (Supplementary Tables 3 and 4). Other than two
subjects from Group 3 with suspected dengue and thus excluded
from analysis, the levels of JE antibodies were signiﬁcantly
reduced with increasing amount of time post-completion of the
two-dose vaccination schedule, generating a gradient of JE
antibodies at the point of YF vaccination (Fig. 1c). Notably,
Group 1 subjects had the most differences in JE antibodies when
compared with the other groups and provided a broad range of JE
antibody titres, covering those observed in Groups 2 and 3. This
allowed us to study the effects of cross-reactive JE antibodies on
subsequent YF vaccination. Our primary endpoint was the YF
neutralizing antibody titres at one month post YF vaccination.
Exploratory endpoints included YF vaccine viraemia and the
systems biology proﬁle of the host response to vaccination.
Antibody-enhanced YF infection results in prolonged viraemia.
No signiﬁcant differences in one month YF neutralizing antibody
titres were observed between the different groups (Supplementary
Fig. 1a). When the YF neutralizing antibody titres one month
post YF vaccination were analysed against the JE antibody titre on
the day of YF vaccination, an inverted U trend (Fig. 2a and
Supplementary Fig. 1b–d) that ﬁtted a second polynomial
function (P = 0.0405) was observed. This trend is similar to
in vitro studies that demonstrate ADE of dengue virus infection of
monocytes, macrophages and dendritic cells (DCs)13,14. YF
neutralizing antibody titres were independent of age, body mass
index, gender and ethnicity (Supplementary Fig. 1e–h). There was
also no correlation between YF and JE antibodies at one month
post YF vaccination, suggesting that the higher YF neutralizing
antibody response is not due to a boosting of the JE memory
response (Fig. 2b and Supplementary Fig. 1i). Instead, YF
neutralizing antibody titres correlated directly with the magnitude
at which pre-YF vaccination sera enhanced YF17D infection in
THP-1 monocytic cells, in vitro (Fig. 2c), which is in contrast
with the control group where no correlation was observed
(Fig. 2d). Collectively, our ﬁnding suggests that cross-reactive JE
antibodies bind YF vaccine to enhance its infection of APCs.
Wenextmeasured how JE vaccination affects YF vaccine viraemia at
days 1, 3 and 7 post-YF vaccination. Subjects in the treatment group
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a Assessed for eligibility (n = 196)
Excluded (n = 112)
• Dengue IgG positive (n = 72)
• Abnormal physical
examination/biochemistry (n = 26)
• Withdrew consent before randomization
 (n = 14)
Enrolment
Randomized (n = 84)
Allocated to intervention (n = 84)
• Group 1: JE followed by YF after 1 month (n = 23)
• Group 2: JE followed by YF after 4 months (n = 17)
• Group 3: JE followed by YF after 9 months (n = 24)
• Group 4: YF only (n = 20)
Received JE and/or YF vaccination (n = 74)
Did not receive allocated intervention (n = 10)
• Ten subjects voluntarily withdrew and/or did not receive
their YF vaccination at the stipulated time
Allocation
Lost to follow-up (n = 4)
• Four subjects voluntarily withdrew from the trial 
before 1 month post YF vaccination
Total analysed (n = 70)
• Group 1 (n = 23)
• Group 2 (n = 11)
• Group 3 (n = 16)
• Group 4 (n = 20)
Excluded subjects that have defaulted the trial (n = 14)
Follow-up
Figure 1 | Clinical trial overview. a, Consort diagram showing the ﬂow of participants through each stage of the randomized trial. b, Diagrammatic
representation of the study. Subjects in the treatment group were vaccinated with Ixiaro followed by Stamaril at 1 month (Group 1, red), 4 months
(Group 2, blue) or 9 months (Group 3, cyan) apart, indicated by §. The control group (Group 4) received YF vaccination only. c, Anti-JE antibody titres of
subjects from Group 1 (n = 23), Group 2 (n = 11) and Group 3 (n = 14) before YF vaccination as measured by PRNT. *P < 0.05, **P < 0.01 (unpaired t-test).
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Figure 2 | Cross-reactive antibodies enhance YF vaccine infection to produce prolonged viraemia and improved immunogenicity. a,b, Correlation between
anti-JE (day 0) (a) and anti-JE (1 month) (b) versus anti-YF (1 month) speciﬁc antibody titres for Groups 1–3 (n = 34) as measured by PRNT. Dotted lines
indicate the 99% conﬁdence interval of the mean titre of Group 4 and the enhancing group, deﬁned as subjects with titre greater than the 99% conﬁdence
interval of Group 4. c,d, Pre-YF immune sera from the treatment group (Groups 1–3; n =48) (c) or the control group (n = 20) (d) were diluted 1:10 and
incubated with YF17D before infecting THP-1 monocytes. YF17D plaque titres, represented by pre-vaccination serum mediated YF17D infection, were
correlated with the log-transformed YF antibody titres (1 month). e–g, YF RNA levels at days 1, 3 and 7 after YF vaccination for Group 4 subjects (n= 20) (e)
and the non-enhancing group (n = 40) (f) and enhancing group (n= 8) (g). h,j, YF RNA levels across the different groups at day 3 (h) and day 7 (j) post-YF
vaccination. Error bars indicate standard error of the mean. i,k, Correlation of log-transformed YF antibody titres (1 month) with log-transformed YF RNA
levels observed on day 3 (i) and day 7 (k) (n= 48). *P <0.05, **P <0.01 (paired t-test for e–g, unpaired t-test for h,j).
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elevated only in the enhancing group (Fig. 3a,c,e) and positively
correlated with YF antibody titres (Fig. 3b,d,f). These ﬁndings suggest
that YF vaccination in the presence of enhancing levels of cross-
reactive antibodies resulted in a greater pro-inﬂammatory response.
Antibody-enhanced YF vaccination leads to increased
semaphorin expression. To glean how enhancing antibodies alter
the gene expression response to YF vaccination, we performed
transcriptional proﬁling of peripheral blood mononuclear cells
(PBMCs) from 30 subjects. Gene-set enrichment analysis (GSEA)16
was used to determine the enriched molecular pathways. Although
some changes in gene expression were observed at day 1, most of
the gene expression changes occurred at day 3. Consistent with
other reports17,18, pathways associated with interferon and innate
antiviral responses were positively enriched in both treatment and
control groups (Supplementary Fig. 2a–e). Furthermore, KAT2B
gene expression, which was previously shown to be associated with
better YF antibody responses19, was also positively correlated with
YF titres in the control group (Supplementary Fig. 2f ). This
correlation, however, was not signiﬁcant for subjects who had
prior JE vaccination (Supplementary Fig. 2g).
As expected, the genes and pathways that were signiﬁcantly
enriched in those with prior JE vaccination compared with the
control group were mostly related to FcγR-signalling pathways
such as protein kinase B (Akt), casitas B-lineage lymphoma (CBL)
and extracellular signal-regulated kinases (ERK) signalling
(Supplementary Fig. 3a,b). Subjects in the enhancing group,
however, showed enrichment in T-cell-related pathways, speciﬁcally
CD28-dependent PI3K-Akt signalling20, interleukin receptor and
IL-2 signalling pathways21, compared with the non-enhancing
group and control group (Fig. 4a). Interestingly, semaphorin-
related pathways, known to have important roles in the regulation
of immune cell responses22,23 were also signiﬁcantly enriched in
the enhancing group (Fig. 4a and Supplementary Fig. 3a). Indeed,
genes in the semaphorin-related pathway were positively correlated
with YF antibody titres, along with interleukin signalling genes, in
subjects with prior JE vaccination (Fig. 4b). In contrast, no signiﬁ-
cant correlation was observed in the control group.
Validation of the GSEA hits (Fig. 4c) using quantitative real-time
polymerase chain reaction (qPCR) produced a similarly signiﬁcant
correlation between the transcripts of semaphorin-related genes at
day 3 post-YF vaccination and YF antibody responses (Supplementary
Fig. 3c). Similarly, independent veriﬁcation of these immune
semaphorins in another ten trial subjects using qPCR produced
similar ﬁndings (Supplementary Fig. 3d). Taken collectively, we
conclude that semaphorins SEMA4A, SEMA6A and SEMA7A
and its corresponding receptor, ITGA1, were signiﬁcantly and
positively correlated with YF antibody responses (Fig. 4d).
Semaphorins were ﬁrst identiﬁed to serve as axonal guidance
factors during neuronal development24. Subsequently, a subset of
semaphorins was discovered to play important roles in regulating
immune cells, especially APC and T cell interaction as well as cellular
trafﬁcking25–27. Consistent with the gene expression ﬁndings, serum
cytokine measurements identiﬁed two cytokines that were signiﬁ-
cantly correlated with YF neutralizing antibody titres, both of
which regulate T cell expansion and activation (Supplementary
Table 6b). First, platelet-derived growth factor isoform-BB
(PDGF-BB), which affects T cell expansion28, was signiﬁcantly
reduced in the control and non-enhancing groups at day 7 relative
to day 0, but not in the enhancing group (Supplementary Fig. 4a,
b). Second, a reduced level of vascular endothelial growth factor-D
(VEGF-D), which inhibits T cell proliferation and activation29,30,
was observed in the enhancing group post-YF vaccination, but
not in the control and non-enhancing groups (Supplementary
Fig. 4c). VEGF-D levels were also negatively correlated with YF anti-
body titres (Supplementary Fig. 4d). The cytokine data thus support
the gene expression ﬁndings. Collectively, these data suggest that YF
vaccination in the presence of enhancing levels of cross-reactive
antibodies induces expression of genes and cytokines that
augment T cell responses.
Increased semaphorin expression is mediated by activating FcγR
signalling. The fact that semaphorin genes were upregulated upon
YF vaccination only in those individuals with prior JE vaccination is
intriguing, and may indicate a signalling pathway intrinsic to
activating FcγR triggered by ADE. To test this possibility, because
SEMA4A is known to be expressed in monocytes, we measured
SEMA4A expression in THP-1 monocytes following inoculation
with YF17D virus opsonized with an enhancing concentration of
mouse–human chimaeric antibody 4G2 (h4G2). This antibody
binds the conserved fusion loop of ﬂaviviruses, including YF17D
virus (Supplementary Fig. 5a). Immune complexes formed
between YF17D and h4G2 (Supplementary Fig. 5b) resulted in
upregulation of SEMA4A mRNA (Supplementary Fig. 5c) and
protein levels (Fig. 4e and Supplementary Fig. 5d) at 24 h post-
infection, but inoculation of h4G2 or YF17D alone did not
change SEMA4A expression. Similarly, YF17D opsonized with
pre-YF vaccination serum from the enhancing group subjects
(Supplementary Fig. 5e) upregulated SEMA4A expression in
primary monocytes (Fig. 4f ), which was signiﬁcantly reduced
when activating FcγRs were blocked with monoclonal antibodies
(Fig. 4g). Furthermore, crosslinking of the activating Fc-receptors
alone with anti-FcγRI or FcγRIIA monoclonal antibodies resulted
in signiﬁcant upregulation of SEMA4A in both THP-1 (Fig. 4h)
and primary monocytes (Fig. 4i). Together, these results indicate
that activating FcγR signalling directly induces semaphorin
expression in monocytic cells.
As DCs are central to the initiation of primary immune responses,
we investigated the expression of semaphorins in DCs when FcγRs are
co-ligated. YF17D opsonized with h4G2 or pre-YF vaccination serum
from the enhancing group increased YF17D infection in monocyte-
derived DCs (Supplementary Fig. 5f–h). Crosslinking of FcγRIIA
but not FcγRI resulted in signiﬁcant upregulation of SEMA4A
(Fig. 4j) and SEMA7A (Fig. 4k), consistent with previous reports
demonstrating that DCs express low levels of FcγRI (ref. 31).
Collectively, these results indicate that engagement of activating
FcγRs upregulates semaphorins in FcγR-bearing antigen-presenting
cells, leading to improved cell-mediated responses.
Activating FcγR signalling leads to increased activation,
maturation and expression of semaphorins in dendritic cells,
in vivo. The in vitro experiments have shown that FcγR signalling
induces semaphorin expression, but prior JE immunization may
also induce other adaptive immune responses that alter
semaphorin expression independent of activating FcγRs. To
exclude this possibility, we investigated in vivo the effects of cross-
reactive antibodies on YF vaccination in the absence of cross-
reactive cellular immunity. C57BL/6 mice were ﬁrst immunized
with inactivated JE vaccine. After day 21, the IgG fraction was
puriﬁed from mouse sera and transferred to immunologically
naive animals. Thereafter, YF vaccine was administered in these
mice and the draining lymph nodes (DLNs) were isolated 24 h
post-vaccination to assess for migration and activation of DCs
(Fig. 5a). The gating strategy to identify DCs is shown in
Supplementary Fig. 5i. With increasing concentrations of cross-
reactive JE IgG antibodies, the total DCs (Fig. 5b) and activated
DCs (Fig. 5c) in the DLNs increased in a dose-dependent
manner. Consistent with in vitro observations, a low
concentration of JE cross-reactive antibodies (1 µg) resulted in an
increased percentage of SEMA4A+ DCs (Fig. 5d,e) with higher
mean ﬂuorescence intensity (MFI) for SEMA4A (Fig. 5f ). In
contrast, no differences in SEMA4A MFI were observed across the
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Figure 4 | Cross-reactive antibodies upregulate immune semaphorins via activating FcγR ligation. a, GSEA analysis of the enriched signalling pathways in
enhancing group (n = 6) compared with subjects from non-enhancing and control groups (n = 23) at day 3 post YF-vaccination. Normalized enrichment
scores were computed by GSEA and these pathways have gene-set nominal P values < 0.05 (n = 21). b, GSEA analysis of enriched signalling pathways at
day 3 post YF-vaccination that correlate with YF antibody titres for subjects with prior JE vaccination (black bars) (n = 21). White bars indicate corresponding
enrichment scores for the control group (n = 7). Nominal gene-set P values were <0.05 for black bars and >0.05 for white bars. PLC, phospholipase C.
SHC, Src homology 2 containing transforming protein. c, Immune semaphorin genes (in red) identiﬁed by GSEA to be enriched in subjects from the enhancing
group. d, Pearson correlation (r) of YF antibody titres, as measured by PRNT, with log2-transformed values of fold changes (day 3 versus day 0) of SEMA4A,
SEMA6A, SEMA7A and ITGA1 (n = 25). P values indicate signiﬁcance of the slope. e, Localization and expression of SEMA4A (green) in THP-1 exposed to
media, h4G2, YF17D or h4G2-opsonized YF17D (ADE) for 24 h. DAPI staining is blue. Values in white indicate the corrected total cell ﬂuorescence of
SEMA4A, normalized to DAPI. Scale bars, 20 µm. f, SEMA4A protein expression levels in primary monocytes exposed to media, YF17D or YF17D opsonized
with pre-YF vaccination serum (1:10) from an enhancing group subject for 24 h. Relative expression is normalized to GAPDH. g, SEMA4A expression when
YF17D opsonized with pre-vaccination serum from an enhancing group subject is added to primary monocytes blocked with either isotype antibodies or
anti-FcγRI and FcγRII antibodies. h, SEMA4A protein expression in THP-1 when FcγRI, FcγRII or both receptors are ligated for 6 h. i–k, Quantitative PCR
analysis of SEMA4A and SEMA7A in primary monocytes (i) and dendritic cells (j,k) when FcγRI, FcγRII or both receptors are ligated for 6 h (n= 4). Values
were corrected for expression of the control gene (GAPDH). *P <0.05, **P < 0.01 (unpaired t-test). Error bars indicate standard deviation of the data.
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total cells in the DLNs, or in mice given pre-immune sera
(Supplemntary Fig. 5j–l), suggesting that YF immune complexes
induce SEMA4A in DCs (Fig. 5g). Overall, these in vivo results
indicate that enhancing levels of cross-reactive antibodies alone
increased DC migration and activation, as well as semaphorin
upregulation, which contributes to enhanced immunogenicity.
Discussion
Our clinical trial and experimental ﬁndings collectively indicate that
cross-reactive antibodies, within a limited range, enhance the
immunogenicity of LAV by augmenting infection and activating
host responses downstream of activating FcγR. They also authenti-
cate the ADE of viral infection32–34 clinically. Indeed, only a small
minority of dengue patients secondarily infected with a cross-reactive
serotype of dengue virus develop severe disease35,36.
That immunogenicity enhancement was observed within a
restricted range of pre-existing JE antibody titres can be explained
by the stoichiometry requirement for optimal co-ligation of activat-
ing FcγR. Low titres of antibody could be suboptimal for activating
FcγR co-ligation37,38, whereas high titres of cross-reactive antibody
could aggregate YF vaccine to instead co-ligate the inhibitory
FcγRIIB, which reduces the uptake of vaccine by APCs (ref. 39).
With ADE, infection led to prolonged viraemia and FcγR-dependent
signalling that could have, at least in part, resulted in upregulation
of inﬂammatory metabolites. This interpretation is consistent with
previous reports showing that immune complexes can upregulate
thesemetabolites, resulting in increased phagocytosis40,41 and improved
immune responses42,43. In addition, genes, pathways and cytokines
that are known to regulate T cell activation and differentiation
were upregulated, although demonstration of an actual improve-
ment in T cell function will need to be shown in a separate study.
These observations could potentially explain why individuals with
pre-exposure to ﬂavivirus infection demonstrated improved efﬁcacy
of the chimaeric YF-dengue virus vaccine compared with immunologi-
cally naive individuals9–11.
The association of immune semaphorin expression with enhanced
immunogenicity is interesting. It is possible that semaphorins alter
the efﬁciency of YF vaccine infection of APCs and hence immuno-
genicity. However, given the known function this set of genes has
in regulating immune cell interaction and trafﬁcking25–27, it is more
likely that their induction by activating FcγR augmented APC and
T cell crosstalk for enhanced immunogenicity. The exact mechanism
of the action of semaphorins in regulating immunogenicity will need
to be investigated further.
Multiple factors have been proposed to inﬂuence vaccine efﬁcacy.
These include host genetics, the human microbiome and other
environmental inﬂuences44–46. Our study highlights that vaccine
efﬁcacy can be positively inﬂuenced by past exposure to heter-
ologous viruses, provided that the cross-reactive antibody titre is
optimal for LAV enhancement. It suggests that, if possible, ADE
could be exploited to deliver LAVs to overcome a key limitation of
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Figure 5 | Cross-reactive antibodies increase DC activation, migration and semaphorin expression for improved antigen presentation during YF
vaccination. a, Diagrammatic representation showing how cross-reactive antibodies from mice immunized with Ixiaro were transferred to non-immunized
mice to study their effects on YF vaccination. b,c, Total (b, CD11c+) and activated DCs (c, CD11c+CD80+CD86+) in DLNs after YF vaccination with
pretreatment of different doses of cross-reactive JE IgG (n = 6). d–f, Percentage of SEMA4A+ DCs (d), representative histograms (from n = 6) showing
SEMA4A staining on DCs (e) and mean ﬂuorescence intensity (MFI) of SEMA4A+ staining on DCs (f) with pretreatment of different doses of cross-reactive
JE IgG (n = 6). g, SEMA4A MFI of LN cells (n = 6). *P < 0.05, **P < 0.01 (unpaired t-test). Error bars indicate standard deviation of the data.
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immune responses soon after vaccination18,47. Although these
responses are needed to stimulate adaptive immune responses
against the LAV, they may also rapidly clear the vaccine, thereby
limiting the window available for the adaptive immune response
to be exposed to the antigen. Indeed, our ﬁndings that viraemia
levels at day 7, but not day 3, post YF vaccination correlated with
eventual YF neutralizing antibody titre indicate that the duration
of LAV infection inﬂuence immunogenicity. Not surprisingly, there-
fore, even highly potent LAVs such as those for measles and polio
require a booster to sustain the long-term immunity that typically
arises following natural wild-type viral infection48,49. The improved
immunogenicity of the live attenuated YF vaccine in those with
enhancing titres of cross-reactive antibodies thus suggests an
approach to overcoming short-lived immunity with vaccination. It
could also lead to reducing the need for multiple dosing regimes
to achieve adequate neutralizing antibody titres sufﬁcient for protec-
tive immunity. Determining the vaccine doses that achieve the anti-
body–antigen stoichiometry optimal for activating FcγR co-ligation
to enhance LAV infection and immunogenicity could thus be a
pragmatic approach to achieving longer-lasting vaccine efﬁcacy.
In conclusion, we have shown that cross-reactive antibodies enhance
LAV immunogenicity and infection while activating host responses,
including activating the FcγR intrinsic pathways that improve innate
and adaptive immune crosstalk (Supplementary Fig. 6). Strategies
that exploit ADE to improve vaccine immunogenicity should thus be
explored at the onset of vaccine design and development.
Methods
Ethical approval. Trial approval for this study was obtained from Singhealth
Centralised Institutional Review Board (ID:2013/385/E) and is registered under
clinicaltrials.gov registration no. NCT01943305. All participants gave written
informed consent.
Clinical trial design. The detailed study design has been described previously50.
Brieﬂy, healthy adults, prescreened to be negative for anti-dengue antibodies (Panbio
Dengue IgG, Alere) were enrolled on receiving informed consent. These subjects were
randomized into two arms, with subjects in the treatment arm (Groups 1–3) receiving
two doses of inactivated JE vaccine (Ixiaro, Novartis (Singapore) Pte Ltd), and subjects
in the control arm (Group 4) received no JE vaccination. The treatment arm was
further subdivided into three groups, for which YF vaccine (Stamaril, Sanoﬁ Pasteur
SA 2) was administered at different time intervals post-JE vaccination: 1 month
(Group 1), 4 months (Group 2) or 9 months (Group 3). The control group received
only YF vaccination. Serum was extracted on day 0 (immediately before YF
vaccination) as well as on days 1, 3 and 7 and 1 month post-YF vaccination. The
primary endpoint of the trial was the YF antibody titre at 1 month post-YF vaccination.
Throughout the entire trial period, subjects documented all local and systemic
symptoms experienced after JE and/or YF vaccination, including local and
systemic symptoms.
Cells and viruses. Vero, BHK-21 and THP-1 were purchased from ATCC. THP-1
was authenticated by ﬂow cytometry13 and all cell lines were tested for mycoplasma
contamination. YF17D virus was isolated from Stamaril by passaging once in Vero
cells. JE (SA-14-14-2) was cultured in Vero cells. Viruses were stored at −80 °C until
use. Infectious titre was determined by plaque assay.
Plaque reduction neutralization test. A plaque reduction neutralization test
(PRNT) was performed on BHK-21 cells. A serial twofold dilution of serum in
RPMI maintenance medium (MM) was incubated with 40 p.f.u. of JE (SA-14-14-2)
or 40 p.f.u. of YF17D virus, in equal volumes, for 1 h before adding to BHK-21
(100 µl per well). After 1 h incubation at 37 °C, medium was aspirated and cells were
overlaid with 1% carboxymethyl cellulose in MM. After 5 days at 37 °C, cells were
ﬁxed with 20% formaldehyde and stained with 1% crystal violet. PRNT50 values
were determined using a sigmoid dose–response curve ﬁt and reported as
reciprocal values.
Antibody-dependent infection of THP-1. Pre-dose serum (diluted 1:10 or titrated)
or h4G2 was incubated with 2 × 105 p.f.u. per 100 µl of YF17D at 37 °C for 1 h before
adding to THP-1 cells (multiplicity of infection (MOI) = 10). After 3 days
incubation at 37 °C, the resultant YF17D viral titres were quantiﬁed by plaque
assay as previously described39.
Viraemia assessment with qPCR. RNA from sera was extracted using the viral RNA
isolation kit (Qiagen) followed by cDNA synthesis (Biorad) and real-time qPCR
(Roche) according to the manufacturer’s protocol. The primers used were as
previously reported51. RNA copy number standards were synthesized by
amplifying the YF17D amplicon with EcoRI and XbaI ﬂanking sites, for cloning
into pCMV6-XL5 (Origene). RNA copy numbers were calculated as previously
described51. The limit of detection was determined to be 10 genome copies µl−1.
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) proﬁling. Sera
from patients collected on days 0, 1, 3 and 7 were collected for metabolomics
analysis. Untargeted metabolomics were performed as previously described with
modiﬁcations52. The supernatant fraction from the sample preparation step was
analysed using an Agilent 1290 ultrahigh pressure liquid chromatography system
equipped with a 6520 QTOF mass detector. The column used for the separation was
an Agilent rapid resolution HT Zorbax SB-C18 (2.1 × 100 mm, 1.8 mm; Agilent
Technologies). The gradient elution involved a mobile phase consisting of (A) 0.1%
formic acid in water and (B) 0.1% formic acid in methanol. The initial condition was
set at 5% B. A 7 min linear gradient to 70% B was applied, followed by a 12 min
gradient to 100% B, which was held for 3 min, then a return to starting conditions
over 0.1 min. Electrospray ionization mass spectra were acquired in positive ion
mode. Mass data were collected betweenm/z 100 and 1,000 at a rate of two scans per
second. The ion spray voltage was set at 4,000 V and the heated capillary
temperature was maintained at 350 °C. The drying gas and nebulizer nitrogen gas
ﬂow rates were 12.0 l min–1 and 50 p.s.i., respectively. Two reference masses were
continuously infused to the system to allow constant mass correction during the run:
m/z 121.0509 (C5H4N4) and m/z 922.0098 (C18H18O6N3P3F24).
For targeted lipidomic analysis, reversed-phase liquid chromatography (RPLC)-
MS analysis was performed with an Agilent 1290 Ultra Pressure Liquid
Chromatography device (UPLC) coupled to an electrospray ionization with iFunnel
Technology device on a triple quadrupole mass spectrometer (6490 QQQ, Agilent
Technologies). Chromatographic separation of extracted eicosanoids was achieved
using an HT Zorbax SB-C18 column (2.1 × 100 mm, 1.8 µm; Agilent Technologies)
with a ﬂow rate of 0.40 ml min–1 at 40 °C. The initial condition was set at 15% B; an
11 min linear gradient to 60% B was then applied, followed by a 17 min gradient to
100% B, which was held for 5 min, then a return to starting conditions over 0.1 min,
while using solvents A, 0.1% aqueous acetic acid, and B, 50:50 vol/vol acetonitrile/
isopropanol. Electrospray ionization was performed in negative mode with the
following source parameters: drying gas (N2) at a temperature of 200 °C with a
ﬂow rate of 14 l min–1, nebulizer gas pressure of 30 p.s.i., a sheath gas temperature of
400 °C with a ﬂow rate of 11 l min–1, capillary voltage of 3,000 V and nozzle voltage
of 800 V. Eicosanoids were quantiﬁed in multiple reaction monitoring (MRM)
mode. Data acquisition and processing for both global and targeted analyses were
performed using MassHunter software (Agilent Technologies).
Cytokine proﬁling. Sera were assayed for 45 cytokines, chemokines and growth
factors (Supplementary Table 6) using a multiplex suspension bead immunoassay
(Ebioscience), according to the manufacturer’s protocol. All samples were
randomized and run in duplicates. Data analysis of experimental data was carried
out using ﬁve-parameter logistic regression modelling on the Bio-Plex system
(BioRad). Calibrations and validations were performed before runs and on a
monthly basis, respectively.
Gene expression analysis. Whole blood was extracted and stored in Tempus Blood
RNA tubes at −80 °C. At the respective time points, RNA isolation proceeded
according to the manufacturer’s protocol. Microarray was performed at the
Duke–NUS Genome Biology Core Facility. cRNAs were hybridized to Illumina
Human HT-12 v4 Beadchips according to the manufacturer’s instructions. Data
analysis was performed using Partek software, and the signiﬁcantly enriched
pathways or correlated pathways were analysed with GSEA against the reactome
database, using a nominal P value of 0.05 as the cutoff. Microarray data are available
in the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under accession
no. E-MTAB-4669. For microarray validation, cDNA synthesis was performed with
iScript cDNA kit (Bio-Rad) and real-time qPCR was performed according to the
manufacturer’s protocol (Roche SYBR Green). Primers used for validation were
obtained from Origene.
Generation of primary monocytes and DCs. Primary monocytes were isolated
from the principal investigator and cultured as previously described39. Monocyte-
derived DCs were generated by culturing primary monocytes in 50 ng ml–1
granulocyte macrophage–colony stimulating factor (GM-CSF) and 50 ng ml–1 IL-4
for 5 days. Flow cytometry analysis conﬁrmed that more than 90% of treated
monocytes expressed DC markers including DC-SIGN, CD80 and CD86
(Supplementary Fig. 5f ).
h4G2 binding to YF17D. 4G2 chimaeric human/mouse IgG1 (h4G2) was
constructed as previously described53. Brieﬂy, cDNA encoding the variable regions
of 4G2 was synthesized from hybridoma cells and then used as the template to
amplify both heavy- and light-chain variable regions into the human IgG1 constant
region expression vector. The chimaeric antibodies were then expressed in the
FreeStyle 293 expression system (Invitrogen). To assess binding of h4G2 to YF17D,
ELISA was performed as previously described39.
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FcγR crosslinking and blocking. Cells (2 × 105 cells ml−1) were incubated with
0.5 µg ml–1 of either anti-FcγRI (eBioscience) or anti-FcγRIIA (Stem Cell Biology)
or both at 4 °C for 1 h, with agitation every 15 min. IgG1, IgG2b or both antibodies
were used, respectively, as isotoype controls. After this, cells were washed once with
MM. For FcγR blocking studies, these cells were incubated with YF17D opsonized
with 1:10 of pre-vaccination serum from the enhancing group at 37 °C for 24 h. For
the crosslinking experiments, anti-mouse IgG was added and incubated at 37 °C for
6 h. Thereafter, cells were collected for qPCR or western blot analysis.
Gene transcript levels. For qPCR assessment of genes, cells were washed once in
PBS followed by RNA extraction using an RNeasy kit, cDNA synthesis and real-time
qPCR according to the manufacturer’s protocol. Primers used for the genes were
obtained from Origene.
Immunoﬂuorescence. After infection, THP-1 was subjected to cytospin at 800g for
3 min and washed with PBS. Rabbit anti-SEMA4A (1:200, Abcam ab70178) was
added and incubated overnight at 4 °C. After washing with PBS, anti-rabbit
Alexa488 was added and incubated at room temperature for 1 h. Thereafter, Mowiol
with 4,6-diamidino-2-phenylindole (DAPI) was added for viewing under a Zeiss
confocal microscope.
Western blot. Western blot was performed and analysed as previously described13,
using rabbit SEMA4A (1:200, Abcam ab70178) or mouse GAPDH (1:3,000, Abcam
ab8245) as primary antibody, with horseradish peroxidase-conjugated anti-rabbit
(1:3,000, Abcam ab6721) or anti-mouse (1:1,000, Dako), respectively, as
secondary antibody.
Mouse model to assess effects of cross-reactive antibodies. Mice (C57Bl/6) were
obtained from InVivos (Singapore) and were housed in the Duke–NUS vivarium for
the duration of the experiment. Protocols were approved by the SingHealth IACUC.
Mice were vaccinated by intraperitoneal injection with 1 µg of human inactivated JE
vaccine (Ixiaro). After 21 days, the mice were killed and the blood was collected by
intracardiac puncture. IgG was puriﬁed from the pooled mouse serum using the Nab
Protein A/G Spin Kit (ThermoScientiﬁc). Puriﬁed IgG were quantitated by
nanodrop, then transferred to naive mice at three different concentrations (1, 10 and
100 µg) by intraperitoneal injection. The control group was given saline alone. After
24 h, all groups were challenged with Stamaril, 200 UI per mouse, subcutaneously in
rear footpads. Lymph nodes (n = 6 independent lymph nodes per group) were
isolated after an additional 24 h, and single cell suspensions were prepared using a
70 µm nylon cell strainer (Falcon) after treatment for 30 min with collagenase
(Sigma) in a tissue culture incubator. Cells were blocked with PBS containing 1%
bovine serum albumin (BSA, Gibco). To determine the numbers of activated DCs
and levels of SEMA4A, cells were stained with antibodies against CD11c-Paciﬁc Blue
(ThermoScientiﬁc), CD80-BV605 (BD Biosciences), CD86-BV510 (BD Biosciences)
and SEMA4A (Abcam) in a buffer consisting of PBS containing 1% BSA. After
washing with PBS, anti-rabbit AlexaFluor488 was used for secondary staining. After
washing, cells were ﬁxed with 4% paraformaldehyde. Data were acquired using a
Fortessa ﬂow cytometer (BD Biosciences) and analysed and prepared for publication
using FlowJo and Prism Software. Female mice were 6–8 weeks old at the beginning
of the experiments. Sample size calculations were not performed in advance and no
randomization or blinding procedures were used.
Data availability.Microarray data have been deposited in the ArrayExpress database
(www.ebi.ac.uk/arrayexpress) under accession no. E-MTAB-4669.
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Molecular determinants of plaque 
size as an indicator of dengue virus 
attenuation
Kenneth Choon Meng Goh1, Choon Kit Tang1, Diana Catherine Norton2, Esther Shuyi Gan1, 
Hwee Cheng Tan1, Bo Sun2, Ayesa Syenina1, Amjad Yousuf3, Xin Mei Ong1, 
Uma Sangumathi Kamaraj1, Yin Bun Cheung1, Duane J Gubler1, Andrew Davidson3, 
Ashley Lauren St John1, October Michael Sessions1 & Eng Eong Ooi1
The development of live viral vaccines relies on empirically derived phenotypic criteria, especially 
small plaque sizes, to indicate attenuation. However, while some candidate vaccines successfully 
translated into licensed applications, others have failed safety trials, placing vaccine development 
on a hit-or-miss trajectory. We examined the determinants of small plaque phenotype in two dengue 
virus (DENV) vaccine candidates, DENV-3 P
3ͶFRhL3, which produced acute febrile illness in 
vaccine recipients, and DENV-2 PD53, which has a good clinical safety profile. he reasons behind the 
failure of P
3ͶFRhL3 during phase 1 clinical trial, despite meeting the empirically derived criteria 
of attenuation, have never been systematically investigated. Using in vitro, in vivo and functional 
genomics approaches, we examined infections by the vaccine and wild-type DENVs, in order to 
ascertain the diơerent determinants of plaue size. e show that P
3ͶFRhL3 produces small 
plaues on BH-21 cells due to its slow in vitro growth rate. In contrast, PD53 replicates rapidly, but 
is unable to evade antiviral responses that constrain its spread hence also giving rise to small plaques. 
herefore, at least two diơerent molecular mechanisms govern the plaue phenotypeǢ determining 
which mechanism operates to constrain plaque size may be more informative on the safety of live-
attenuated vaccines.
The in vitro replication rate of pathogens is a common measure of fitness. A rapidly replicating virus in culture is 
interpreted as having greater fitness than slower growing strains1–3. Correspondingly, the size of plaques, which 
are caused by necrosis or apoptosis upon infection of a cell monolayer, is a common proxy measure of viral fitness. 
This empirically derived measurement of fitness is used in the development of live attenuated vaccines (LAVs), 
where strains that produce small plaques are repeatedly selected and purified for clinical development1,4,5.
While this empirical approach in vaccine development has yielded successful vaccines including measles6, 
mumps7 and yellow fever8,9, it has also led to failed clinical trials, where candidate vaccines caused acute disease. 
These undesired outcomes suggest that in vitro replication rate alone is not a reliable indicator of a virus’ clinical 
fitness10,11. We recently showed that an epidemiologically fitter strain of dengue virus (DENV) that emerged dur-
ing the 1994 dengue outbreak in Puerto Rico paradoxically replicated more slowly than the virus it displaced12. 
The fitter virus “sacrificed” its genomic RNA to form more subgenomic RNA, which downregulated type-I inter-
feron expression by binding a RIG-I signalling pathway intermediate. The reduced type-I interferon signalling 
likely then allowed DENV to spread to more susceptible cells, eventually reaching higher viraemia levels for more 
efficient vector-borne transmission12. Our findings thus indicate that viral replication rate is not invariably corre-
lated with viral fitness in an epidemiological or clinical setting.
To gain clinically informed insights into the molecular determinants of attenuation, we examined a LAV 
candidate that caused acute illness in phase I clinical trials. The strains in the tetravalent dengue LAV developed 
at Mahidol University were selected for passaging primarily based on the small plaque phenotype; DENV in 
cells surrounding small plaques were purified and expanded after every five passages4. Other empirically defined 
1DueǦ eica cooǡ inapore 1ͼ98ͻ7ǡ inapore. 2Duke University School of Medicine, Durham, North 
aroina 27710ǡ . 3niersit of ristoǡ risto 8 1Dǡ . orresponence an reuests for materias sou 
e aresse to ..O. ȋemai: eneon.ooi̻ueǦnus.eu.sȌ
receie: 09 Decemer 201ͻ
ccepte: 27 pri 201ͼ
Puise: 17 a 201ͼ
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | ͼ:2ͼ100 | DOI: 10.1038/srep2ͼ100
markers used to determine attenuation were temperature sensitivity and reduced neurovirulence in suckling 
mice4,5. Despite this uniform approach, the vaccine candidates had contrasting clinical outcomes.
DENV serotype 3 (DENV-3) vaccine strain DENV-3 PGMK30FRhL3 (hereafter referred to as PGMK30) 
was generated by passaging wild-type DENV-3 16562 thirty times in primary green monkey kidney cells 
(PGMK) and three times in primary foetal rhesus lung (FRhL) cells. In a human safety trial, however, all volun-
teers who received tetravalent LAV formulation containing PGMK30 developed symptoms and signs consistent 
with acute dengue, with detectable DENV-3 viraemia10. Following the disappointing clinical trial results, this 
DENV-3 vaccine strain was further passaged in Vero cells using the same Mahidol University protocol to yield 
the Vero-derived Vaccine (VDV3) strain, which again met the same phenotypic criteria for attenuation previously 
used. When VDV3 was administered to healthy volunteers, it again caused disease in recipients13,14. In contrast, 
the DENV-2 vaccine strain, PDK53, which was generated from wild-type virus (16681) after 53 passages in pri-
mary dog kidney (PDK) cells was clinically safe and has since been used as a backbone to construct chimeric vac-
cines for the other DENV serotypes15,16. Although follow up investigations on PGMK30 found differences in host 
cell responses compared to wild-type DENV-313, the underlying reasons for why PGMK30 caused acute illness in 
vaccine recipients despite meeting the empirical criteria for attenuation were never determined. Understanding 
the mechanisms that operate to yield divergent clinical outcomes despite the similar small plaque phenotype in 
these two LAV candidates could enable a more objective and accurate approach to selecting attenuated strains for 
development into LAVs.
Results
Attenuation status is not correlated with rate of cell-to-cell spread or genomic replication of 
DENV. We first confirmed the small plaque phenotype displayed by the attenuated PDK53 and PGMK30 
strains, and their wild-type counterparts, on BHK-21 cells (Fig. 1A). The back-titrations of the viral inoculum 
(1 × 105 pfu/mL) used in our experiments were verified using plaque as well as focus-forming assays to ensure 
that the viral titres were not underestimated due to the small plaque size. Both plaque and focus-forming unit 
assays produced consistent findings (Fig. 1B). Full genome sequencing of all four virus strains (Accession num-
bers in Supplementary Table 1) showed that passage of these viruses in our laboratory resulted in a variant with 
one amino acid substitution in the NS4A protein (N22D) of 61.33% of PDK53. This mutation is not known to be 
associated with a change in viral fitness. Importantly, the genome sequence of our 16681 strain exactly matched 
previous reports, while the three mutations in PDK53 previously shown to be critical for the attenuated state of 
PDK535 were all preserved.
To measure the in vitro replication rate and cell-to-cell spread of the viruses, HuH-7 cells were infected with 
each of the DENV-2 or DENV-3 strains. At 24 hours post-infection (hpi), flow cytometry showed that PDK53 
paradoxically infected a significantly higher proportion of cells (30%) than wild-type 16681 (5%). The proportion 
of 16681-infected cells at 24 hpi was instead equivalent to PDK53 infection at 10-fold lower MOI (Fig. 1C, left) 
although the proportion of 16681-infected cells overtook that for PDK53 at 96 hpi (42% versus 39%) (Fig. 1C). 
Conversely, the proportion of 16562-infected cells was significantly greater at 24, 48 and 72 hpi compared to 
PGMK30, with the former achieving infection percentages of 1%, 27% and 53% whilst the latter obtained 0.3%, 
5% and 19%, respectively (Fig. 1C, right).
The RNA replication rate of these viruses was also measured using quantitative RT-PCR (qPCR)17. Consistent 
with the flow cytometry findings, PDK53 at 2 hpi had significantly greater RNA than 16681 when both viruses 
were inoculated onto Huh-7 cells at 10 MOI (Fig. 1D, left). Compared to PDK53 infection at 1 MOI, 16681 RNA 
levels at 10 MOI showed similar intracellular viral RNA initially, although by 24 hpi, PDK53 showed higher RNA 
levels than 16681 (Fig. 1D). In contrast, the RNA levels of the two DENV-3 strains were similar to each other in 
the first 24 hours of infection (Fig. 1D).
To rule out virions bound to the cell membrane but not internalized as a potential source of this difference in 
viral RNA, we treated HuH-7 cells with 1 mg/mL pronase, a non-specific mixture of proteases able to cleave off 
surface-bound virions without causing cell lysis18. At 2 hpi and after pronase treatment, the viral RNA levels for 
16681 at 10 MOI infection were equivalent to PDK53 at 1 but not 10 MOI (Fig. 2A). To verify that this was not 
unique to Huh-7 cells, we infected Raji cells stably expressing the dendritic cell-specific intercellular adhesion 
molecule-3-grabbing non-integrin (DC-SIGN) receptor, previously shown to facilitate DENV entry19,20. A similar 
trend to that observed in Huh-7 cells was obtained at 2 hpi (Fig. 2B). To ensure that our findings were not influ-
enced by possible differences in the proportion of mature and immature virions, we infected THP-1 cells with 
PDK53 opsonized with enhancing concentrations of humanized 4G2 monoclonal antibody (mAb). 4G2 binds the 
highly conserved fusion loop of the E protein – only available for binding in mature virions – and standardizes 
viral entry through activating Fc receptors; infection rates of THP-1 cells without opsonising antibody is mini-
mal21,22. Infection through this pathway produced similar trends in viral RNA levels to Huh-7 at 2 hpi (Fig. 2C). 
Conversely, in these same assays, we observed no differences in uptake between 16562 and PGMK30 (Fig. 3A–C).
Collectively, these findings indicate that the different levels of 16681 and PDK53 viral RNA post-inoculation 
is independent of cell type or receptor used to initiate entry. Furthermore, the higher than expected level of cyto-
plasmic RNA and proportion of infected cells for PDK53 suggest that plaque formation and the resultant plaque 
size are not determined by viral replication rate alone. Instead, host cell factors may regulate cell-to-cell spread: 
playing a critical role in the DENV-2 strains, and a much lesser one in DENV-3.
PD53 but not P
3Ͷ induces a robust antiviral response upon infection, limiting its in vivo 
spread. To compare the host response to the wild-type viruses and their respective small plaque-sized deriv-
atives, we used an unbiased whole genome microarray to study changes in host gene expression. To ensure that 
the amount of cytoplasmic viral RNA is similar between 16681 and PDK53, we included infection with PDK53 
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at 1 and 10 MOI and compared the former to 16681 inoculated at 10 MOI (Fig. 2A). Infection with 16562 and 
PGMK30 was done at 10 MOI.
Interestingly, there were relatively few differentially expressed genes upon 16681 infection compared to unin-
fected control. In contrast, PDK53 infection resulted in significant changes in gene expression at both MOIs 
(Fig. 4A, top). Few differences were also observed in cells infected with either DENV-3 strain (Fig. 4A, bottom). 
Pathway analysis of genes upregulated by PDK53 infection reveals many with known antiviral functions, includ-
ing cytokines, interferon-β (IFN-β ), IL29 and interferon-stimulated genes (ISGs) (Fig. 4B). Because both DENV-3 
strains minimally perturbed gene expression, we performed proteomic analysis only on DENV-2-infected cells. 
The results indicate increased expression of endoplasmic reticulum (ER) stress proteins, indicating that PDK53 
infection resulted in increased transcriptional and translational activities in host cells (Fig. 4C).
Figure 1. Properties of the vaccine and wild-type strains. (A) Representative photographs of viral plaques 
(left) and their corresponding plaque sizes in BHK-21 cells (right). (B) Plaque assay titres (left) and focus 
forming assay titres (right) of viral inoculum diluted to 10MOI (1 × 105 per mL) for cell culture experiments, 
confirming that all strains have the same inoculum titres, and that the PFU and FFU titres corresponded to each 
other. (C) Cell-to-cell spread of virus in HuH-7 cells as measured by flow cytometry. At 24 hpi, 1MOI of PDK53 
infected 10% of cells, approximately 10-fold more than 1MOI of 16681 (1%). Proportion of cells infected with 
PDK53 (0.1MOI) was similar to those infected with 16681 (1MOI) at 24 hpi although the latter overtook the 
former by day 4 of infection (left). In contrast, PGMK30 did not spread as rapidly as 16562 (right). (D) Viral 
RNA replication in HuH-7 cells as measured by qPCR in the first 24 hours of infection. At the earliest time 
point, 3 hpi, 10MOI of PDK53 produced significantly more viral RNA than 10MOI of 16681. Viral RNA levels 
were balanced with 16681 (10MOI) when PDK53 was infected at 1MOI. When starting levels of viral RNA are 
balanced, PDK53 replicated more rapidly than 16681 in the first 24 hours of infection (left). PGMK30 and 16562 
replicated at the same rate (right).
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The observed induction of antiviral response in HuH-7 cells by PDK53 but not PGMK30 or the wild-type 
viruses could be replicated in primary human monocytes. Infection of primary monocytes with PDK53 at both 1 
and 10 MOI resulted in greater levels of CXCL10, ISG20 and IFIT2 mRNA levels compared to 10 MOI of 16681 
(Fig. 4D). These ISGs are known to be important for the control of DENV replication in infection23. Infection 
with either 16562 or PGMK30 did not significantly induce the expression of these ISGs (Fig. 4D).
Thus far, our results suggest that PGMK30, despite its slow growth rate, remains able to evade antiviral 
activation unlike PDK53. To test if these antiviral responses played a role in controlling the spread of PDK53 
in vitro, we used siRNAs to knock down signalling intermediates of their activation – MAVS, TRIF, and IRF3 – in 
HuH-7 cells. Treated cells were then infected with the four viruses as before. We found that only IRF3 knockdown 
increased the spread of PDK53 relative to control siRNA treatment (Supplementary Fig. 1). MAVS and TRIF 
knockdown did not affect the proportion of cells infected by PDK53; and the other three viruses were unaffected 
by any of the siRNA treatments. These findings suggest that of the four viruses, only PDK53 is constrained in 
spreading by antiviral responses; additionally, PDK53 appears capable of triggering more than one cellular pattern 
recognition receptor as MAVS or TRIF knockdown alone is not sufficient to affect its spread.
The in vitro control of viral spread by the antiviral response could also have implications on the ability of PDK53 
to spread in vivo, and thereby cause viraemia. To test how these viruses spread in vivo, we used an immunocompe-
tent mouse model previously described24,25. The footpads of C57BL/6 mice were inoculated with one of the 4 viruses. 
Figure 2. Viral RNA 2 hpi measured by qPCR of D2 infections. (A) DENV-2 RNA in Huh-7 cells treated 
with pronase to remove bound extracellular virions. Uptake of 10MOI PDK53 was approximately 10-fold 
greater than equivalent MOI of 16681. (B) DENV strains opsonised with humanised 4G2 monoclonal antibody 
infected THP-1 cells via Fc-receptor mediated uptake. 4G2 binds the fusion loop which is only exposed in 
mature virions. Uptake of 10MOI of PDK53 was 10-fold greater than 10MOI of 16681. (C) DENV-2 RNA in 
Raji cells expressing the DC-SIGN receptor. Uptake of PDK53 (10MOI) was 10-fold greater than equivalent 
MOI of 16681. All data points were calculated from at least 4 biological replicates; Error bars indicate standard 
deviation. P-values were calculated using a two-tailed t-test; *indicates p < 0.05 and **indicates p < 0.01 
respectively.
Figure 3. Viral RNA 2 hpi measured by qPCR of DENV-3 infections. (A) DENV-3 RNA in pronase-treated 
Huh-7 cells. (B) DENV-3 RNA in THP-1 cells infected via antibody-dependent pathway. (C) DENV-3 RNA 
in Raji cells expressing the DC-SIGN receptor. In all cases, the amount 16562 and PGMK30 uptake by cells 
were similar. All data points were calculated from at least 4 biological replicates; Error bars indicate standard 
deviation. P-values were calculated using a two-tailed t-test; *indicates p < 0.05 and **indicates p < 0.01 
respectively.
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After 24 hours, the draining popliteal lymph nodes were then dissected and stained for DENV. Confocal microscopy 
analysis found that PGMK30 was able to spread to the draining lymph nodes, just as well as wild-type 16562 and 
16681. In contrast, PDK53 produced weak signals of infection in the draining lymph nodes (Fig. 5A).
Figure 4. Host cell responses to infection with different DENV strains. (A) Unbiased whole genome 
microarray hits of significant transcriptomic changes in infected HuH-7 cells (> 2-fold change relative to 
uninfected cells, corrected p-value < 0.05) showing how only PDK53, whether at 1MOI or 10MOI, induced 
significant changes in gene transcription relative to uninfected cells. Cells infected by PGMK30 and both wild-
type strains at 10MOI remained largely unperturbed by infection. Upregulated genes are depicted in red, and 
downregulated genes in blue. (B) Transcription changes in HuH-7 cells detected by microarray of selected 
genes, grouped by antiviral function. Only PDK53 consistently upregulated antiviral gene expression. Few 
changes were observed in PGMK30 relative to 16562 infection. (C) Translational differences (left heat map) and 
their corresponding microarray transcript levels (right heat map) of the most differentially enriched proteins 
in HuH-7 cells infected with either 16681 or PDK53. (D) mRNA levels of selected ISGs measured by qPCR of 
infected primary human monocytes (right side of graph), alongside their corresponding microarray transcript 
values of infected Huh-7 cells (left side of graph). Error bars indicate standard deviation. P-values were 
calculated using a two-tailed t-test; *indicates p < 0.05 and **indicates p < 0.01 respectively.
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The inability of PDK53 to evade antiviral activation in humans may be due to its adaptation to canine cells. 
Both 16681 and PDK53 infected Madin-Darby Canine Kidney (MDCK) cells, a dog kidney cell line (>5% 
infected cells at 24 hpi, and an increase in the proportion of infected cells on the second day of infection) (Fig. 5B) 
whereas 16562 or PGMK30 only yielded negligible levels of infection (<1% at both 24 hpi and 48 hpi) as measured 
by flow cytometry (Fig. 5C). Unlike infection in human cells, PDK53 induced IFN-α and-β expression at levels 
similar to 16681 in MDCK cells and is significantly lower than cells stimulated with the synthetic dsRNA ana-
logue, poly I:C. In contrast, both 16562 and PGMK30 induced greater IFN-α and-β expression at 6 hpi (Fig. 5D).
Innate immune responses controls the plaue size of PD53 but not P
3Ͷ. The observed dif-
ferences in antiviral induction and growth rates between the DENV-2 and DENV-3 strains suggest that two fun-
damentally different mechanisms could be regulating the process of viral spread between PDK53 and PGMK30. 
PDK53 spread appears regulated by antiviral responses, while PGMK30 is merely slower at spreading to other 
cells. Thus far, these findings have been considered in HuH-7 cells, primary monocytes and in mice. Given that 
vaccine strain development is based primarily on plaque selection and purification, we examined if these two 
different mechanisms operate to determine viral plaque formation.
To test whether the plaque size of PDK53 was limited by antiviral responses, we conducted an immunofluorescence- 
based focus-forming assay on BHK-21 cells, a cell line commonly used for plaque assays. Using confocal micros-
copy, we measured nuclear translocation of phosphorylated STAT1 (pSTAT1) in uninfected BHK-21 cells sur-
rounding foci of viral infection (Fig. 6A). Increased levels of nuclear-translocated pSTAT1 were observed in 
IFN-treated or yellow fever vaccine (YF-17D)-infected cells that served as positive controls, relative to the unin-
fected negative controls (Fig. 6B). Likewise, significantly increased amounts of nuclear-translocated pSTAT1 were 
also observed in cells surrounding foci of PDK53 infection. In contrast, PGMK30, along with both wild-type 
viruses, did not elevate levels of nuclear-translocated pSTAT1 in the periphery of viral foci (Fig. 6B).
If the plaque size of PDK53 were limited by the antiviral response, then interfering with its activation – by 
silencing IRF3, STAT1 and NF-kB – would be expected to change the plaque characteristics of PDK53, but not 
PGMK30 or the wild-type viruses. Representative photographs of the resulting plaques in BHK21 cells, which 
are commonly used for plaque assays, are shown in Fig. 7A. Firstly, when infected onto the plaque assay wells at 
Figure 5. In vivo spread of DENV and adaptation to canine cells. (A) Immunofluorescence of DENV in 
popliteal lymph nodes 24 hours after inoculation of virus into the footpads of C57BL6 mice. 1 × 105 pfu of 
DENV was injected subcutaneously into the footpads of immunocompetent C57BL/6 mice. The draining 
popliteal lymph nodes were dissected 24 hpi then stained for viral dsRNA (green). (B) Percentage of Madin-
Darby Canine Kidney (MDCK) cells infected with DENV-2 as measured by FACS at 24 hpi (left) and 48 hpi 
(right). At 10MOI, PDK53 infected significantly more MDCK cells (44%) than 10MOI of 16681 (6%). At 1MOI, 
PDK53 infected fewer cells at 24 hpi (4%), but caught up with 16681 (6%) at 48 hpi. (C) MDCK cells infected 
DENV-3 at 24 hpi (left) and 48 hpi (right). Both DENV-3 strains infected approximately 1% of cells at both time 
points. (D) IFNα (left) and IFNβ (right) transcript levels in infected MDCK cells. PDK53, like 16681, did not 
significantly upregulate interferon expression, unlike infection with either DENV-3 strains or treatment with 
poly I:C.
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the same inoculum of 30 pfu per well, PDK53 yielded more plaques when IRF3, STAT1 or NF-kB were silenced, 
indicating that many PDK53 infections do not normally form visible plaques or foci of infection due to antiviral 
activation. In contrast, silencing any of these genes did not result in significant change in the plaque count for 
PGMK30 or either wild-type DENV (Fig. 7B).
Secondly, the plaque phenotype also appeared to change with some siRNA treatments. The increase in plaque 
counts and plaque sizes due to siRNA treatment could not be discriminated by flow cytometry as both would 
result in an increased proportion of infected cells. Calculations of mean plaque size were similarly confounded by 
the appearance of new plaques of varying sizes, and hence could not be directly compared.
We thus analysed whether IRF3, STAT1 or NF-kB knockdowns caused plaque sizes to become unimodally or 
bimodally distributed, with bimodal distribution indicating that some enlarged plaques occurred in a background 
of new, smaller plaques. We mathematically fit the respective plaque size measurements into both unimodal and 
bimodal distributions, and then calculated Bayesian information criterion (BIC; the smaller the more plausible) 
scores for both types of distributions. When cells were treated with control siRNA, the resulting plaques better 
fitted a unimodal distribution except for PDK53, which was equivocal. BIC scores suggest that with IRF3 knock-
down, PDK53 plaques fell into a bimodal distribution while PGMK30 plaques were unimodally distributed. Of 
the two wild-type strains, 16681 appeared to be bimodal, while 16562 was equivocal (Fig. 7C). The plaque size 
distribution of PDK53 in STAT1 or NF-kB p50 subunit knockdown cells, and 16681 in STAT1 knockdown cells 
also favoured bimodal distribution. Both DENV-3 strains yielded plaque size distributions that were either uni-
modal or equivocal; none showed clear bimodal distribution (Supplementary Fig. 2).
Discussion
The goal of LAV development is to derive a viral strain with reduced virological fitness that causes asymptomatic 
acute infection; the immune response to this infection protects against subsequent wild-type infection. The pro-
cess of generating attenuated strains has remained fundamentally unchanged since pioneering work by Sabin and 
others in developing the oral polio vaccine26. Unfortunately, the empirical nature of serial passaging in cells means 
that successful attenuation is a hit-or-miss affair. For viruses without reliable preclinical predictors of attenuation, 
testing for vaccine effectiveness can only happen in phase I clinical trial – posing problems of both safety and 
cost. Understanding the molecular basis behind viral attenuation is thus a critical step towards improving LAV 
development.
Collectively, our findings indicate that serial passaging in canine cells coupled with small plaque selection 
has yielded a canine-adapted viral strain that has lost its ability to evade human antiviral defences. Conversely, as 
monkeys are evolutionarily closer to humans, viruses adapted to PGMK likely retained their ability to suppress 
the human antiviral response. Consequently, selecting for small plaques could have yielded a strain that replicates 
slowly but which remains virulent in humans.
Previous studies on successful LAVs have identified key genomic correlates of protective immune responses13,14,27–30. 
Of particular interest is the prior work done comparing responses in human myeloid dendritic cells infected with 
Figure 6. STAT1 activation in BHK-21 cells. (A) Representative images of confocal microscopy images of cells 
that were uninfected and untreated (negative control), interferon-treated (positive control), surrounding YF-
17D or DENV focus of infection. Top row: 10X low power magnification view of viral foci, showing cell nuclei 
(blue), YF-17D or DENV (red), and pSTAT1 (green); Second row: Single cell nucleus composite image of an 
uninfected cell near focus of infection; Third and fourth rows: Single-channel images of the same cell showing 
pSTAT1 or cell nucleus, respectively. (B) Mander’s co-localisation coefficient measurements for nuclear-
translocated pSTAT1 measured in uninfected cells in the periphery of viral foci. Levels of nuclear translocated 
pSTAT1 were similar for PDK53 and YF-17D, both of which were significantly higher compared to 16681, 
16562 and PGMK30. P-values were calculated using a two-tailed t-test; **indicates p < 0.01.
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16562, the Vero-derived successor of PGMK30 (VDV3), or the yellow fever-dengue chimeric vaccines (CYD1-
4). These studies found differences in the transcription of key ISGs, pro-inflammatory cytokines, and dendritic 
cell activation markers – with the strongest activation by CYD vaccines, while minimal immune activation was 
observed with the reactogenic VDV3 strain14. Despite differences in infection protocols and the viruses used, as 
well as their smaller subset of genes tested by cDNA macro-array, the broad conclusions agree with our findings, 
that successful live-attenuated vaccines trigger larger-scale and more robust changes in whole-genome transcrip-
tion compared to unattenuated virus strains27,28.
The transcriptional changes induced by DENV-2 strains were also previously studied, in which 16681 was found 
to have induced greater transcriptomic changes in infected primary human monocytes compared to their vaccine 
strain31. These findings contrast with ours although the inoculum was based on MOI rather than internalised viral 
RNA nor were the proportion of infected cells ascertained to be equal between 16681 and PDK53. Moreover, as with 
Figure 7. Effects of siRNA knockdown of antiviral activators on plaque size phenotype. (A) Photographs of 
representative plaque assays for each of the DENV strains in cells transfected with either scrambled siRNA or 
siRNA that targed IRF3, STAT1 or NF-kB subunits. (B) Plaque counts (per well of a 24-well plate) for each of 
the DENV strains in cells transfected with either scrambled siRNA or siRNA that targed IRF3, STAT1 or NF-kB 
subunits. Significant increase in pfu was observed in PDK53 when inoculated onto cells transfected with IRF3, 
STAT1 or NF-kB knockdown. Significant increase in 16562 pfu was observed with NF-kB p50 knockdown. The 
other viruses and treatments showed no significant change. P-values were calculated using a two-tailed t-test;  
** indicates p < 0.01. (C) Plaque size distributions of the four virus strains for control and IRF3 knockdown, 
along with corresponding Bayesian Information Criterion (BIC) scores for unimodal or bimodal distribution. 
Lower BIC scores indicate better fit. All four control siRNA treatments yielded unimodal plaque size 
distributions. With IRF3 knockdown, PDK53 and 16681 plaques better fit a bimodal distribution, although the 
differences in plaque sizes were more distinct in PDK53. 16562 was neither more unimodal nor bimodal, whilst 
PGMK30 better fit a unimodal distribution.
www.nature.com/scientificreports/
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the DENV-3 studies, the authors used a cDNA macro-array restricted to 268 pre-selected genes and were therefore 
not able to sample changes in the transcriptome globally upon infection with either DENV-2 strain.
Besides detailing the host response to infection, our findings further expand on the literature by identifying 
determinants of plaque size, which is often the primary selection criterion for attenuation. Our study thus adds 
a layer of information unaddressed in prior work, which is critical for the field to avoid repeating costly failures. 
Our data collectively indicate that there are at least two distinct molecular determinants of the small plaque 
phenotype in dengue LAV strains. PDK53 grows rapidly immediately upon infection but its cell-to-cell spread 
is curtailed by its inability to evade antiviral responses in primate or rodent cells. In human recipients, these 
responses limit the spread of PDK53 while triggering adaptive immunity. In contrast, the small plaque phenotype 
of PGMK30 is due to its slow growth rate, without compromising its ability to evade immune detection. It thus 
spreads more effectively in vivo, possibly with a longer incubation period before disease onset.
Collectively, these findings suggest that selection for strains that have adapted to evading antiviral activation 
in non-primate species and are thus unable to evade antiviral responses in humans is a key safety feature. Indeed, 
the yellow fever YF-17D vaccine was passaged through mouse brain followed by chicken embryos32. Measles 
and mumps vaccine were developed in eggs6,7. Rubella vaccine is an exception to this trend as it was passaged 
in human diploid fibroblast cells but adapted to replication at 30 °C, compromising replication at fever tempera-
tures33. Conversely, other attempts to passage viruses in primate or human cells, such as the Towne11 or AD16934 
strains for human cytomegalovirus, and even the VDV3 vaccine strain14, ultimately yielded reactogenic viruses.
Another interesting finding is the higher than expected viral content of PDK53 at equal MOIs with 16681. We 
conclude that the higher viral titer comes from additional productive infections, which are only revealed in the 
plaque assay after antiviral activation is impaired. Because the additional plaques fall into a bimodal distribution 
with IRF3 knockdown, we also conclude that the original plaques must have also increased in size once the con-
straint on viral spread is impaired. We are unable to determine if our NS4A variant subpopulation contributed to 
these findings. However, since our PDK53 genome sequence otherwise matches previously published sequences, 
including the genome position 5270 A/T variant35, and contain no reversions to wild-type, the additional muta-
tion is more likely to increase rather than decrease attenuation. We thus believe that the presence of this amino 
acid variant does not affect our overall interpretation of live vaccine safety. There is therefore a possibility that the 
higher than expected PDK53 inoculum could contribute to immunogenicity although this interpretation cannot 
be fully ascertained in the background of the NS4A variant. As for the wild-type 16681 strain, although its plaque 
sizes also split into a bimodal distribution with IRF3 knockdown, there are no additional plaques that result from 
siRNA treatment and so this likely represents a broadening of the range of plaque sizes, rather than any ability to 
trigger antiviral responses.
In conclusion, our findings indicate that at least two different molecular mechanisms govern the plaque phe-
notype and that determining which mechanism operates to cause small plaque size may be a more accurate way 
to select future live-attenuated vaccine strains for clinical development.
Materials and Methods
ells, Viruses, and Reagents. HuH-7 and Raji cells stably expressing DC-SIGN (gift from Timothy 
Burgess20,36) were cultured in Dulbecco’s Modified Essential Medium (DMEM) while THP-1 and BHK21 cells 
were cultured in RPMI Medium 1640 (Gibco) supplemented with 10% foetal calf serum. Primary human mono-
cytes were derived from blood obtained from the principal investigator using a protocol previously described37. 
DENV strains of the original Mahidol stocks (DENV-2 16681, DENV-2 PDK53, DENV-3 16562 and DENV-3 
PGMK30FRhL3) were obtained from Dr Claire Huang (Centers for Disease Control and Prevention, USA) and 
were passaged three times in C6/36 cells in our laboratory. To achieve sufficiently high titres for subsequent 
experiments, supernatant of PDK53 cultures were concentrated by high-speed centrifugation and reconstituted 
in 1/100 of its original culture volume. Viral genome sequences were uploaded to GenBank with the accession 
numbers listed in Supplementary Table 1. Yellow fever YF-17D was commercially obtained (Sanofi Pasteur).
Transcriptomic Analysis. HuH-7 cells seeded in a confluent monolayer were infected with 10MOI of 
DENV-2 16681 or the DENV-3 strains; or 1MOI and 10MOI of DENV-2 PDK53. At 24 hpi, total cellular RNA was 
extracted using the RNEasy Mini kit (Qiagen) and then analysed on the Illumina HumanHT-12 v4 Expression 
Beadchip (Illumina). Results were analysed using Partek Genomics Suite v6.6 ©2014 (Partek). Pathway analysis 
was done using Gene Set Enrichment Analysis (Broad Institute, USA)38,39.
Flow cytometry. Proportion of infected cells was assessed by flow cytometry. Cells were fixed and permea-
bilised with 3% paraformaldehyde and 0.1% saponin (Sigma-Aldrich) respectively, stained for DENV envelope 
(E) protein with mouse monoclonal 4G2 antibody (ATCC) and AlexaFluor488 anti-mouse secondary antibody
(Invitrogen); then analysed on a BD FACSCanto II (BD Bioscience). Each data point represents a minimum of
5000 events and three biological replicates.
uantification of Viral RNA ptake and Replication. Total cellular RNA was extracted using the 
RNEasy Mini kit (Qiagen), and complementary DNA synthesised using the iScript cDNA Synthesis kit (Bio-Rad). 
To measure total viral RNA, quantitative real-time PCR was done with iQ SYBR Green Mastermix (Bio-Rad) 
using a primer targeting a highly conserved region of the 3′ UTR common to all four serotypes of dengue as pre-
viously reported40; inter-sample normalization was done using GAPDH as a control. Primer sequences are listed 
in Supplementary Table 2. Pronase (Roche) was used at a concentration of 1 mg/mL and incubated with infected 
cells for five minutes on ice, before washing with ice cold PBS. Total cellular RNA was then extracted from the cell 
pellets in the manner described above.
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Animal models. C57BL/6 mice were purchased from InVivos (Singapore) and maintained in the Duke-NUS 
Vivarium for the duration of the experiment. The SingHealth Institutional Animal Care and Use Committee 
approved all mouse experiments and experiments were carried out in accordance with approved guidelines. Mice 
were infected by injecting 100 µ L of 1 × 106 pfu/mL DENV subcutaneously into the hind footpads. Draining 
popliteal lymph nodes were collected 24 h post-infection, snap frozen in O.C.T. Compound (Tissue-Tek), 
then cryosectioned (10 µ m thick sections). Sections were fixed with acetone at 4 °C then stained using J2 
anti-dsRNA antibody (English and Scientific Consulting) and FITC-conjugated anti-mouse antibody (Jackson 
ImmunoResearch). Slides were imaged by confocal microscopy. Images were prepared for publication using 
ImageJ (National Institutes of Health, USA)41.
Plaue and Focus-Forming Assays. Culture supernatant, or virus samples, underwent serial 10-fold 
dilutions, then incubation on a monolayer of BHK-21 cells for 1 h at 37 °C. Samples were removed and replaced 
with 0.8% carboxymethylcellulose in RPMI supplemented with 3% foetal calf serum. Cultures for plaque 
assay were incubated for 6 days at 37 °C, then fixed with 20% formaldehyde and stained with 1% crystal violet 
(Sigma-Aldrich) to visualize plaques. Cultures for focus forming assay were incubated for 3 days at 37 °C, then 
fixed with 3% paraformaldehyde, permeabilised with 0.1% saponin, then stained with mouse 4G2 monoclonal 
antibody and anti-mouse horseradish peroxidase antibody. Viral foci were stained with 3-3′ -diaminobenzidine 
(DAB Chromogen) (Dako) and enumerated visually.
onfocal Imaging for Viral Foci. BHK-21 cells in a confluent monolayer on glass coverslips were 
infected with 30 pfu of virus and incubated for 72 hours at 37 °C. IFNα (Abcam) was used as a positive con-
trol. The cells were fixed and permeabilised with 3% paraformaldehyde and 0.1% saponin, then stained with 
anti-phospho-STAT1 (Y701) rabbit polyclonal IgG (R&D Systems), J2 anti-dsRNA mouse antibody, DAPI, 
AlexaFluor488 anti-rabbit, and AlexaFluor594 anti-mouse secondary antibodies (Invitrogen). Coverslips were 
affixed onto glass slides using Mowiol 4–88 (Sigma-Aldrich) and imaged using an LSM 710 confocal microscope 
(Carl Zeiss).
Immune pathway knockdown and plaue phenotype studies. BHK-21 cells seeded in a conflu-
ent monolayer were treated with the specified hamster-specific siRNA at 100 nM final concentration complexed 
with Dharmafect 4 (GE Healthcare) for 48 hours. siRNA sequences used are listed in Supplementary Table 3. 
Following siRNA knockdown, each well was infected with 30 pfu of virus, and then incubated as for the plaque 
assay. Resultant plaques were photographed using an EOS 5D digital SLR camera (Canon) at a fixed distance. 
Plaque sizes were measured in pixels using ImageJ.
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Dengue virus compartmentalization 
during antibody-enhanced infection
Eugenia Z. Ong1,2, Summer L. Zhang2, Hwee Cheng Tan2, Esther S. Gan2, Kuan Rong Chan2 & 
Eng Eong Ooi2,3,4,5
Secondary infection with a heterologous dengue virus (DENV) serotype increases the risk of severe 
dengue, through a process termed antibody-dependent enhancement (ADE). During ADE, DENV 
is opsonized with non- or sub-neutralizing antibody levels that augment entry into monocytes and 
dendritic cells through Fc-gamma receptors (FcγRs). We previously reported that co-ligation of 
leukocyte immunoglobulin-like receptor-B1 (LILRB1) by antibody-opsonized DENV led to recruitment 
of SH2 domain-containing phosphatase-1 (SHP-1) to dephosphorylate spleen tyrosine kinase (Syk) and 
reduce interferon stimulated gene induction. Here, we show that LILRB1 also signals through SHP-1 to 
attenuate the otherwise rapid acidification for lysosomal enzyme activation following FcγR-mediated 
uptake of DENV. Reduced or slower trafficking of antibody-opsonized DENV to lytic phagolysosomal 
compartments, demonstrates how co-ligation of LILRB1 also permits DENV to overcome a cell-
autonomous immune response, enhancing intracellular survival of DENV. Our findings provide insights 
on how antiviral drugs that modify phagosome acidification should be used for viruses such as DENV.
Over the last decade alone, the global burden of dengue has doubled, with an estimated 50 to 100 million symp-
tomatic cases annually1. The risk of severe disease is augmented when dengue virus (DENV) is opsonized with 
non- or sub-neutralizing levels of antibodies that ligate Fc-gamma receptors (Fcγ Rs) for enhanced entry and 
replication in monocytes, macrophages and dendritic cells. This phenomenon, termed antibody-dependent 
enhancement (ADE), engenders the elevated viraemia and vascular leakage that is characteristic of severe den-
gue. Indeed, we have recently demonstrated ADE clinically and identified how this process could be exploited to 
enhance live attenuated viral vaccination2.
ADE modifies DENV entry into target cells through Fcγ R. However, activation of various receptor-mediated 
pathways, such as downregulation of intracellular innate and adaptive antiviral mechanisms, could also con-
tribute to enhanced dengue pathogenesis3. Activating Fcγ Rs are known to signal through phosphorylation of 
immunoreceptor tyrosine-based activation motif (ITAM) and spleen tyrosine kinase (Syk)4. Activated Syk con-
trols a number of pathways, including actin remodelling necessary for phagocytosis5 and STAT-1-dependent 
interferon-stimulated gene (ISG) induction independent of interferon receptor signaling4. Induction of ISGs 
would create an intracellular environment unfavorable for enhanced DENV replication. To counter this early 
activating Fcγ R-triggered antiviral response, DENV co-ligates the inhibitory leukocyte immunoglobulin-like 
receptor B1 (LILRB1) during ADE6. LILRB1 recruits SH2 domain-containing phosphatase-1 (SHP-1) to dephos-
phorylate Syk and downregulate STAT-1 induction of ISG response6,7.
Besides inhibiting early ISG induction, it is also possible that DENV alters cellular compartmentalization, 
which is a cell-autonomous immune response8, for enhanced replication by co-ligating LILRB1. This is especially 
since the ITAM-Syk signaling axis also governs Fcγ R-mediated phagocytosis5. Previous studies focusing on cel-
lular uptake of DENV were performed on epithelial cell lines such as C6/36, Vero, BS-C-1 and Huh-79–12, that 
collectively showed that DENV enters the host cell via clathrin-mediated endocytosis. DENV is then trafficked 
in Rab5 (early) and Rab7 (late) endosomes, before undergoing fusion in acidic late endosomes. However, DENV 
uptake and trafficking routes may vary according to type of host cell and the type of receptor used for entry9–12. 
Moreover, our understanding of DENV trafficking following Fcγ R-mediated uptake, and the implication of how 
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Fcγ R signaling through ITAM and Syk could modulate trafficking and enhance viral replication during ADE 
remains nascent. Here, we show that LILRB1 signaling directs DENV-containing phagosomes into less acidified 
compartments that prevent rapid lysosomal degradation of DENV. Likewise, inhibition of phagosomal acidifi-
cation by lysosomotropic drugs also led to increased antibody-dependent infection, suggesting caution on using 
such drugs for anti-dengue therapy.
Results
Isolation and characterization of DENV endocytic vesicles. We had previously obtained two 
subclones from limiting dilution of THP-1 cells, namely THP-1.2R (ADE-resistant) and THP-1.2S (ADE-
susceptible)6. While both subclones supported similar levels of DENV uptake and infection under DENV only 
conditions, infection under ADE conditions led to significantly higher DENV-2 titres in THP-1.2S compared to 
THP-1.2R. The difference in susceptibility to ADE was due to higher levels of LILRB1 expression on THP-1.2S. 
Antibody-opsonized DENV co-ligated LILRB1 to down-regulate activating Fcγ R-mediated signaling, reducing 
induction of ISGs for enhanced DENV replication in THP-1.2S6. Since LILRB1 signaling modulates Syk activity, 
which in turn regulates phagosome trafficking and maturation13, we examined here if reduced Syk activity results 
in altered phagosomal compartmentalization of DENV that could also contribute to enhanced viral replication 
during ADE.
To investigate how compartmentalization was modified, we adapted a protocol previously used for purifi-
cation of latex bead-containing phagosomes on a step sucrose gradient14 to isolate DENV endocytic vesicles 
following infection of THP-1 subclones under DENV only or ADE conditions (Supplementary Fig. S1). Recovery 
of DENV RNA was most abundant in fraction 3, or the densest fraction collected (Fig. 1A). Similar findings 
were obtained when DENV endocytic vesicles were isolated using a continuous sucrose gradient, which allows 
flotation of DENV-containing vesicles at their buoyant density. Importantly, the peak in viral RNA recovery using 
both methods of isolation corresponded to fractions of similar density, reinforcing the reproducibility of this 
assay (Fig. 1B). As the yield of viral RNA recovery during purification of DENV endocytic vesicles with a step 
sucrose gradient was higher, this method was used for subsequent experiments.
Particles in isolated fractions of step sucrose gradient were further characterized using Nanosight, which ena-
bles quantification and sizing of nanoparticles. As the sizes of endosomal and lysosomal compartments range from 
200 nm to 600 nm15,16, the use of Nanosight allows tracking of DENV with cellular endocytic machinery. DENV 
was first labeled with DiD (1,1′ -dioctadecyl-3,3,3′ ,3′ – tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate 
salt), a lipophilic fluorescent dye. Following uptake and fusion of the virus and host cell membranes, its fluo-
rescence unquenches, allowing discrimination of DiD-particles using Nanosight under fluorescence mode. The 
modal size of DiD-particles was 2 to 3 fold larger than modal size of nanoparticles detected under light scatter 
mode (Fig. 1C, Supplementary Fig. S1). Importantly, the majority of DiD-particles were detected in fraction 3 in 
both DENV only and ADE infection (Fig. 1C), consistent with the bulk of viral RNA being recovered from frac-
tion 3 (Fig. 1A). The modal size of 274 nm and 246 nm for DiD-particles isolated following DENV only and ADE 
infection, respectively, also suggests the possibility that DENV is contained within endosomal vesicles (Fig. 1C).
DENV is trafficked to lysosomal compartments upon FcγR-mediated entry. Western blot prob-
ing for the expression of endosomal trafficking markers from isolated fractions revealed lower expression of 
Rab-5 and EEA-1, markers for early endosomal compartments, relative to Rab-7 and LAMP-1, markers for late 
endosomal compartments (Supplementary Fig. S1). This suggests that at 2 hours post-infection, DENV is com-
partmentalized in late endosomes or lysosomes following uptake into the host cell. The enrichment of endosomal 
markers in isolated fractions relative to whole cell lysate is further validation that purification of DENV endocytic 
vesicles can be performed on a step sucrose gradient (Supplementary Fig. S1). Organelle markers were also used 
to verify the purity of DENV endocytic vesicle isolation. Although Golgi apparatus (GM130) and peroxisomes 
(PMP70) were not detected, both ER (calnexin and BiP) and mitochondria (HSP60) co-isolated with DENV 
endocytic vesicles (Supplementary Fig. S1). ER proteins are known to mediate phagosome trafficking and have 
been co-isolated with latex bead phagosomes17. HSP60, which could be important for DENV replication as siRNA 
knockdown of HSP60 in U937 monocytic cells led to reduced viral replication and increased IFN-α production18, 
was also detected in our Western blots.
To attain a more granular level of information on how DENV compartmentalization is altered during ADE, 
we performed isobaric tag for relative and absolute quantitation (iTRAQ) analysis on DENV endocytic vesi-
cles isolated from fraction 3. Interestingly, lysosomal proteins were enriched in THP-1.2R but reduced in THP-
1.2S during ADE (Fig. 1D). Conversely, proteins involved in endocytosis and Fcγ R-mediated phagocytosis were 
enriched in THP-1.2S during ADE (Fig. 1D). That DENV was trafficked to lysosomal compartments in THP-1.2R 
during ADE was substantiated by activation of lysosomal hydrolases, which are processed to their catalytically 
active form upon phagosome acidification. Specifically, the expression of active cathepsin D (CatD), a lysosomal 
protease with optimal activity at acidic pH, was higher in THP-1.2R compared to THP-1.2S (Fig. 1E).
LILRB1 modulates DENV phagosome acidification. Enrichment of lysosomal proteins and activation 
of lysosomal hydrolases suggests higher levels of phagosome acidification in THP-1.2R during ADE. To test if Syk 
activity affects DENV phagosome acidification, a hallmark of phagosome maturation, we labeled DENV with both 
pH-sensitive pHrodo dye, and pH-insensitive Alexa Fluor 488 (AF488) dye to track intracellular DENV. Since acid-
ification of the subcellular environment increases fluorescence intensity of pHrodo but not AF488, the ratio of flu-
orescence intensity between pHrodo and AF488 served as a semi-quantitative measure of phagosome acidification. 
This approach was previously used to assess phagosome acidification during infection with bacteria that was simul-
taneously labelled with pHrodo and a pH-insensitive fluorescent probe19,20. Only batches of DENV that showed at 
least 70% of co-labelling with pHrodo and AF488 (Supplementary Fig. S2) were used for subsequent experiments.
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Figure 1. Isolation of DENV endocytic vesicles reveals DENV compartmentalization during ADE.  
(A) Viral RNA copy numbers recovered from step sucrose gradient purified fractions collected from THP-1.2R
or THP-1.2S at 2 hours post-infection (hpi) under DENV-2 or h3H5-opsonized DENV-2 infection (ADE).
(B) Viral RNA copy numbers recovered from continuous sucrose gradient purified fractions collected from
THP-1.2R at 2 hpi under ADE conditions. Fractions indicated are correlated to their corresponding sucrose
concentrations. (C) Concentration and modal size (numbers indicated) of DiD-labelled nanoparticles from
fractions collected from THP-1.2S at 2 hpi under DENV-2 or ADE conditions. Solid line indicates mean, and
dotted lines indicate s.d. (D) Heat map showing log2 fold change of proteins (fraction 3) enriched in THP-
1.2R and THP-1.2S at 2 hpi under DENV-2 or ADE conditions, relative to uninfected cells. (E) Western blot
showing higher levels of active CatD (34 kDa) in fraction 3 of THP-1.2R compared to THP-1.2S, in cells that
were infected under DENV only or ADE conditions, or uninfected control cells. Whole cell lysate (WCL) was
obtained before ultracentrifugation of cell lysates to obtain subcellular fractions. Numbers below Western blot
indicate active CatD levels relative to CatD precursor proteins (47 kDa and 52 kDa) in fraction 3. Data expressed
as mean ± s.d. from three independent experiments.
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To test if pHrodo/AF488-labeled DENV would be sensitive to changes in phagosome acidification, we infected 
Vero cells pre-treated with different concentrations of chloroquine (CQ). As pH of intracellular compartments 
increased with concentration of CQ used, fluorescence intensity of pHrodo decreased and we observed reduced 
overlap of pHrodo and E protein (Supplementary Fig. S2). This indicates that pHrodo/AF488-labeled DENV is 
sensitive to changes in pH and can be used to examine semi-quantitatively differences in phagosome acidification.
Use of pHrodo/AF488-labeled DENV to infect subclones under ADE conditions showed higher levels of 
phagosome acidification during ADE in THP-1.2R relative to THP-1.2S (Fig. 2A,B). In contrast, no difference 
in phagosome acidification was observed during DENV only infection in both subclones (Fig. 2A,B). Reduction 
in LILRB1 expression through pre-transfection with siRNA against LILRB1 in THP-1.2S resulted in increased 
phagosome acidification, compared to pre-transfection with scrambled control siRNA (Fig. 2C). Conversely, 
overexpression of LILRB1 in THP-1.2R led to an expected increase in pSHP-1 levels and reduced phagosome 
acidification during ADE (Fig. 2D).
Similar findings were recapitulated in primary monocytes. Increased phagosome acidification following ADE 
infection was observed following pre-treatment of primary monocytes with sodium stibogluconate, a SHP-1 
inhibitor (Fig. 3A,B). Likewise, blocking LILRB1 with anti-LILRB1 antibodies in primary monocytes increased 
phagosome acidification during ADE infection (Fig. 3C,D). Collectively, our data indicates that LILRB1 sig-
nals through SHP-1 for reduced acidification in DENV phagosomes, which likely prevents DENV from being 
degraded by lysosomal enzymes before the virus completely uncoats.
Inhibition of phagosome acidification enhances DENV replication. DENV is an enveloped virus 
that depends on low pH as a catalyst for E protein trimerization, which is thought to be the conformation neces-
sary for membrane fusion and release of its genome into the cytosol for replication21. However, Fcγ R-mediated 
uptake of antibody-opsonized DENV during ADE also leads to rapid DENV phagosome acidification and 
Figure 2. Differential phagosome acidification in THP-1 subclones is modulated by LILRB1 signaling.  
(A) Co-localization of pHrodo (red) and AF488 (green) labelled DENV-2 with LAMP-1 (cyan) in THP-
1.2R and THP-1.2S at 2 hpi under DENV-2 or ADE conditions. Scale bar is 5 µ m. (B) DENV-2 phagosome 
acidification expressed as relative fluorescence intensity (RFI) of pHrodo and AF488 in THP-1.2R and THP-
1.2S at 2 hpi under DENV-2 or ADE conditions, normalized to DENV infection in THP-1.2R. (C) RFI of 
pHrodo and AF488 at 2 hpi after LILRB1 knockdown in THP-1.2S, normalized to DENV infection in THP-1.2S 
transfected with control siRNA. (D) RFI of pHrodo and AF488 at 2 hpi after LILRB1 overexpression in THP-
1.2R, normalized to DENV infection in THP-1.2R transfected with empty vector. Numbers below Western blot 
indicate LILRB1 or pSHP-1 levels relative to GAPDH or SHP-1. Each dot represents a single virus particle, data 
expressed as mean ± s.d. from two independent experiments. ***P < 0.0001, **P < 0.01.
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Figure 3. DENV phagosome acidification is reduced upon co-ligation of LILRB1 in primary monocytes. 
(A,B) Co-localization of pHrodo (red) and AF488 (green) labelled DENV-2 with LAMP-1 (cyan) (A) and 
RFI of pHrodo and AF488, normalized to ADE infection in PBS-treated primary monocytes (B) at 2 hpi in 
PBS- or sodium stibogluconate (SSG)-treated primary monocytes infected under DENV-2 or ADE conditions. 
(C,D) RFI of pHrodo and AF488, normalized to ADE infection in primary monocytes pre-treated with isotype 
antibody control (C) and co-localization of pHrodo (red) and AF488 (green) labelled DENV-2 with E protein 
(cyan) (D) at 2 hpi in primary monocytes pre-treated with isotype antibody control or polyclonal anti-LILRB1 
antibody and infected under DENV-2 or ADE conditions. Scale bar is 2 µ m. Each dot represents a single virus 
particle, data expressed as mean ± s.d. from two independent experiments. ***P < 0.0001.
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activation of lysosomal enzymes that can result in DENV degradation. Reducing or slowing phagosome acidifi-
cation during ADE could allow DENV to escape lysosomal degradation thus promoting enhanced intracellular 
survival of DENV, albeit with delayed viral uncoating and fusion. To clarify if phagosome acidification is a critical 
determinant for viral release and subsequent viral replication, we tested if inhibition of phagosome acidification 
with the lysosomotropic weak bases, ammonium chloride (NH4Cl) and CQ, could result in enhanced infection 
during ADE.
We first verified that we could reproduce the inhibition of both viral replication (Fig. 4A) and infectious 
DENV titres (Fig. 4B) following DENV infection in HEK-293T cells pre-treated with NH4Cl, with no significant 
increase in cellular cytotoxicity (Supplementary Fig. S3). In contrast, pre-treatment of THP-1 subclones with 
either NH4Cl or CQ led to increased viral replication when infected under ADE condition, with a larger magni-
tude observed in THP-1.2R (Fig. 4C,D, Supplementary Fig. S4). In contrast, viral replication in THP-1 subclones 
infected under DENV only condition was not significantly reduced with either CQ or NH4Cl pre-treatment 
(Supplementary Fig. S4).
Pre-treatment of primary monocytes with either CQ or NH4Cl before infection also led to increased 
viral replication, with a larger fold increase under ADE compared to DENV only conditions (Fig. 4E,F, 
Figure 4. Inhibition of phagosome acidification results in production of immature DENV. (A) Viral RNA 
copy numbers normalized to GAPDH at 20 hpi under DENV-2 conditions in HEK-293T cells treated with 
ammonium chloride (NH4Cl) or PBS (dashed line, shaded areas reflect s.d.). (B) Plaque titres at 48 hpi following 
DENV-2 infection on PBS- or NH4Cl-treated HEK-293T cells. (C,D) Fold change in DENV RNA copy numbers 
at 20 hpi under ADE conditions in THP-1.2R and THP-1.2S pre-treated with NH4Cl (C) or chloroquine (CQ) 
(D), relative to cells pre-treated with PBS. (E,F) Fold change in DENV RNA copy numbers at 16 hpi in primary 
monocytes pre-treated with NH4Cl (E) or CQ (F), relative to primary monocytes pre-treated with PBS.  
(G,H) Ratio of DENV-2 genomic copies to infectious plaque titres at 48 hpi in primary monocytes pre-treated 
with NH4Cl (G) or CQ (H). Data expressed as mean ± s.d. from three independent experiments. ***P < 0.0001, 
**P < 0.01, *P < 0.05.
www.nature.com/scientificreports/
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Supplementary Fig. S4). The increased viral replication following CQ or NH4Cl pre-treatment conse-
quently resulted in increased production of new viral progenies in the culture supernatant during ADE 
(Supplementary Fig. S4). Although these virions had reduced infectivity (Fig. 4G,H) due to the expected reduc-
tion in viral maturation (Supplementary Fig. S4) from reduced acidification-dependent furin activity, these 
immature viruses could nonetheless be pathologically important. The abundant presence of non-neutralizing 
anti-prM antibodies in patients with secondary DENV infection22 could render these immature virions infectious 
again, through ADE23.
Discussion
In both professional and non-professional phagocytes, cellular compartmentalization is utilized as a means 
of self-defence against human pathogens. Compartment borders restrict pathogen access to the cytosol, and 
the expression of pattern recognition receptors and danger receptors aid pathogen detection and elimination8. 
Determining how DENV is compartmentalized, depending on the mode of entry, is thus a hitherto unexplored 
investigation that could provide unique insights into the pathogenesis of dengue.
Plasma membrane receptor signaling during virus uptake can modulate DENV compartmentalization and the 
outcome of infection. That DENV is destined for phagolysosomal degradation following Fcγ R-mediated uptake 
during ADE, is consistent with previous findings that phagosomes containing antibody-opsonized beads matured 
faster into phagolysosomes, compared to uncoated beads24. Furthermore, both Mycobacterium tuberculosis (Mtb) 
and Helicobacter pylori opsonized with IgG resulted in more rapid phagosome maturation and were more effi-
ciently destroyed than non-opsonized bacterial particles25,26. The findings of our study add to this body of knowl-
edge. During ADE, antibody-opsonized DENV co-ligates the ITIM-bearing LILRB1, which signals through 
SHP-1 to dephosphorylate Syk. Reduced Syk signaling not only results in suppressed ISG induction6, it also 
downregulates phagosome acidification, permitting DENV to escape lysosomal degradation. SHP-1 is thought 
to inhibit phagosome acidification by acting on membrane fusion during phagosome trafficking19. Defects in 
phagosome acidification have also been observed in SHP-1 deficient mouse macrophages27. Our findings thus 
agree with recent studies that have demonstrated increased viral fusion during ADE, which leads to enhanced 
production of infectious DENV titres28.
Besides DENV, other human pathogens are also known to subvert phagosome acidification for replicative 
survival. For example, Mtb expresses the bacterial protein tyrosine phosphatase PtpA, which dephosphorylates 
vacuolar protein sorting 33B. This inhibits recruitment of vacuolar-type H+-ATPase (V-ATPase) proton pumps 
to the phagosome, and inhibits phagosome acidification during Mtb infection19. Likewise, Leishmania donovani 
expresses the glycolipid lipophosphoglycan, which inserts into phagosome membranes and inhibits the recruit-
ment of cathepsin D and V-ATPase, which are critical for phagosome acidification29. Without expressing pro-
teins that specifically modify phagosome acidification, DENV indirectly alters the phagosome environment by 
co-ligation of LILRB1 during antibody-dependent infection.
As rapid phagosome acidification for lysosomal protein activation is a key early defense mechanism against 
infective organisms in the phagosomal cargo, therapeutic approaches that rely on raising intracellular pH should 
be considered cautiously. We detected increased magnitude of viral replication in both THP-1 subclones and 
primary monocytes that were pre-treated with CQ or NH4Cl during infection under DENV and ADE conditions. 
Consistent with our findings, the infectivity of both human immunodeficiency virus type 1 and severe acute res-
piratory syndrome coronavirus were also raised following pre-treatment of lysosomotropic drugs on host cells, 
as the virus was able to escape lysosomal degradation and enter host cells via a separate endocytic pathway30,31.
Our findings also potentially explain, at least in part, why CQ failed to show therapeutic efficacy in a 
proof-of-concept clinical trial in dengue patients32. Although CQ and NH4Cl treatment-related increase in viral 
RNA replication is more abundantly secreted as immature DENVs, these could nonetheless be detrimental in 
patients experiencing secondary dengue infections, which formed the majority of the trial subjects32. Prior DENV 
infection in such patients would likely have produced abundant cross-reactive anti-prM antibodies22, which 
would bind immature DENV particles to enable entry into Fcγ R-bearing cells where subsequent furin activity 
renders them infectious23.
Collectively, our findings suggest that DENV adopts a “festina lente” model to escape phagolysosomal deg-
radation, ensuring its intracellular survival during ADE. Although reduced or slowed phagosome acidification 
during ADE may delay viral fusion and uncoating, it is probably a necessary trade-off that ultimately permits 
DENV to escape lysosomal degradation in favor of intracellular survival.
Methods
Cells and viruses. THP-1.2R and THP-1.2S were sub-cloned from THP-1 by limiting dilution6. Primary 
monocytes were isolated from principal investigator and cultured as described previously33. DENV-2 (ST) is a 
clinical isolate from the Singapore General Hospital. The method for DiD labeling of DENV was as previously 
described33. Dual labeling of DENV with pHrodo and Alexa Fluor 488 is detailed in Supplementary Methods.
Virus infection. Endotoxin-free (LAL Chromogenic Endotoxin Quantitation Kit, Pierce) 3H5 chi-
meric human/mouse IgG1 antibodies were constructed as previously described34. DENV was incubated with 
media or humanized 3H5 antibody (0.391 µ g/ml) for 1hr at 37 °C before adding to cells at moi of 10. In some 
experiments, DENV was dual labeled with pHrodo Red and Alexa Fluor 488 or DiD before use for infection 
(Supplementary Methods). For drug assays, cells were pre-treated with chloroquine (Sigma-Aldrich) or ammo-
nium chloride (Sigma-Aldrich) 1hr before infection, or sodium stibogluconate (Santa Cruz Biotech) 6 hrs 
before infection. Cell viability was assessed using CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(Promega) according to manufacturer’s protocol. Subsequently, virus replication was assessed using qPCR at 
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indicated time points and plaque assay at 48 hrs or 72 hrs post-infection. Protein and protein phosphorylation 
levels were assessed using Western blots and analyzed with ImageJ.
Isolation of DENV endocytic vesicles. Isolation of DENV endocytic vesicles was performed using a pro-
tocol previously used for the isolation of latex bead phagosomes14. Briefly, DENV was incubated with media or 
h3H5 (0.391 µ g/ml) for 1 hr at 37 °C before adding to THP-1.2R and THP-1.2S (moi 10). Cells were incubated 
with DENV immune complex at 4 °C for 20 min before transferring to 37 °C for 2hrs. Cells were washed with 
PBS, homogenized on ice in 25 strokes using a 30-G syringe and DENV endocytic vesicles were isolated on either 
a step or continuous sucrose gradient. 250 µ l fractions from the continuous sucrose gradient were collected and 
subjected to viral RNA extraction using QiaAmp Viral RNA Mini kit (Qiagen). Fractions at the interfaces of step 
sucrose gradients were collected, with 140 µ l subjected to viral RNA extraction. DENV endocytic vesicles were 
resuspended in 10 ml cold PBS containing protease inhibitors and washed by ultracentrifugation. The protein pel-
let was resuspended in 100 µ l lysis buffer (1% Nonidet P-40, 150 mM NaCl, 50 mM Tris, pH 8.0) in the presence of 
protease and phosphatase inhibitors (Sigma). Protein concentration of DENV endocytic vesicles was determined 
using Pierce BCA Protein Assay Kit (Pierce) and endocytic vesicle proteins (3 µ g) separated on a SDS-PAGE gel 
for immunoblotting.
Nanoparticle tracking analysis (NTA). Characterization of DENV endocytic vesicles was performed with 
Nanosight LM10, customized with a 692 nm bandpass filter for use under fluorescence mode. Washed DENV 
endocytic vesicles were resuspended at an appropriate dilution in HNE buffer before injection into the LM unit 
with a 1 ml syringe. NTA 2.3 analytical software was used to capture and analyze data. For each sample, 5 videos 
of 90 s duration were recorded, with a 5 s delay between recordings and chamber temperature recorded at the end 
of each video.
Assessing phagosome acidification with pHrodo/AF488-labeled DENV. pHrodo/AF488-labelled 
DENV were incubated with media or h3H5 (0.391 µ g/ml) for 1hr at 37 °C before adding to THP-1 cells (moi 10). 
Cells were synchronized on ice for 20 min, followed by 2 hrs infection at 37 °C and fixed with 3% PFA. Confocal 
immunofluorescence was used to assess localization of antibody–virus complexes and fluorescence intensities of 
pHrodo and AF488 on DENV in the cell. Detailed description is provided in Supplementary Methods.
Statistical Analysis. All experiments were conducted with at least 3 biological replicates and repeated at 
least twice. Mann-Whitney test was used to compare differences in phagosome acidification. In other experi-
ments, to compare between any two means, two-tailed unpaired Student t test was performed using GraphPad 
Prism v5.0 (P < 0.05).
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